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ABSTRACT
Dupuytren’s disease is a common fibroproliferative condition of the hand that results in 
disability through progressive digital contracture. Despite advances in operative 
technique, recurrence remains an unsolved problem. The matrix metalloproteases 
(MMPs) are a large family of proteolytic enzymes that have been shown to play a 
critical role in cell-mediated collagen contraction and tissue scarring. The aim of this 
project was to investigate the effect of ilomastat, a broad-spectrum MMP inhibitor, on 
matrix contraction and remodelling by Dupuytren’s fibroblasts in vitro.
Paired nodule and cord-derived fibroblasts were isolated by explant culture from five 
Dupuytren’s patients, carpal ligament fibroblasts acted as the control. We employed two 
different in vitro models to assess the effect of ilomastat on contraction and remodelling 
by each cell population. A stress-release fibroblast populated collagen lattice (FPCL) 
model was employed to assess collagen contraction. Generation of mechanical tension 
was determined using a culture force monitor (CFM). Following dynamic force 
generation, treatment with cytochalasin-D was used to assess residual matrix tension 
(RMT) in the collagen lattice, allowing quantification of matrix remodelling. The 
expression of a range of MMPs (MMP-1, MMP-2, MT1-MMP) and Tissue Inhibitors 
of Metalloproteinases (TIMP-1, TIMP-2), was established by RT-PCR. Protein levels 
and enzyme activity were assessed by western blotting, zymography and ELISA.
In the FPCL model, ilomastat significantly (p<0.01) inhibited contraction by all tissue- 
derived fibroblasts at lOOpM. In the CFM model, ilomastat significantly reduced force 
development by cord and nodule-derived fibroblasts (p<0.01), but did not significantly 
affect RMT. In both models, treatment with ilomastat suppressed activity of MMP-1 
and MMP-2, however gene expression and levels of secreted protein were unaffected. 
Conversely, the expression and activity of MT1-MMP was upregulated in response to 
ilomastat, whereas, TIMP-1 and TIMP-2 were unaffected.
Our findings demonstrate an important role for MMP activity in matrix processing and 
organisation by Dupuytren’s fibroblasts in vitro and suggest that inhibition of MMP 
activity may well provide a means of controlling or reducing contracture in vivo, by 
reducing fibroblast-mediated matrix contraction and remodelling.
ACKNOWLEDGEMENTS
This thesis was the product of the collective support, enthusiasm and goodwill of many 
people. I would like to begin by expressing my sincere gratitude to Mr. Adriaan 
Grobbelaar for being an inspiring and motivating supervisor throughout this project. I 
am also indebted to my scientific supervisor, Dr. Alison Cambrey, who demonstrated 
considerable patience and skill in guiding me through my two years as an MD student. 
She set high standards for my work and provided the necessary support and 
encouragement to help me realise them. Part o f the work involved collaborating with 
the Institute o f Ophthalmology and I received great help from all members of Professor 
Khaw’s team.
The environment at RAFT was a pleasure to work in and many others contributed to my 
experience including both members o f the administrative team (Hilary, Stephanie, 
Amanda, Christine, Sheila) as well as scientists (Miss J Richardson, Mrs. E. Clayton, 
Mr. J. Shelton, Dr. C. Linge). Dr K. Rolfe was instrumental in imparting her technical 
wisdom in the laboratory especially with regard to PCR and proved very tolerant of my 
incessant questioning. I am also grateful to Kate Beckett, the previous Dupuytren’s 
fellow, whose thesis inspired this work and who has continued to provide valuable 
support despite busy clinical commitments.
This work would not have been completed without the valuable financial support from 
the Royal College of Surgeons of England, The Dunhill Trust, and all the Trustees of 
the Restoration and Function Trust
DECLARATION OF ORIGINALITY
I declare that the laboratory research for this thesis is original and that the ideas were 
developed in conjunction with my supervisors. I performed the experiments myself with 
the guidance and technical assistance o f the laboratory and scientific staff at the 
Restoration of Appearance and Function Trust (RAFT) Institute, Mount Vernon 
Hospital, and the Institute of Ophthalmology at Moorefleld’s Eye Hospital.
This thesis is dedicated to my 
loving and beautiful wife 
Nathalie
ABBREVIATIONS
5-FU 5-Flourouracil
bFGF Basic fibroblast growth factor
BSA' Bovine serum albumin
CFM Culture force monitor
CM Cell-conditioned media
DEPC Diethylprocarbonate
DMSO Dimethyl sulphoxide
DNA Deoxyribonucleic acid
ECM Extracellular matrix
EGF Epidermal growth factor
ELISA Enzyme-linked immunosurbent assay
FCS Fetal calf serum
FPCL Fibroblast-populated collagen lattice
GFM Gelatinase-free media
MCPJ Metacarpophalangeal joint
MMP Matrix metalloproteinase
MPI Matrix metal loproteinase inhibitor
mRNA Messenger ribonucleic acid
NGM Normal fibroblast growth medium
OD Optical density
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDGF Platelet-derived growth factor
PFC Palmar fascial complex
PIPJ Proximal interphalangeal joint
RMT Residual matrix tension
RT Reverse transcriptase
SEM Standard error o f the mean
SMA Smooth muscle actin
TBS Tris buffered saline
TEMED T etramethy lethylenediamine
TGF Transforming growth factor
TIMP Tissue inhibitor o f metalloproteinase
CONTENTS
ABSTRACT ii
ACKNOWLEDGEMENTS iii
DECLARATION OF ORIGINALITY iv
LIST OF ABBREVIATIONS vi
LIST OF CONTENTS vii
CHAPTER INDEX vii
INDEX OF FIGURES xiii
INDEX OF TABLES xviii
CHAPTER 1 1
INTRODUCTION
1.1 OVERVIEW 2
1.2 AETIOLOGY 3
1.3 ANATOMY 4
1.3.1 Normal anatomy 4
1.3.2 Pathological anatomy 5
1.3.3 Microscopic anatomy 5
1.4 PRESENTATION 5
1.5 TREATMENT 7
1.5.1 Non-operative management 7
1.5.2 Surgical correction 8
1.5.3 Recurrence 8
1.6 CONSIDERATIONS IN DUPUYTREN’S PATHOGENESIS 10
1.6.1 Mechanical tension 10
1.6.2 Similarities with wound healing 10
1.7 THE EXTRACELLULAR MATRIX 11
1.8 CHANGES IN THE ECM IN DUPUYTREN’S DISEASE 12
1.8.1 Collagen 12
1.8.2 Proteoglycans 13
1.9 MYOFIBROBLASTS 14
1.10 GROWTH FACTOR CHANGES IN DUPUYTREN’S DISEASE 15
1.11 MATRIX REMODELLING 15
1.12 MATRIX METALLOPROTEINASES (MMPs) 16
1.12.1 Regulation of MMP activity 19
1.12.2 Endogenous MMP inhibitors 20
1.12.3 MMPs in disease 21
1.12.4 MMPs in Dupuytren’s disease 22
1.13 MODELS OF TISSUE ORGANISATION 23
1.14 GENERATION OF CONTRACTILE FORCE 26
1.15 THE INFLUENCE OF MECHANICAL TENSION ON MATRIX
REMODELLING 28
1.15.1 Mechanochemical transduction 28
1.15.2 Matrix synthesis 28
1.15.3 Matrix degradation - mechanical tension and MMP activity 29
1.15.4 Tensional homeostasis 29
1.16 EFFECT OF MECHANICAL TENSION ON DUPUYTREN’S FIBROBLASTS
30
1.17 GENERATION OF CONTRACTURE: CONTRACTION AND REMODELLING
31
1.18 MMP INHIBITORS 34
1.18.1 Synthetic MMP inhibitors 34
1.18.2 Contraction 34
1.18.3 Clinical trials 36
1.19 INTRODUCTION TO THESIS 37
1.20 QUESTIONS TO BE ANSWERED 37
viii
CHAPTER 2 38
MATERIALS AND METHODS
2.1 GENERAL CELL CULTURE 39
2.1.1 Tissue selection 39
2.1.2 Histology 40
2.1.3 Cell strains 41
2.1.4 Isolation o f cells from explant tissue 42
2.1.5 Cryostorage of cells 43
2.1.6 Propagation o f cells from cryostorage 44
2.1.7 Cell viability and counting 44
ASSESSMENT OF CELL PROLIFERATION 44
2.2.1 Background to the metabolic proliferation assay 45
2.2.2 Correlation o f cell density with optical density 46
2.2.3 Effect o f ilomastat on cell proliferation 46
MODELS OF MATRIX CONTRACTION 47
FIBROBLAST-POPULATED COLLAGEN LATTICE (FPCL) 47
2.4.1 Construction o f FPCL model 48
2.4.2 Assessment of matrix contraction 49
2.4.3 Determination of appropriate time course 49
2.4.4 Optimal ilomastat dose determination 49
2.4.5 Effect o f ilomastat on matrix contraction 50
2.4.6 Isolation of membrane-bound and intracellular proteins 50
CULTURE FORCE MONITOR (CFM) 51
2.5.1 Calibration of the Culture Force Monitor 54
2.5.2 Construction of the CFM lattice 55
2.5.3 Contraction profile determination 56
2.5.4 Effect o f ilomastat on force generation 57
2.5.5 Effect o f ilomastat on matrix remodelling 57
2.5.6 Removal and processing of lattices from the CFM 58
2.6 DETERMINATION OF MMP SECRETION AND ACTIVITY 59
2.6.1 Determination o f protein concentration 59
2.6.2 Western blot analysis 61
2.6.3 Gelatin zymography 63
2.6.4 Enzyme-linked immunosurbent assay (ELISA) 65
2.7 DETERMINATION OF MMP GENE EXPRESSION 69
2.7.1 General precautions to prevent contamination 69
2.7.2 mRNA extraction 69
2.7.3 Determination of RNA yield and quality 69
2.7.4 Obtaining cDNA from RNA 70
2.7.5 The polymerase chain reaction (PCR) 71
2.7.6 Amplification plot 73
2.7.7 Oligonucleotide primers 74
2.7.8 Data analysis 76
2.8 STATISTICAL ANALYSIS 76
CHAPTER 3 77
OPTIMISATION OF CONDITIONS FOR MATRIX CONTRACTION IN THE 
FPCL MODEL
3.1 INTRODUCTION 78
3.2 AIMS 78
3.3 METHODS 78
3.4 RESULTS 79
3.4.1 Optimal cell density for proliferation assay 79
3.4.2 Effect o f ilomastat on fibroblast proliferation 81
3.4.3 FPCL contraction over 5 days 88
3.4.4 Effect o f  ilomastat dose on contraction by cord-derived fibroblasts 90
3.4.5 Effect o f ilomastat dose on contraction by nodule-derived fibroblasts
91
3.4.6 Effect o f ilomastat dose on contraction by carpal ligament 92
3.5 DISCUSSION 95
3.6 SUMMARY 97
x
CHAPTER 4 98
EFFECT OF ILOMASTAT ON MATRIX CONTRACTION IN THE FPCL MODEL
4.1 INTRODUCTION 99
4.2 AIMS 99
4.3 METHODS 100
4.4 RESULTS 100
4.4.1 Maximum lattice contraction under basal conditions 100
4.4.2 Effect of ilomastat on contraction by cord-derived fibroblasts 102
4.4.3 Effect of ilomastat on contraction by nodule-derived fibroblasts 103
4.4.4 Effect o f ilomastat on contraction by carpal ligament 105
4.4.5 Differential effect of ilomastat on carpal ligament, cord and nodule 106
4.4.6 Analysis of MMP protein levels by western blotting 108
4.4.7 Gelatin zymography 114
4.4.8 Enzyme-Linked Immunosorbent Assay (ELISA) 116
4.5 DISCUSSION 120
4.6 SUMMARY 122
CHAPTER 5 123
GENERATION OF CONTRACTILE FORCE, MATRIX REMODELLING MMP 
GENE EXPRESSION AND ACTIVITY: MODULATION BY ILOMASTAT
5.1 INTRODUCTION 124
5.2 AIMS 124
5.3 METHODS 124
5.4 RESULTS 125
5.4.1 Force generation in acellular lattices 125
5.4.2 Effect o f ilomastat on contraction and remodelling by cord-derived 
fibroblasts 126
5.4.3 Effect of ilomastat on contraction and remodelling by nodule-derived 
fibroblasts 128
5.4.4 Effect o f ilomastat on contraction and remodelling by carpal ligament- 
derived fibroblasts 129
5.4.5 Comparison between cord, nodule and carpal ligament 130
5.4.6 RT-PCR: MMP and TIMP gene expression 137
5.4.7 Western blot analysis: estimation of protein levels 142
5.4.8 Effect o f ilomastat on MMP activity 147
5.5 DISCUSSION 151
5.6 SUMMARY 153
CHAPTER 6 154
GENERAL DISCUSSION
6.1 OVERVIEW 155
6.2 CORD AND NODULE -  TWINS OR SIBLINGS? 156
6.3 INFLUENCE OF MMP ACTIVITY ON CONTRACTION, FORCE 
GENERATION AND REMODELLING 157
6.4 PATTERN OF EXPRESSION AND ACTIVITY OF SPECIFIC MMPs 165
6.5 ILOMASTAT -  THERAPEUTIC POTENTIAL? 169
6.6 CONCLUDING REMARKS 171
6.7 PROPOSAL FOR FUTURE WORK 172
INDEX OF FIGURES
CHAPTER 1
1. Normal anatomy o f the digital fascia and pathological fascial structures associated 
with Dupuytren’s disease 4
2. Dupuytren’s disease affecting the little finger MCPJ and PIPJ contracture 7
3. Recurrent Dupuytren’s disease affecting the little fingers 9
4. General domain structures of MMPs 17
5. Regulation of MMP activity 20
6. The three FPCL models 24
7. Culture Force Monitor 25
8. Myofibroblast differentiation 27
9. ‘Slip and ratchet’ theory o f matrix contracture 32
10. Structure and selectivity o f ilomastat 35
CHAPTER 2
1. Illustration of Dupuytren’s tissue 39
2. Haematoxylin and eosin-stained section of a Dupuytren’s cord and nodule 41
3. Cleavage of the tetrazoiium salt WST-1 45
4. Photograph of stressed and contracting lattices 49
5. Components o f the culture force monitor 52
6. Demonstration o f lattice position in well 53
7. Illustration o f the culture force monitor positioned in the incubator 53
8. Scatter graph illustrating calibration of the CFM 55
9. CFM force generation plot 58
10. Processing o f CFM lattice at termination of experiment 59
11. Example o f protein standard curve 60
12. Identification of active MMP enzymes by ELISA 65
13. Standard curve for MMP-1 activity 66
14. Standard curve for MMP-2 activity 67
15. Standard curve for MT1-MMP activity 68
16. An illustration o f the three stages of PCR 72
17. PCR amplification plot 73
18. PCR dissociation curve 74
CHAPTER 3
1. An illustration o f the relationship between optical density and cell number 80
2. Illustration of the relationship between optical density and cell number at lower cell 
densities 80
3. Proliferation of Dupuytren’s and control fibroblasts in response to NGM at 24 hours 
and 48 hours 82
4. Effect of serial dilutions o f ilomastat on the proliferation of cord-derived fibroblast
proliferation over a 48-hour time period 83
5. Effect of serial dilutions of DMSO on the proliferation o f cord-derived fibroblasts 
over a 48-hour exposure period 84
6. Effect of serial dilutions o f ilomastat and DMSO on the proliferation o f nodule- 
derived fibroblasts 85
7. Effect o f serial dilutions of ilomastat and DMSO on the proliferation of carpal
ligametitHlcvived fibroblasts 87
& Ad iUottnttkm of lattice contraction by cord-derived fibroblasts 88
9. A Mmpiiiiiin of lattice contraction mediated by carpal ligament, cord and nodule- 
dcrivffltfibrobtasts over time 89
10. A CQMfMhttl o f change in lattice contraction over time mediated by carpal
UgMHfenit cdfet and nodule-derived fibroblasts 90
11. Ilomastat on lattice contraction by cord-derived fibroblasts 91
12. Effect of ilomastat on lattice contraction by nodule-derived fibroblasts 91
13. Digital photograph o f fibroblast-seeded lattices exposed to varying concentrations 
o f ilomastat 93
14. Effect of ilomastat on lattice contraction by carpal ligament fibroblasts 93
15. Ilomastat-mediated inhibition in lattice contraction relative to NGM 94
xiv
CHAPTER 4
1. Comparison o f contractile activity o f multiple cell strains derived from carpal 
ligament, Dupuytren’s cord and nodule in response to GFM 101
2. Comparison o f contractile activity between fibroblasts in the initial 24-hour period 
after lattice release and the final 24 hours 102
3. Graph illustrating change in mean area of lattices seeded with cord-derived 
fibroblasts over time 103
4. A digital photograph of lattices seeded with nodule-derived fibroblasts 48 hours 
after release 104
5. Graph illustrating change in mean area of lattices seeded with nodule-derived 
fibroblasts over time 105
6. Graph illustrating change in mean area of lattices seeded with carpal ligament- 
derived fibroblasts over time 106
7. Comparison of inhibition o f FPCL contraction relative to basal conditions 107
8. Sample of western blot analysis of MMP-1 production 109
9. Quantification of MMP-1 protein production of fibroblasts seeded in contracting 
lattices 110
10. Sample of western blot analysis of MMP-2 production 111
11. MMP-2 protein production as determined by mean band density 112
12. W esteni blotfanalysis of MT1 -MMP production 113
13. Activ**i$Wfcl*4P protein levels as determined by mean band density 113
$4. AodytiM ftSftltitinolytic activity produced in conditioned media collected from 
d W H f r i  m a n )  and contracting (post-release) collagen lattices 115
141 Atfflptita^tgelaitinolytic activity produced in conditioned media collected from 
fc fM M fartp o s t -release) collagen lattices 116
16. Qtf**ift6ation o f MMP-1 activity by ELISA 117
17. Quantification o f MT1 -MMP activity by ELISA 119
xv
CHAPTER 5
1. Contraction profile of an acellular collagen lattice 126
2. Force generation by cord-derived fibroblasts over time 127
3. Force generation by nodule-derived fibroblasts over time 128
4. Force generation by carpal ligament-derived fibroblasts over time 130
5. Maximum force generated over a 48 hours 131
6. Rate of increase in force development over the first 24 hours 132
7. Flistogram demonstrating residual matrix tension 133
8. Histogram demonstrating cell-mediated contractile force generation 135
9. Histogram demonstrating proportion o f maximum force generated in terms of RMT
and cellular components 136
10. Comparison of MMP and TIMP gene expression under basal conditions 138
11. Comparison of MMP and TIMP gene expression profiles by nodule relative to cord-
derived fibroblasts 139
12. Comparison of MMP and TIMP gene expression by cord 140
13. Comparison of MMP and TIMP gene expression by nodule 141
14. Comparison of MMP and TIMP gene expression by carpal ligament 142
15. Western blot analysis o f pro and active MMP-1 production 143
16. Western blot analysis of MMP-2 production 143
17. MMP-2 protein production as determined by mean band density 144
18. Western blot analysis o f pro and active MT1 -MMP expression 145
19. Active*MT1-MMP protein production as determined by mean band density of
blots 145
20. W M ptifblot analysis of TIMP-1 production 146
21. Tni jftrtfhfrit analysis of TIMP-2 production 147
22. Quantification o f MMP-2 activity 148
23. Quantification o f levels of MT1 -MMP activity 150
xvi
CHAPTER 6
1. The three phases o f force generation in the culture force monitor 162
2. Possible effect of an MMP inhibitor on permanent matrix shortening 164
3. Schematic representation of the involvement of MMPs in the degradation of 
collagen type I 165
'■
xvii
INDEX OF TABLES
CHAPTER 1
1. The normal anatomical palmar fascial precursors of Dupuytren’s disease 6
2. Reported recurrence and extension rates of Dupuytren’s disease 9
3. A list of MMPs that have been demonstrated in humans 18
4. Comparison o f benefits and drawbacks o f FPCL and CFM models o f matrix
contraction 25
CHAPTER 2
1. The Demographics and associations of Dupuytren’s patients 42
2. The mean force recorded by the CFM for each known weight and the equivalent 
calculated force 54
3. Details of the primary MMP antibodies and corresponding secondary antibodies 
used 63
4. The constituents of the reverse transcriptase working mix 71
5. Primer sequences for the target MMP and TIMP target genes 75
xviii
Introduction
CHAPTER 1 
INTRODUCTION
1
Introduction
1.1 OVERVIEW
Dupuytren’s disease is a common fibrocontractile condition of the hand that causes 
disability through progressive digital contracture. Through its numerous associations, 
Dupuytren’s disease crosses all borders of medicine and is frequently encountered by 
surgeon, physician and general practitioner alike. It tends to affect mainly the elderly, 
although younger patients carry a worse prognosis. The clinical significance of Dupuytren’s 
primarily lies in the vast number of people affected (an estimated 2 million in the UK), 
accounting for lost workdays in the young and stolen dignity and diminished independence 
in the elderly.
The only widely accepted mode of treatment is surgery. Although surgery readily corrects 
contracture, the disease frequently recurs, as is often the case with fibroproliferative 
conditions. Unfortunately, the operative risks associated with recurrent procedures mount 
as the chance of delivering a fully functioning hand dwindles. Untreated, the disease can 
progress, leading to irreversible joint deformity and in severe cases, the prospect of 
amputation. Hence the quandary: of the current treatments, surgery undoubtedly provides 
the best outcome, but may lead to a vicious cycle of recurrent disease followed by surgical 
correction, that results in a spiralling deterioration in function. Hence, there is considerable 
impetus to develop a non-operative adjunct to surgery that will prevent both disease 
progression and recurrence and thereby allow patients to maintain hand function.
There is considerable evidence that MMPs play an important role in normal wound healing 
and in fibrocontractile scarring such as that found in Dupuytren’s disease. This thesis 
intends to investigate the effects of ilomastat, a broad-spectrum MMP inhibitor, on matrix 
contraction and remodelling by Dupuytren’s fibroblasts in vitro, with the aim of 
establishing its possible therapeutic potential as an agent to prevent recurrence and 
progression of contracture.
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1.2 AETIOLOGY
Dupuytren’s disease typically affects elderly men of Northern European descent. 
Prevalence varies widely according to the selected population, ranging from 2 to 42% (Ross 
1999). This is not purely an environmental coincidence: it is underpinned by a genetic 
predisposition, since the high prevalence follows Northern Europeans to warmer climes 
such as Australia (Hueston 1962). The possible mode of inheritance appears, in several 
cases, to conform to a Mendelian autosomal dominant trait with variable penetrance (Ling 
1963; Matthews 1979).
Genetic studies have yet to detect a specific gene or set of genes as the primary origin of 
Dupuytren’s disease, although research into possible associations with different genetic 
polymorphisms may provide the first breakthrough. Bayat and colleagues (Bayat et al. 
2003) have unravelled an association between Dupuytren’s disease and allele frequency of 
a transcription factor (Zinc finger 9) for transforming growth factor p (TGF P), a pro- 
fibrotic gene. More recently, Hu and colleagues (Hu et al. 2005) established genetic linkage 
in a Swedish family affected by Dupuytren’s, pinpointed to a region on chromosome 16. 
The locus harbours several interesting candidate genes, including some encoding matrix 
metal loproteinases.
Development of disease appears to be contingent on an environmental trigger as well as a 
genetic predisposition. Smoking and excessive alcohol intake are independent risk factors 
for disease development, and in both cases the relation is dose dependent (Godtfredsen et 
al. 2004). Chronic liver disease is not a risk factor independent of alcohol consumption 
(Attali et al. 1987). The condition is more prevalent among diabetics, especially those 
dependent on insulin (Godtfredsen et al. 2004). Controversy exists as to the significance of 
either anticonvulsant drugs or epilepsy (Critchley et al. 1976; Arafa et al. 1992). As many 
studies have established a relation between Dupuytren’s disease and manual labour as have 
refuted one (McFarlane 1991). Most experts would concede, however, that a one-off hand 
injury can rarely trigger Dupuytren’s disease, but that a history of manual labour indicates a 
worse prognosis.
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1.3 ANATOMY
1.3.1 Normal anatomy
An appreciation of the normal anatomy is key to understanding the deformities associated 
with Dupuytren’s disease and the surgical basis of their correction. Dupuytren’s disease 
affects the palmar fascial complex (PFC) -  a tough aponeurotic sheet that lies deep to the 
dermis and fans outwards from the wrist, taking origin from the palmaris longus tendon, 
where present (Ritter 1973), or, if absent, from the flexor retinaculum. The PFC proceeds 
distally across the volar aspect of the palm as a woven 3-dimensional fascial framework 
terminating in the digital fascia. The PFC serves to support the palmar skin against 
compressive and shearing forces, to protect deeper structures, and to maintain the 
transverse arch and cupping of the hand through fixation to the metacarpals. It also allows 
conformation of the palmar skin to assist grasping objects.
Grayson's
ligamant
Neurovascular
bundle
Natatory
ligament
Spiral
band
Pretendinous
band
Figure 1. Normal anatomy o f the digital fascia (left) and pathological fascial structures associated with 
Dupuytren’s disease (right).
Cleland's
ligament
Lateral
digital
sheet
Lateral
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cord
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cord
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1.3.2 Pathological anatomy
The lesions o f Dupuytren’s disease can be explained in terms o f involvement of different 
elements of the PFC. The normal bands and ligaments of the PFC are the precursors o f the 
diseased nodules and cords, the two main lesions observed in Dupuytren’s disease (Figure 
1). Nodules are firm fleshy masses that form along the lines of the longitudinal fibres of the 
palm (McGrouther 1982), usually superficial to the pretendinous band. Cord is the term 
used to describe affected bands (Luck 1959). Cords are prone to contracture, resulting in 
progressive shortening of the diseased fascia and subsequent digital flexion deformity. The 
continuity between palmar and digital fascia ensures that contracture is continuous from 
palm to digit.
1.3.3 Microscopic anatomy
Nodules and cords are discrete entities that relate to different stages o f disease, which can 
be readily distinguished by histological analysis in addition to clinical observation. The 
nodule is a highly vascularised tissue containing a high population o f fibroblasts, with a 
distinct subset of myofibroblasts (Vande Berg et al. 1984; Bisson et al. 2003). The cord, by 
contrast, is relatively acellular with a paucity of myofibroblasts, but a high collagen content 
when compared to the nodule. The distinction is important because fibroblasts derived from 
nodules behave differently from fibroblasts derived from cord (Bisson et al. 2004) and 
therefore merit separate investigation.
1.4 PRESENTATION
Pitting and thickening of the palmar skin are the earliest manifestations of Dupuytren’s 
disease, but the key to early diagnosis is recognition of the nodule, a firm painless mass 
fixed to skin and deeper fascia that is pathognemonic of Dupuytren’s. Nodules can be 
encountered in the palm or digits and classically precede development of cords which form 
firm tendon-like structures (Rayan 1999). Contraction of cords results in predictable 
deformity as they cross joints (Table 1): the palmar cords (pretendinous) cause flexion 
contracture at the metacarpophalangeal (MCP) joint; the digital cords (lateral, central,
5
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spiral) contribute to proximal interphalangeal (PIP) joint contracture. The spiral cord is 
responsible for both PIPJ contracture and superficial displacement of the neurovascular 
bundle, making it more susceptible to accidental division at surgery.
NORM A L PA T H O LO G IC C L IN IC A L
STRU CTU RE CO R D E FFE C T
Pretendinous band Pretendinous cord MCPJ deformity
Central fibrofatty tissue Central cord PIPJ deformity
Displaces neurovascular
Spiral band Spiral cord bundle superficially
Lateral digital sheet Lateral cord P1PJ/D1PJ contracture
Table 1. The normal anatomical palmar fascial precursors o f  the pathological structures observed in 
Dupuytren’s disease and their clinical effect.
Contracture is a common presenting complaint (Figure 2), although it may be the fear of 
malignancy or embarrassment of a handshake that precipitates initial consultation. The 
main consequence is impaired function. Contractures can affect activities at the work place 
(manual labour, wearing gloves) and in the home (washing, dressing), posing a threat to 
independence and dignity.
The condition is frequently bilateral and often associated with involvement of other areas of 
the body, so called ectopic disease; Garrod’s knuckle pads (44-54%), plantar fibromatosis 
(Ledderhose disease, 6-31%) and penile fibromatosis (Peyronie’s disease, 2-8%) (Rayan 
1999). A diathesis is recognised in Dupuytren’s and describes disease affecting young 
Caucasian men with a strong family history, bilateral involvement, severe disease and 
ectopic manifestations. Recognition of this clinical type is essential as it carries with it a 
more serious prognosis and warrants aggressive follow-up and treatment.
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Figure 2. Dupuytren’s disease affecting the little finger. MCPJ and PIPJ contracture due to a tight cord o f  
tissue.
1.5 TREATMENT
The majority of patients with Dupuytren’s disease do not require treatment and can be 
managed expectantly as disease often remains confined to the palm and does not progress 
to digital flexion deformity (Rayan 1999). Intervention is almost exclusively surgical and 
should be considered where function is impeded or where deformity is disabling. Referral 
to a specialist is advisable when contracture develops, because the longer deformity 
prevails, the greater the chance of joint contracture becoming irreversible, with ligaments 
remodelling in the contracted position.
1.5.1 Non-operative management
Despite much unravelling of the biochemical and cellular processes underlying 
Dupuytren’s Disease, there has so far been no translation into medical treatment. Several 
non-operative treatments, including radiotherapy (Keilholz et al. 1996), ultrasonic therapy
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(Stiles 1966), steroids (Ketchum et al. 2000), topical vitamin A (Shelley et al. 1993), 5-FU 
(Bulstrode et al. 2004), gamma interferon (Pittet et al. 1994) and the enzyme, collagenase 
(Badalamente et al. 2002) have been assessed. However, none has gained popularity.
The continuous elongation technique (TEC) was pioneered as a non-operative means of 
correcting contracture (Messina et al. 1993). The digits are subjected to mechanical tension 
on an adjustable frame that slowly extends them until they are straight. Although reduction 
in contracture is usually achieved, recurrence often occurs rapidly unless surgical excision 
is subsequently performed, making this technique most suitable as a preparatory step for 
surgery.
1.5.2 Surgical correction
The aim of surgery is to restore function and correct deformity with minimal complications. 
Broadly speaking, surgical options involve either fasciotomy, in which the cord is simply 
divided, or fasciectomy, in which the diseased fascia is excised. Fasciectomy can be either 
limited, where all macroscopically diseased tissue is excised, or segmental, where only 
segments of the diseased tissue are removed (Moermans 1996). Intraoperative 
complications are rare (1-2%) but include digital nerve or vessel injury and buttonholing of 
skin flaps (Bulstrode et al. 2005). In the early postoperative period, heamatoma, infection 
and flap necrosis occur relatively frequently (19%) (McFarlane 1983). Such wound 
complications may be reduced by segmental fasciectomy, which involves a more minimal 
dissection compared to limited fasciectomy (Moermans 1996).
1.5.3 Recurrence
Although surgery corrects contracture, it does not cure disease. Over time, recurrence is 
likely, with new Dupuytren’s tissue appearing within areas previously cleared at operation, 
and the disease extending into previously untreated areas (Figure 3, Table 2). Recurrence 
appears to be an early postoperative event that particularly affects young patients (Hueston 
1963) and those with aggressive disease (Rodrigo et al. 1976).
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Figure 3. Recurrent Dupuytren’s disease affecting the little fingers. Multiple recurrences o f  Dupuytren’s 
disease in the left hand has led to amputation.
STUDY PATIENTS
(hands)
FOLLOW -UP
(years)
RECURRENCE
(% )
EXTENSION
(% )
FASCIOTOM Y
(Foucher et al. 2003) 100 3.2 58 11
LIM ITED FASCIECTOM Y
(Rom bouts ct al. 1989) 63 (77) 5.3 39 32
(Makela et al. 1991) 127 (153) 3.2 27 7
(Foucher et al. 1992) 54 (67) 5.6 41 39
(Moermans 1996) 141 (173) 2.9 47 31
(Armstrong et al. 2000) 103 (143) 5.8 8.4 *
Table 2. Reported recurrence and extension rates o f  Dupuytren’s disease. 
♦Numbers not available in published series.
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1.6 CONSIDERATIONS IN DUPUYTREN’S PATHOGENESIS
1.6.1 Mechanical tension
Mechanical tension has been proposed as a cause or trigger of Dupuytren’s disease. In part, 
this relates to the much debated possible association between Dupuytren’s and manual 
labour or trauma. Circumstantial evidence and clinical observations add weight to the 
suggestion that mechanical tension is an important influence in disease pathogenesis. A 
reduced mechanical load applied exogenously to a scar in vivo modifies the wound healing 
response, leading to a finer resultant scar (Meyer et al. 1991). In a clinical trial investigating 
the influence of mechanical tension on Dupuytren’s disease (Citron et al. 2003), patients 
with isolated metacarpophalangeal joint contracture were assigned to fasciotomy through 
one of two incisions, transverse or longitudinal. Longitudinal incisions were closed with z- 
plasties to reduce skin tension. Recurrence rates were significantly reduced in the 
longitudinal incision group leading the investigators to propose that mechanical tension is a 
contributing factor to Dupuytren’s pathogenesis. This observation has not been 
substantiated by further clinical studies (Citron et al. 2005). However, as will be 
subsequently shown, mechanical tension is an important influence on fibroblast behaviour 
in vitro although its role in disease pathogenesis remains to be determined.
1.6.2 Similarities with wound healing
Although Dupuytren’s tissue appears to have several features in common with neoplastic 
conditions (McFarlane 1990; Jemec et al. 1999), the disease evolves at the cellular and 
connective tissue level, similar to a healing wound (Fitzgerald et al. 1999). As well as 
fibroblast proliferation, both conditions are marked by extracellular matrix deposition. 
Similarly, the myofibroblast, a fibroblast derivative associated with contractile force, is 
prominent in both granulation tissue, where it assists wound closure, and Dupuytren’s 
tissue. Growth factor production, stimulated by injury, is essential for coordinating repair in 
the healing wound. Similarly, upregulation of various growth factors and their receptors 
also occurs in Dupuytren’s tissue (Baird et al. 1993) and may propagate the disease process.
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The above observations suggest that many of the matrix and cellular events that are 
common to wound healing also occur in Dupuytren’s disease, but without the same level of 
control. Whereas wound healing is induced by dermal injury, there is no obvious 
precipitating event identifiable in Dupuytren’s disease, although hypoxia-induced free 
radicals and microtrauma to collagen fibres have been identified as possible triggers 
(McGrouther 1982; Murrell et al. 1987). Moreover, wound healing proceeds in a very 
regulated manner, delivering new epithelialised dermis in a very time-specific and 
controlled way. The response subsides as wound closure occurs and resolution or repair is 
achieved. By contrast, the disease process in Dupuytren’s is uncontrolled, leading to a 
persistent or progressive response similar to the pathological healing response that defines 
keloid and hypertrophic scarring.
1.7 THE EXTRACELLULAR MATRIX
The extracellular matrix (ECM) is the environment in which cells are embedded. It 
provides a supportive scaffold through a network o f macromolecules and acts as an 
important reservoir of biologically active molecules. It therefore contains the necessary 
components to protect and guide cell movement and provides an intricate molecular milieu 
capable of influencing and participating in cell signalling as well as facilitating cell 
behaviour such as growth, differentiation and migration (Lin et al. 1993). The ECM is not a 
passive, static structure, but rather a dynamic organisation, evolving to meet the 
requirements of an environment subject to mechanical and biological changes. Together, 
the ECM and the cells embedded in it form connective tissue, which provides the 
connecting and structural framework of the body. An appreciation of the reciprocal 
relationship between cells and the ECM is integral to gaining insight into the abnormalities 
underlying connective tissue diseases such as Dupuytren’s disease. Cells such as fibroblasts 
produce matrix components and can therefore determine ECM composition. Conversely, 
the ECM can influence cell behaviour by sequestering signalling molecules, such as growth 
factors and growth-factor binding proteins, and by acting as ligands for cellular adhesion 
receptors, such as integrins, that transduce signals to the interior (Streuli 1999).
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There are four major classes of macromolecules that make up the ECM -  collagens, 
proteoglycans, glycoproteins and elastin (Haralson et al. 1995). Collagen is the most 
abundant protein in the body (van der Rest et al. 1991). Collagen in fact encompasses a 
large family of structurally similar molecules predominantly synthesised by fibroblasts that 
share a characteristic triple helical arrangement. Type 1 is found in all connective tissues 
(skin, tendon, bone etc.); type II occurs in hyaline cartilage, and type III in distensible 
tissues (skin, lung, vessels). Collagen types I, II and III are the major fibrous collagens 
providing structural support, whereas, type IV has a mesh-like structure and is an important 
constituent of basement membranes where it aids filtration (e.g. glomeruli in the kidney). 
Alterations in collagen structure account for numerous diseases; for example, osteogenesis 
imperfecta and Ehlers-Danlos syndrome. The glycoproteins include fibronectin, an 
important cell-adhesion molecule, and laminin, another component of basement 
membranes. Elastin is a structural protein that confers distensibility on tissues. ECM 
production is controlled by cell type, cell number and many growth factors, whereas matrix 
breakdown is controlled by specific proteases, the matrix metalloproteases (Haralson et al. 
1995).
All matrix proteins can interact both with cells, through specific cell surface receptors, and, 
other matrix molecules through specific binding domains. The result is a fusion of matrix 
molecules and cells that are in constant communication, enabling maintenance of tissue 
structure and adaptation of function. These qualities are especially important in guiding 
embryogenesis and tissue repair. However, changes in matrix metabolism (both in synthesis 
and degradation) are associated with a number of acquired diseases, including Dupuytren’s 
contracture (Tomasek et al. 2002).
1.8 CHANGES IN THE ECM IN DUPUYTREN’S DISEASE
1.8.1 Collagen
There are two major abnormalities of collagen synthesis in Dupuytren’s tissue compared to 
normal palmar fascia. Firstly, there is an overall increase in the collagen content of
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Dupuytren’s tissue and secondly, there is an abundance of type-1 II collagen, which is 
virtually absent in normal palmar fascia (Menzel et al. 1979; Gelberman et al. 1980; 
Brickley-Parsons et al. 1981). These changes mirror those occurring in the granulation 
tissue of dermal wounds and hypertrophic scars (Bailey et al. 1975). However, whereas the 
stimulus for continued type III collagen disappears in a normal healing wound as the scar 
matures, such stimulus inexplicably persists in Dupuytren’s disease. It has been proposed 
that the increase in newly synthesised collagen encountered in Dupuytren’s tissue may be 
accounted for by an increase in fibroblast density rather than an aberration in collagen 
production (Murrell et al. 1991).
A defining feature of Dupuytren’s disease is tissue contracture, specifically a progressive 
shortening of the longitudinal axis of the palmar fascia. In theory, this contracture could 
result from a change in the collagen organisation through either fibril plication or 
shortening by disruption o f the triple helical structure of collagen. However, x-ray 
diffraction studies indicate that there is no evidence of either plication or collagen 
denaturation (Brickley-Parsons et al. 1981). In fact, the alignment of collagen fibrils in 
Dupuytren’s palmar fascia is, if anything, better than seen in controls and is therefore an 
unlikely source o f contracture.
1.8.2 Proteoglycans
Kozma (Kozma et al. 2005) demonstrated significant differences in the proteoglycan profile 
of Dupuytren’s tissue compared to normal palmar fascia. Specifically, increased amounts o f 
biglycan and chondroitin sulphate were found in Dupuytren’s tissue, together with 
significant alterations in the chain structure of decorin. Proteoglycans play a role in matrix
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assembly and can influence matrix permeability. It was therefore postulated that the 
observed proteoglycan changes might affect the matrix properties and disease progression.
1.9 MYOFIBROBLASTS
The term ‘myofibroblast’ derives from the morphological features the cell shares in 
common with both fibroblasts and smooth muscle cells. Myofibroblasts were first observed 
in the granulation tissue of healing wounds (Gabbiani et al. 1971), but have subsequently 
been identified in many fibrotic tissues, including Dupuytren’s (Gabbiani et al. 1972). 
Rayan and Tomasek (Rayan et al. 1994) demonstrated that myofibroblasts in Dupuytren’s 
disease are likely to derive from differentiation of fibroblasts, as opposed to smooth muscle 
cells. Fibroblasts from normal palmar aponeurosis cultured within a collagen lattice 
acquired morphological characteristics, including stress fibres similar to myofibroblasts in 
Dupuytren’s diseased fascia.
Myofibroblasts are virtually absent from normal dermis and normal palmar fascia (Bisson 
et al. 2003). They do occur in normal wound healing as the differentiation of fibroblast to 
myofibroblast facilitates wound contraction and re-epithelialisation. After successful 
resolution or repair of a wound, myofibroblasts undergo apoptosis and disappear. However, 
in pathological scarring conditions such as keloid and hypertrophic scars, myofibroblasts 
persist (Ehrlich et al. 1994). The presence of myofibroblasts is in fact a common finding in 
many fibrotic diseases (Thannickal et al. 2004) including Dupuytren’s disease, they have 
been associated both with the involutional stage of disease (Meister et al. 1979) and with 
nodule phenotype (Hueston et al. 1976). Furthermore, McCann (McCann et al. 1993) 
suggested that the presence of dermal myofibroblasts may be linked to recurrence after 
surgery. The role of myofibroblasts in generating contractile force will be discussed in 
subsequent sections.
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1.10 GROWTH FACTOR CHANGES IN DUPUYTREN’S DISEASE
Growth factors are naturally occurring polypeptides that influence a wide range of cellular 
activities such as migration, proliferation, differentiation and matrix synthesis. There is 
increasing evidence that various growth factors play an important role in the 
pathophysiology of Dupuytren’s disease (Badalamente et al. 1999; Cordova et al. 2005).
Similar to the healing wound, Dupuytren’s tissue is an environment rich in biologically 
active molecules. Platelet-derived growth factor B (PDGF-B), basic fibroblast growth 
factor (bFGF), and transforming growth factor-pi (TGF-pi) have been found in increased 
levels in Dupuytren’s tissue, together with increased levels of their receptors (Gonzalez et 
al. 1992; Terek et al. 1995; Badalamente et al. 1996). PDGF-a stimulates cellular 
proliferation, whereas TGF-pl induces myofibroblast differentiation and collagen 
production (Alioto et al. 1994; Tomasek et al. 2002) -  all fundamental processes in 
Dupuytren’s pathogenesis. Augoff (Augoff et al. 2005) observed that epidermal growth 
factor (EGF) varies with the stage of disease and may be particularly important in 
contracture development.
1.11 MATRIX REMODELLING
Fibroblasts possess the ability to remodel the surrounding extracellular matrix through a 
combination of matrix degradation, synthesis and organisation. These activities are critical 
for maintaining tissue homeostasis during development and in response to injury. The 
interaction nurtured between cells and the ECM is both dynamic and reciprocal. The matrix 
communicates with cells both directly, through interaction with cell surface proteins to 
initiate signal transduction pathways and indirectly, through release or activation of 
sequestered growth factors. Hence, modulation of the ECM through the remodelling of its 
structure and activity can profoundly influence function of both the matrix and the cells 
residing within it. Any remodelling process inevitably involves the removal of matrix
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molecules and although many enzymes participate, matrix degradation is largely mediated 
by matrix metal loproteinases.
1.12 MATRIX METALLOPROTEINASES (MMPS)
The matrix metal loproteinases (MMP) are a family of zinc-dependent endopeptidases that 
cleave extracellular matrix (ECM) components and participate in many biological 
processes. Several reviews have been consulted to crystallise information in this section 
(Nagase et al. 1999; Visse et al. 2003; Lemaitre et al. 2006; Nagase et al. 2006). Through 
matrix resorption, MMPs facilitate tissue remodelling, cell migration and release of 
biologically active molecules that regulate fundamental cellular processes such as 
proliferation, growth, signalling and differentiation. In addition to matrix substrates, MMPs 
also cleave cell surface molecules and pericellular non-matrix proteins such as clotting 
factors and other proteinases. At the tissue level, MMPs influence diverse physiological 
processes such as embryonic development, tissue morphogenesis and wound repair. There 
is also an accumulating body of evidence that implicates MMP activity in numerous 
pathological processes such as arthritis, glaucoma, atherosclerosis and cancer.
MMPs are distinguished from other metalloproteinases by a highly conserved motif 
containing three histidines that bind zinc at the catalytic site and by a conserved methionine 
turn that sits beneath the active site zinc. Figure 4 illustrates the generic domain structure of 
MMPs. They are either secreted from the cell as inactive zymogens, requiring activation, or 
anchored to the cell membrane. Each MMP has distinct but often overlapping substrate- 
specificities and together they can cleave all ECM proteins (Stemlicht et al. 2001). The 
characteristic of redundancy safeguards against any loss of MMP activity but underlines the 
complexity of the MMP family, making it difficult to associate individual MMPs with 
specific functions or disease processes.
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In addition, they may also have:
□  Cysteine switch 
S 3  Hinge region
cT~ "" Haemopexin-like domain
Figure 4. General domain structures o f  MMPs. The lengths o f  the domains are not drawn in proportion to the 
actual number o f  amino acid residues.
Twenty-three MMPs have been described in humans, which, depending on substrate 
specificity, sequence similarity and domain structure, are assigned to different groups -  
collagenases, gelatinases, stromelysins, matrilysins and membrane-bound MMPs. Table 2 
illustrates the common MMPs described in humans.
Collagenases are distinguished by the ability to cleave the triple helix o f  interstitial
collagens I, II and III. Gelatinases readily digest denatured collagens and gelatins.
Stromelysins share similar structure and substrate specificity, and, in addition to digesting 
ECM components, strom elysin-1 activates several proMMPs, such as MMP-1. Matrilysins 
process cell surface m olecules and ECM components. The membrane-type MMPs (MT- 
MMPs) are characterised by the presence o f  a transmembrane domain and are involved in 
the activation o f  proM M Ps as well as matrix processing.
All MMPs include:
c = i  Signal peptide 
Pro-domain 
Catalytic domain
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Enzyme Common name M atrix Substrates
MMP-1 Collagenase-1 Collagen I, II, III, VII, aggregan
MMP-2 Gelatinase A
Gelatin, Collagen I, IV, V, VII, X, 
fibronectin, tenascin, fibrillin
MMP-3 Stromelysin-I
Collagen IV, V, IX, X, fibronectin, 
gelatin, laminin
MMP-7 Matrilysin
Collagen IV, elastin, fibronectin, 
laminin, tenascin
MMP-8 Collagenase-2 Collagen I, II, III, aggregan
MMP-9 Gelatinase B
Gelatin, Collagen IV, V, VII, XI, 
elastin, fibrillin
MMP-10 Stromelysin-2
Collagen IV, V, IX, X, fibronectin, 
gelatin, laminin
MMP-11 Stromelysin-3 Fibronectin, laminin
MMP-12 Metal loelastase
Collagen IV, fibronectin, gelatin, 
laminin, elastin, fibrillin
MMP-13 Collagenase-3
Collagen I, II, III, IV, VII, IX, X, 
gelatin, fibronectin, laminin
MMP-14 MT1-MMP
Collagen I, II, III, gelatin, laminin, 
vitronectin
MMP-15 MT2-MMP
Fibronectin, laminin, aggrecan, 
tenascin, nidogen
MMP-16 MT3-MMP
Collagen III, fibronectin, gelatin, 
cartilage, proteoglycan
MMP-17 MT4-MMP Gelatin
MMP-20 Enamelysin Amelogenin
Table 3. A list o f  MMPs that have been demonstrated in humans.
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1.12.1 Regulation of MMP activity
In order that MMP proteolysis does not lead to widespread matrix destruction, MMPs must 
be activated or inhibited appropriately. Control is essential. Hence, MMPs are tightly 
regulated at the transcriptional and post-transcriptional levels. Control is also exercised at 
the protein level via activators and inhibitors (Figure 5).
The level of MMP expression is very low in vivo and in unstimulated cells in vitro. 
However, MMP expression is induced by various signals, including growth factors, 
cytokines, physical stress and cell-matrix and cell-cell interactions. In fact, the biologic 
function o f individual MMPs is largely dictated by their differential patterns of expression, 
since substrate specificities often overlap and are therefore not necessarily distinguishing 
features. Thus, most MMPs are tightly regulated at the level of transcription, with the 
exception of MMP-2, which is often controlled through enzyme activation. Post- 
transcriptional mechanisms of control include stabilisation of mRNA transcripts by phorbol 
esters (MMP-1, MMP-3) or hormones (e.g. glucocorticoids, MMP-13). Following 
translation of mRNA transcripts, most MMPs are constitutively secreted with the exception 
of those integrated into the cell membrane.
MMPs are secreted as inactive zymogens that are mostly subsequently activated by 
cleavage of a pro-domain. Exceptions include MMP-11 and MT1-MMP, which are 
activated intracellularly by Golgi-associated proteases prior to secretion (MMP-11) or 
membrane expression (MT1-MMP). Individual enzyme activation occurs in a stepwise 
fashion whilst collectively, MMPs are activated in a cascade, enabling finer regulatory 
control. Activated MMPs can participate in the processing of other MMPs. Activation by 
plasma proteinases such as plasmin appears to be an important physiological pathway in 
vivo. ProMMP-2 is not readily activated by general proteinases. Instead, activation of pro- 
MMP-2 takes place on the cell surface and is mediated by MT-MMPs including MT1- 
MMP.
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Secretion °  o°
°  o°
C e ll m e m b r a n e  o °  o  °
i:
j  1. Transcription
2. Translation
•  •  o
3. Activation
I
4. Inhibition o f enzyme 
activity (e.g. by TIMPS)
Figure 5. Regulation o f  MMP activity occurs at many different levels ranging from gene transcription, 
through protein production, to activation and inhibition o f  secreted enzymes. Most MMPs are constitutively 
secreted.
1.12.2 Endogenous MMP inhibitors
The tissue inhibitors o f  matrix metalloproteinases (TIMPs) represent a family o f at least 
four secreted proteins that are the major endogenous inhibitors o f  MMP activity in the 
tissue. They reversibly inhibit MMPs in a 1:1 stoichiometric fashion. Individual TIMPs 
differ in their tissue-specific patterns o f gene expression, as well as in their ability to inhibit 
various MMPs. In addition to their metalloproteinase inhibitory activity, TIMPs 
demonstrate additional biological functions. TIMP-1 and TIMP-2 have growth-promoting 
effects that are independent o f their effect on MMP activity. Conversely, TIMP-3 has been 
shown to induce apoptosis o f  human colon carcinoma cells (Smith et al. 1997). 
Furthermore, TIMP-2 is required in the activation o f proMMP-2 mediated by MT1-MMP 
(Wang et al. 2000). The plasma protein, a2-macroglobulin, is an additional MMP inhibitor 
that may be important in tissue fluids, whereas TIMPs may act more locally.
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The net balance of MMP activity in the extracellular space is therefore the result of an 
intricate, multidimensional system of regulation that sets a physiological level of matrix 
turnover for normal biological processes.
1.12.3 MMPs in disease
Aberrant MMP expression occurs in several disease states including tendon degeneration, 
arthritis, atherosclerosis, gastric ulcers, fibrotic diseases and cancer. Although the precise 
pattern appears to be disease-specific, a few common threads run through all conditions. 
Firstly, it is the collective influence of abnormal MMP activity that is implicated in the 
pathogenic process, rather than the influence of individual MMPs, as evidenced by gene 
disruption experiments (knockout mice). Individual MMP deficiencies (e.g. MMP-2, -3, -7 
or -9) have little impact on mouse phenotype, presumably because other MMP family 
members with overlapping substrate specificities can compensate (Mudgett et al. 1998; 
Haro et al. 2000; Itoh et al. 2002). Secondly, the ratio of MMP-to-TIMP activity is 
frequently modified, favouring a net increase in MMP activity and unregulated ECM 
turnover.
Neely (Neely et al. 1999) demonstrated that MMP-2 activity is increased in hypertrophic 
and keloid scar tissue, two fibroproliferative conditions similar to Dupuytren’s disease. 
Riley (Riley et al. 2002) established an increase in MMP-1 activity associated with rotator 
cuff tendon degeneration and rupture. Furthermore, distinct MMP gene expression profiles 
have been demonstrated for normal, painful and rupture Achilles tendons (Jones et al. 
2006). In rheumatoid arthritis, active forms of MMPs (1, 3, 9) are expressed by synovial 
cells and are upregulated by inflammatory cytokines such as interleukin-1 (IL-1) and 
tumour necrosis factor a  (TNFa) (Mengshol et al. 2002), which has been the focus of s 
possible therapeutic strategy (Jain et al. 2002). By contrast, T1MP levels do not appreciably 
increase, or may even decrease, leading to an imbalance in the MMP-to-TIMP ratio, which 
favours MMP-mediated joint destruction (Malemud 2006). MT1-MMP knockout mice 
develop dwarfism, arthritis and a prominent fibrotic synovitis (Holmbeck et al. 1999). 
Conversely, treatment with a broad-spectrum MMP inhibitor, G il68, significantly reduced
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ankle swelling and cartilage destruction in an experimental arthritis model (Conway et al. 
1995).
There is an abundance of circumstantial clinical evidence to suggest that MMPs play a 
salient role in cancer progression. MMPs can degrade basement membrane ECM proteins 
that may facilitate tumour invasion into surrounding connective tissues (Zucker et al. 2004). 
MMP-2, which is normally expressed in stromal cells, where it promotes migration 
(Giannelli et al. 1997), is highly elevated adjacent to metastasising carcinomas (Li et al. 
2005). Similarly, serum MMP-2 levels have been shown to correlate with both the presence 
of pulmonary metastases and the response to therapy (Garbisa et al. 1992). In addition, 
MMP-2 and MMP-9 have been associated with progression from benign to advanced 
ovarian carcinoma (Schmalfeldt et al. 2001) and with survival in gastric carcinoma (Sier et 
al. 1996).
1.12.4 MMPs in Dupuytren’s Disease
Little work has been undertaken to establish the precise role of MMPs in Dupuytren’s 
disease. A few studies have looked directly at tissue levels and serum MMP expression. 
Qian (Qian et al. 2004) demonstrated an upregulation of MMP-2 expression in Dupuytren’s 
tissue excised at surgery, compared to adjacent (uninvolved) tendon. Furthermore, in one 
study (Tarlton et al. 1998), a direct relationship was found between mechanical stress and 
release of MMP-2 by Dupuytren’s tissue in vitro. However, the pattern of tissue-level 
mRNA expression does not appear to match serum MMP levels. Ulrich and colleagues 
(Ulrich et al. 2003) measured serum MMP levels in 22 Dupuytren’s patients by enzyme- 
linked immunosorbent assay. Dupuytren’s patients were shown to have elevated TIMP-1 
serum levels compared to controls, but no significant differences in MMP-1, MMP-2 and 
MMP-9 serum concentrations. Furthermore, Dupuytren’s patients had a significantly lower 
MMP-to-TIMP ratio compared to controls, which was postulated to reflect increased 
collagen synthesis over degradation, thus favouring matrix deposition. However, snapshot 
systemic enzyme levels may be a poor reflection of localised tissue activity. Furthermore, 
many external factors influence MMP expression, including conditions of blood collection
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(M eisser et al. 2005) and associations such as smoking, diabetes and alcohol consumption, 
that are common to this population.
1.13 MODELS OF TISSUE ORGANISATION
Fibroblast-populated collagen lattices (FPCLs) have been developed as in vitro models o f 
wound contraction, enabling cell-matrix interactions to be studied (Bell et al. 1979) and 
Fibroblast-mediated matrix contraction to be quantified. Fibroblasts cultured in three- 
dimensional collagen lattices demonstrate an ability to reorganise the collagen fibril 
network into a dense, tissue-like structure (Elsdale et al. 1972). Furthermore, fibroblasts 
exhibit functional, morphologic and metabolic characteristics, which are distinct from cells 
cultured in monolayer in vitro (Grinnell 2003). FPCLs therefore provide a valuable model 
for studying cell-mediated tissue organisation.
Changes in the mechanical environment can influence fibroblast behaviour (Brown et al. 
1998). Therefore, three variations o f  FPCLs (Figure 6) have been developed to investigate 
how mechanical load influences fibroblast-mediated matrix contraction (Grinnell 1994, 
1999, 2000, 2003). In the free-floating model, the fibroblast-embedded matrix is released 
from the culture-dish surface immediately after lattice polymerisation. The fibroblasts 
extend fine protrusions (stellate morphology) and remain mechanically unloaded as they 
contract the matrix. In these circumstances, they do not differentiate into myofibroblasts. In 
the attached model, the collagen lattice remains attached to the culture dish. Isometric 
tension develops as cells become bipolar in morphology, forming large extensions and 
stress fibres that are oriented along lines o f  tension. In the stress-release model, the lattice is 
attached to the culture dish for one or two days before release. Cells in the stress-release 
model develop stress fibres and isometric tension during lattice attachment, which is then 
dissipated on release as the cells revert to a stellate morphology concomitant with 
contraction.
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Each model is thought to represent a different stage o f wound contraction (Grinnell 1999). 
The free-floating lattice model resembles initial wound contraction, whereas, granulation 
tissue formation is represented by the attached lattice model and granulation tissue 
contraction, by the stress-release model. Contraction can be estimated either by reduction in 
lattice area (free-floating, stress-release models) or by lattice height (attached model). 
Although FPCLs provide a simple in vitro model o f fibroblast-mediated tissue organisation, 
they do not allow precise quantification o f matrix contraction, direction o f force or subtle 
manipulation o f mechanical load.
Free-floating Attached Stress-release
1 -5 days
M echanical
release
-5 days
Attached .
1 -2 days I
M echanical release
-5 days
ersprwic
Figure 6. The three FPCL models. In the free-floating model, lattices are released from the well periphery and 
allowed to contract immediately after lattice polymerisation. In the attached model, lattices remain attached, 
enabling the development o f  isometric tension. Lattices in the stress-release model are allowed to develop 
tension over 1 or 2 days before being released. Adapted from (Howard et al. 2003).
More recently, the culture force monitor (CFM, Figure 7), an in vitro kinetic model o f 
lattice contraction, has been developed (Eastwood et al. 1994; Eastwood et al. 1996; 
Eastwood et al. 1998). The CFM allows both precise quantification o f contraction and 
manipulation o f mechanical load. In this model, a fibroblast-populated lattice is attached at 
one end to a fixed strut and at the other, to a strain gauge, which detects lattice contraction. 
Unidirectional mechanical tension develops across the lattice by virtue o f its fixed 
attachments. The CFM model most closely approximates the attached FPCL model. Both
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can be used in parallel as they yield complementary information on the contractile 
behaviour o f  fibroblasts.
Fixed strut
External load 
can be applied
Strain gauge
Lattice contraction 
causes displacement
Figure 7. Culture Force Monitor. Collagen lattices are attached to a fixed strut at one end and a strain gauge at 
the other, which detects finite changes in contractile force developed by fibroblasts.
Table 4 provides a comparison o f the two models. Precise external mechanical loads can be 
applied across the lattice and the ensuing cellular changes monitored. The CFM model 
produces both accurate and reproducible readings, which have led to improved 
understanding o f fibroblast-ECM interactions in both normal and diseased tissue.
FPCL CFM
Advantages Sim ple Sensitive
Time-efficient Allows precise quantification of 
force generation
Multiple lattices can be run 
sim ultaneously
Allows subtle manipulation of 
m echanical load
E ase  of sam pling with minimal 
disruption
Sam pling disrupts m echanical 
environm ent due to sensitivity of 
equipm ent
Disadvantages Relatively insensitive to changes 
in force developm ent
Time-inefficient a s  only one 
lattice can be run at once
M echanical load fixed Expensive
Table 4. Comparison o f  benefits and drawbacks o f  FPCL and CFM models o f  matrix contraction.
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1.14 GENERATION OF CONTRACTILE FORCE
Myofibroblasts are characterised by the presence of a contractile apparatus containing 
bundles of actin microfilaments (termed ‘stress fibres’) and associated contractile proteins 
(Tomasek et al. 2002). Several studies have demonstrated that, in vitro, myofibroblasts can 
generate contractile force (Gabbiani et al. 1972; Hueston et al. 1976). In addition to 
expressing the (3- and y- cytoplasmic actins that are found in fibroblasts, myofibroblasts 
also express a-smooth muscle actin (Darby et al. 1990), which is considered to be the most 
reliable marker of myofibroblast differentiation (Serini et al. 1999). The actin bundles are 
arranged parallel to the long axis of the cell and terminate at the cell surface in the 
fibronexus, a specialised adhesion complex that links intracellular actin with extracellular 
fibronectin fibrils. In vivo, by contrast, fibroblasts in connective tissues lack the stress 
fibres observed in myofibroblasts.
Some have suggested that the increased contractile ability of myofibroblasts over 
fibroblasts may relate directly to a-SMA expression. Fibroblasts transfected with a-SMA 
cDNA exhibit significantly increased collagen lattice contraction compared to transfection 
with p~ or y- cytoplasmic actins (Hinz et al. 2001). Furthermore, expression of a-SMA by 
Dupuytren’s fibroblasts cultured in vitro has been shown to correlate with increased 
contractility (Tomasek et al. 1995).
Another distinguishing feature, indicative of their contractile nature, is that myofibroblasts 
are connected directly to each other through gap junctions (Gabbiani et al. 1978). This 
finding suggests the possibility that myofibroblasts can form multicellular contractile units 
during contraction, similar to smooth muscle cells.
The transformation of the fibroblast into the myofibroblast phenotype has been the subject 
of many studies reviewed by Gabbiani (Gabbiani 2003). The first changes in fibroblast 
modulation involve development of stress fibres, probably induced by mechanical stress 
(Tomasek et al. 2002). At this transient stage, the cell phenotype is termed 
protomyofibroblast. Under the influence of growth factors (e.g. TGF-pl) or a mechanical
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change in the extracellular matrix, the protomyofibroblast may further develop into a 
myofibroblast (Figure 8). The myofibroblast at this stage is characterised by the de-novo 
expression o f a-smooth muscle actin, and large supermature focal adhesion complexes. 
Bisson (Bisson et al. 2003) demonstrated that stimulation with TGF-pi resulted in an 
increase in the myofibroblast phenotype o f cultured Dupuytren’s tissue (both cord and 
nodule), but not o f control flexor retinaculum. As discussed previously, TGF-P 
upregulation and mechanical tension are both important features o f Dupuytren’s 
pathogenesis that may create an environment which, compared to normal palmar fascia, 
facilitates myofibroblast differentiation and the generation o f contractile force.
Nirteus
Mactunical
tension
Focal adhesion site
m: Corlical cytoplasm c  actinc
Cytoplasmic act ins
a  Cmooth musde act in
Fbicneclin
ED A libtoneclin
Proto-m yofibroblast
Differentiated m yofibroblast
TGF-M
ED A Ifcroneclin 
Mechanical tension
Figure 8. Myofibroblast differentiation. Adapted from Tomasek et al. 2002.
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1.15 THE INFLUENCE OF MECHANICAL TENSION ON MATRIX 
REMODELLING
A key parameter underlying regulation of tissue homeostasis and matrix remodelling is 
mechanical tension. All connective tissues appear to be under some sort of mechanical 
tension, even at rest: blood vessels dissected free of their fascial attachments have resting 
lengths 25-30% shorter than their in situ length (Tomasek et al. 2002). Fibroblasts are 
sensitive to mechanical forces and can change their surrounding ECM in response to 
changes in their mechanical environment (Brown et al. 1998). Responses to mechanical 
stimulation are dependent on cell type. However, in general, fibroblasts can respond to 
mechanical stimulation either through physical means - cell contraction or cell alignment - 
or, by modifying the balance between matrix synthesis and breakdown.
1.15.1 Mechanochemical transduction
Connective tissue cells must be able to sense strains (deformations) in the ECM caused by 
mechanical stress and to translate these into an adaptive response, such as an increase or 
decrease in ECM production. Several hypotheses have been put forward to explain 
mechanochemical transduction in non-neuronal cells (Chiquet et al. 1996). These include 
stretch-induced ion channels (Harter et al. 1995), altered response to growth factors and 
hormones through redistribution of cell surface receptors by a stress-induced change in cell 
shape (Adams et al. 1993), and transmembrane proteins such as integrins. In fact, there is 
increasing evidence that integrins, whose role in cell signalling is well established, can act 
as stretch receptors (Chiquet et al. 1997; Sheetz et al. 1998).
1.15.2 Matrix synthesis
Detection of a mechanical stimulus leads to an adaptive response that can activate ECM 
gene expression - a prerequisite for matrix remodelling. Mechanical load has been shown to 
promote procollagen synthesis in dermal fibroblasts both by enhancing gene expression and 
by posttranslational processing of procollagen (Parsons et al. 1999). Ultimately, regulation 
o f gene expression by mechanical stress can occur indirectly, by stimulating release of 
growth factors, or directly, by triggering an intracellular signalling pathway. Expression of
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most ECM components is likely to be controlled indirectly by mechanical stress, for 
example, by TGF-p-dependent induction of the procollagen I gene (Lindahl et al. 2002). 
However, evidence suggests that tenascin-C, a large ECM protein, is an example of a gene 
directly regulated by mechanical stress (Chiquet et al. 2003). In the latter, induction of 
tenascin-C mRNA was found to occur rapidly in fibroblasts under tension both in vivo and 
in vitro and to be independent of prior protein synthesis or growth factors released into the 
medium.
1.15.3 Matrix degradation - mechanical tension and MMP activity
MMP activity can also be regulated by mechanical tension, enabling fibroblasts to alter 
cell-matrix attachments, to influence cell movement and therefore adapt to the mechanical 
demands of the matrix. Dermal fibroblasts, seeded in a collagen lattice, were found to 
upregulate MMP-9 on cyclical loading, whereas, MMP-3 activity was reduced (Prajapati et 
al. 2000). Similarly, an upregulation of MMP-1 mRNA expression by dermal fibroblasts 
was detected on application of a biaxial load (Derderian et al. 2005). Conversely, in a 
stress-release collagen lattice model, release of mechanical tension resulted in an 
upregulation of MMP-3, -9, -13 and MT1-MMP (Lambert et al. 2001). Other studies have 
focused on the effect of mechanical load, as well as cell alignment on MMP expression in 
three-dimensional collagen lattices (Mudera et al. 2000). Fibroblasts aligned parallel to the 
load down-regulated MMP expression, whereas non-aligned fibroblasts increased MMP 
expression, perhaps to facilitate cell movement and remodelling and to promote alignment 
and stress shielding. Interestingly, TIMP activity was found to be poorly mechano- 
responsive, further highlighting the importance of MMP over TIMP activity in matrix 
remodelling.
1.15.4 Tensional homeostasis
Fibroblasts respond mechanically to mechanical signals in the matrix in order to maintain 
tension equilibrium in the tissue, a characteristic referred to as tensional homeostasis 
(Brown et al. 1998). Using a culture force monitor model, Brown and colleagues 
determined quantitatively how fibroblasts respond mechanically to defined tensional loads. 
This study demonstrated that fibroblasts seeded in a collagen lattice react to modify tension
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in the opposite direction from externally applied loads, thus maintaining a constant level of 
endogenous matrix tension or tensional homeostasis. Each tissue type has a distinct 
endogenous matrix tension, which is ‘set’ to meet specific functional requirements; for 
example, the resting tension maintained by aortic smooth muscle cells is likely to be much 
greater than exhibited by colonic smooth muscle cells. Failure of cell-mediated tensional 
homeostasis may therefore be important in disease.
1.16 EFFECT OF MECHANICAL TENSION ON DUPUYTREN’S FIBROBLASTS
Using an FPCL model, Howard (Howard et al. 2003) demonstrated that the synthetic 
capacity of Dupuytren’s fibroblasts varies with changes in isometric tension. Specifically, 
the expression of two ECM components associated with remodelling, p-catenin and 
fibronectin, increased in lattices cultured under stress (attached), but decreased following a 
reduction in isometric tension (release). On the other hand, expression by control 
fibroblasts was not sensitive to changes in mechanical tension. Similarly, Bailey and 
colleagues (Bailey et al. 1994) demonstrated an increase in MMP activity and new collagen 
synthesis in tissue samples excised from patients subjected preoperatively to TEC (and 
therefore to prolonged exposure to mechanical tension). The results suggested that 
mechanical tension induced a remodelling response in Dupuytren’s fibroblasts.
Studies on Dupuytren’s fibroblasts also suggest that defects in tensional homeostasis may 
occur in Dupuytren’s disease. Bisson (Bisson et al. 2004) demonstrated that Dupuytren’s 
fibroblasts contract in response to an externally applied mechanical load, in contrast to 
dermal fibroblasts, which respond by reducing tension (Brown et al. 1998). Similarly, 
Beckett (Beckett 2005) demonstrated that Dupuytren’s fibroblasts, seeded in a collagen 
lattice in the culture force model, continue developing tension over a 48-hour period, 
failing to reach a plateau phase of force generation. In contrast, control carpal ligament and 
dermal fibroblasts attained a plateau phase of force generation, assumed to be analogous to 
endogenous tissue tension.
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1.17 GENERATION OF CONTRACTURE: CONTRACTION AND 
REMODELLING
The hallmark of Dupuytren’s disease is connective tissue contracture. Contracture implies a 
process of permanent tissue shortening that cannot be explained either by increased matrix 
synthesis, which does not necessarily lead to tissue shortening (Brickley-Parsons et al. 
1981; Glimcher et al. 1990), or by cellular contraction, which is a rapid, reversible process 
and too energy-consuming to maintain tissue shortening long term. However, contractile 
force generated by myofibroblasts is a prominent feature of Dupuytren’s disease (Bisson et 
al. 2004) and likely to contribute to contracture, as myofibroblasts are frequently associated 
with scar formation and fibrocontractile conditions such as keloid scarring. Furthermore, 
contraction by myofibroblasts differs from that by smooth muscle cells, which can contract 
connective tissue for decades in the gut or vascular wall without leading to contracture 
(Tomasek et al. 2002). Collagen deposition is also a prominent feature of Dupuytren’s 
disease and an inseparable part of contracture, although it is not the root of tissue 
shortening, since the deposited collagen is neither folded nor plicated (Brickley-Parsons et 
al. 1981).
In fact, researchers (Guidry et al. 1987; Flint et al. 1990) have proposed that contracture is a 
result of two different processes working in parallel, that together lead to incremental, 
anatomical tissue shortening. The process is initiated by fibroblast contraction, which, 
through cell-matrix attachments, can exert a mechanical force or deformation on the matrix, 
leading to shortening. Remodelling of the matrix leads to synthesis of new matrix 
components that stabilise the new matrix configuration, holding it in the shortened position. 
This proposed cycle of myofibroblast contraction and matrix remodelling (Figure 9), coined 
‘slip and ratchet theory’ (Tomasek et al. 2002), can be repeated perpetually, leading to 
small incremental changes and eventual tissue contracture, without the loss of load-carrying 
function.
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a Adjacent myofibroblasts attach to collagen network
b Myofibroblast B contracts, deforming network B
c New collagen secretion stabilizes contracted structure of 
network B. relative to network A
^  New collagen
secretion
d Cell re-spreads and process is repeated 
Figure 9. ‘Slip and ratchet’ theory o f  matrix contracture. Taken from (Tomasek et al. 2002).
Evidence that force generated by myofibroblasts can be translated into a shortened collagen 
matrix that no longer requires active cellular contraction comes from stress-release collagen
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lattice models (Grinnell et al. 2002). Dermal fibroblasts seeded in a collagen lattice 
generated a tensile force that physically reduced the diameter of the lattice. Disruption of 
the cell cytoskeletal motor with cytochalasin-D (an alkaloid drug) resulted in an incomplete 
loss of tension, indicating that a proportion of the physical shortening of the lattice was due 
to a permanent spatial remodelling of the collagen, analogous to in vitro contracture.
These observations have been further developed using a culture force monitor model, 
which enables precise quantification of the remodelling component of lattice tension 
(Marenzana et al. 2006). Marenzana and colleagues demonstrated that the force generated 
by dermal fibroblasts across an isometrically constrained FPCL, was stabilised over time by 
a new, shorter matrix architecture that was able to resist significant tensional force. The 
fixed tension, termed ‘residual matrix tension’, retained within the remodelled collagen 
matrix, was enhanced by three factors: namely, time in culture, exposure to TGF-pi and 
cyclical loading. The strong time dependency suggested a rate-limiting process, such as the 
need for synthesis of new collagen to link existing fibrils, as required for dynamic spatial 
reorganisation. Both TGF-pi and cyclical loading promote collagen synthesis and force 
generation by fibroblasts, which could explain their influence on residual matrix tension.
Recent unpublished work (Beckett 2005) suggests that Dupuytren’s fibroblasts are able to 
remodel the surrounding matrix to a greater extent than control palmar fascia fibroblasts, an 
indication of their theoretical ability to generate contracture in vivo. Beckett demonstrated 
that the residual matrix tension developed in the culture force model was significantly 
greater in Dupuytren’s fibroblast-populated lattices compared to control fibroblasts. This 
process was shown to be time-dependent, as the discrepancy was not perceptible after 8 
hours of culture, whereas, after 48 hours, the difference between Dupuytren’s and control 
fibroblasts was significant. Interestingly, no collagen III deposition was detected in the 
surrounding matrix, suggesting that the residual matrix tension was due to spatial 
reorganisation of the existing collagen I lattice, as opposed to new collagen synthesis.
As discussed, any remodelling process inevitably requires matrix turnover, which is largely 
mediated by MMPs. The precise MMPs involved in matrix degradation leading to
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contracture is unknown, although MMP-1, -2, -3, and -9 have been proposed as possible 
candidates (Tomasek et al. 2002).
1.18 MMP INHIBITORS
As more has been uncovered about the functions and influence of MMP activity, various 
MMP inhibitors have been developed in anticipation of a potential clinical role in the 
prevention of progression of various diseases, notably cancer and arthritis.
1.18.1 Synthetic MMP inhibitors
Naturally occurring inhibitors, including TIMP-1 and TIMP-2, were initially considered as 
potential therapeutic agents for cancer and other diseases. However, technical difficulties 
have prevented their development into useful drugs. Subsequently, small molecules 
containing both hydroxamate and non-hydroxamate zinc bindings sites have been 
developed as synthetic MMP inhibitors (MPIs). These agents include ilomastat (N-L- 
tryptophan methylamide), batimastat and marimastat, which typically inhibit a broad- 
spectrum of MMPs, since the substrate structure can be recognised by multiple MMP 
family members (Skiles et al. 2004). The structure and substrate specificity o f ilomastat are 
demonstrated in Figure 10. Ilomastat is also known as galardin or GM6001. However, for 
the purposes of this thesis, it will, for consistency, henceforth be referred to as ilomastat.
1.18.2 Contraction
Several studies have demonstrated that inhibition of MMP activity reduces FPCL 
contraction in vitro and modulates the wound healing response in experimental in vivo 
models. Scott (Scott et al. 1998) demonstrated that FPCL contraction mediated by dermal 
fibroblasts was inhibited by marimastat. Sheridan (Sheridan et al. 2001) investigated the 
effects of galardin as well as various MMP antibodies on lattice contraction mediated by 
ocular fibroblasts. Collectively, antibodies to MMP-1, -2, -3 and -9 inhibited lattice 
contraction, although individually, they had no effect. Ilomastat inhibited contraction to an 
even greater extent than the combination of MMP antibodies, suggesting that numerous
34
Introduction
MMPs are involved in processing and remodelling of the collagen lattice during 
contraction. Daniels (Daniels et al. 2003) demonstrated a dose-dependent inhibition of 
ocular fibroblast-mediated FPCL contraction by ilomastat. The effect was reversible upon 
removal of ilomastat, suggesting that MMP activity plays an important role in lattice 
contraction.
MMP-3 = 27nM
Figure 10. Structure and selectivity o f  ilomastat. Picture taken from (Mirastschijski et al.), K, values from 
www.m erckbisciences.co.uk.
healing and an integral part of the contraction process (Wong et al. 2004). In an 
experimental model of wound healing, Mirastschijski (Mirastschijski et al. 2004) 
demonstrated that ilomastat inhibited wound repair, specifically epithelialisation, 
granulation tissue development and wound contraction, illustrating the importance of MMP 
function on remodelling processes. Interestingly, in this study, ilomastat did not affect 
TGF-pl mediated lattice contraction by dermal fibroblasts in the CFM model, suggesting 
that ilomastat does not directly block TGF-pl promotion of myofibroblast formation.
Selectivity of ilomastat (K j values) 
MMP-1= 400 pM 
MMP-2 = 500pM
MMP-8 =100pM 
MMP-9 = 200pM
Ilomastat has also been shown to affect epithelial cell migration, a prerequisite for wound
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However, ilomastat reduced a-SMA expression by fibroblasts in granulation tissue as well 
as wound contraction, and may therefore act indirectly by preventing TGF-(31 release from 
the ECM. In another study (Wong et al. 2003), ilomastat was found to reduce the 
postoperative scarring response following experimental glaucoma filtration surgery.
1.18.3 Clinical trials
The association of MMPs with tumour invasion, together with the positive results of 
preclinical studies on cancer models, has led to numerous clinical trials being undertaken. 
There have been some positive results of MPIs suggesting a survival advantage in advanced 
gastric carcinoma (Brown 2000) and a possible delay in progression in relapsed prostate 
cancer (Rosenbaum et al. 2005), although several trials have demonstrated no clear clinical 
benefit (Bramhall et al. 2001). Musculoskeletal side effects such as myalgia and arthralgia 
may limit use of MPIs to sub-therapeutic tissue levels (Wojtowicz-Praga et al. 1998; 
Rosemurgy et al. 1999; Hande et al. 2004). Furthermore, most trials recruit patients with 
advanced disease, although the therapeutic benefit of MPIs would be predicted to wane in 
the late stages of disease, after widespread tumour dissemination has occurred (Coussens et 
al. 2002). Clinical trials are ongoing in the expectation that MPIs have a definite place in 
cancer treatment. Through modification of trial design to recruit patients with earlier stage 
disease as well as improving the selectivity profile of MPIs to limit side effects, a 
framework will be created for uncovering the clinical potential of MPIs.
36
Introduction
1.19 INTRODUCTION TO THESIS
This thesis intends to investigate the effects of ilomastat, a broad-spectrum MMP inhibitor, 
on matrix contraction by Dupuytren’s fibroblasts in vitro, using two different collagen 
lattice models. In particular, we aim to determine the influence of MMP activity on spatial 
remodelling as well as cell-mediated contractile force development. It is intended that the 
results from this in vitro study will help to outline the possible therapeutic potential of an 
MMP inhibitor as an agent to prevent recurrence and progression of contracture.
1.20 QUESTIONS TO BE ANSWERED
1. Does ilomastat affect cell proliferation? Chapter 3
2. Does ilomastat mediate inhibition of FPCL contraction in a dose-dependent
manner? Chapter 3
3. Define differences in matrix contraction by cord, nodule and control fibroblasts 
and assess the pattern of inhibition by ilomastat for the three fibroblast types. 
Chapter 4
4. Which MMPs are important in matrix contraction by Dupuytren’s and control 
fibroblasts and how does ilomastat affect their pattern of activity and secretion? 
Chapter 4
5. Does ilomastat affect both components of lattice contraction, namely cell-
mediated contraction and matrix remodelling, in the CFM model? Chapter 5
6. Does ilomastat modulate MMP activity at the pre or post-transcriptional level?
Chapter 5
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 GENERAL CELL CULTURE
2.1.1 Tissue selection
Following local ethics committee approval (reference EC2002/97) and informed consent, 
fresh tissue specimens were collected from Mount Vernon Hospital theatres. Dupuytren’s 
tissue was obtained from patients undergoing primary fasciectomy; tissue from recurrent 
procedures was discarded. In addition, only specimens that included both an identifiable 
nodule and a length of pathological cord were selected. Identification of cord and nodule 
was carried out by the senior operating surgeon and the primary researcher per-operatively 
and confirmed by subsequent histological evaluation. Paired samples, in other words, cord 
and nodule tissue from the same patient, were chosen to limit interpatient variability and 
therefore to improve the strength of comparisons. When dissected of surrounding fatty and 
loose connective tissue, the specimen would often resemble a ‘drumstick’ shape (Figure 1). 
The tissue was sectioned longitudinally and one half was then used to establish cell 
cultures. The other half was fixed in 5ml 10% formal saline for 2 hours at room 
temperature prior to embedding in paraffin wax for subsequent histological examination. 
Carpal ligament was selected as the control tissue and obtained from carpal tunnel release 
in patients unaffected by Dupuytren’s disease.
Figure 1. Illustration o f  Dupuytren’s tissue. Panel A illustrates removal o f  Dupuytren’s tissue at primary 
fasciectomy. Panel B demonstrates diseased fascia dissected free o f  fatty tissue revealing a distinct cord (C) 
and nodule (N).
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2.1.2 Histology
The fixed specimens of Dupuytren’s tissue were embedded in paraffin blocks with a known 
orientation marked by ink, enabling accurate identification of the areas from which cells 
were harvested for explant culture. Representative sections of the embedded tissue were cut 
and stained with haematoxylin and eosin to confirm clinical typecasting of tissue as either 
nodule or cord. Paraffin blocks were sectioned at 4pm using a Reichert-Jung Microtome 
(Leica Instruments, Germany) and were mounted on glass slides (VWR International, 
Leuven, Belgium). Sections were dewaxed by bathing in xylene (No. 202-422-2, Genta 
Medical, York, UK) for 10 minutes, then rehydrated through bathing in a series of ethanol 
(Hayman Ltd, Essex, UK) dilutions, from 100%, 90%, 70% through to tap water. The 
sections were stained in Harris Haematoxylin (BDH, Poole, Dorset, UK) for one minute, 
differentiated in 1% alcohol for 10 seconds, washed well in running tap water for 3 minutes 
and then immersed in Eosin (1% solution; BDH, UK) for a further minute. After a further 
wash, slides were dehydrated in alcohol solutions, cleared in xylene and mounted using 
DPX (DiaCheM, London, UK) and 22x30 mm cover slips (Menzel-glazer). Examination at 
lOOx and 200x magnification (Zeiss Axioscope 20, Carl Zeiss, Germany) enabled 
confirmation of histological differences between regions clinically corresponding to cord 
and nodule (Figure 2).
The distinction between cord and nodule broadly corresponded to Luck’s classification 
(Luck 1959). Cord-derived tissue was relatively acellular with large amounts of collagen, 
aligned in parallel, representing Luck’s ‘residual phase’. Nodule-derived tissue contained 
dense nests of randomly aligned fibroblasts and minimal collagen deposition, correlating to 
Luck’s ‘proliferative phase’. If the clinical diagnosis of cord or nodule did not correlate to 
histological findings, the cell line and any cell strains isolated were discontinued and 
therefore not used in future experiments.
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Figure 2. Haematoxylin and eosin-stained section o f  a Dupuytren’s cord (left) and nodule (right) x 200 
magnification. Cord-derived tissue was relatively acellular with an abundance o f  aligned collagen fibrils, 
whereas nodule-derived tissue was highly cellular with a relative paucity o f  extracellular matrix.
2.1.3 Cell strains
In all, tissue samples were harvested from 17 patients with Dupuytren’s disease and 5 
patients undergoing carpal tunnel release. Table 1 illustrates the demographics and risk 
factors for the Dupuytren’s patients. Some tissue samples were unpaired (cord and nodule 
not easily distinguished on clinical or histological observation). Furthermore, some paired 
samples yielded only one cell strain as either cord or nodule-derived fibroblasts grew 
poorly in the culture medium or underwent premature senescence. Analysis was therefore 
confined to cell strains from 5 paired nodule and cord samples. The unpaired cell strains 
were used to validate assays.
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No.
Demographics
Patients 16
Age (median) 65
Operated hands 17
Male 14(81%)
Bilateral disease 11 (69%)
Associations
Smoking 5(31%)
Alcohol excess 3 (19%)*
Diabetes Mellitus 1 (6%)
Epilepsy 0
Table 1. Table illustrating the demographics and associations o f  Dupuytren’s patients who donated fascia 
samples to the tissue bank for fibroblast isolation. *represents consumption o f  alcohol above current 
recommended guidelines (28u/week for males, 21u/week for females).
2.1.4 Isolation of cells from explant tissue
An explant method was used to establish primary cell cultures from the harvested material 
(Jones et al. 1979). Cord, nodule and carpal ligament-derived tissue was prepared 
separately. Each surgical specimen was minced into l-2mm pieces using a scalpel and 
forceps, which had been previously sterilized in 70% Industrial Methylated Spirits (IMS) 
and allowed to air dry. Each piece of macerated tissue was placed on the base of a T25cm2 
tissue culture flask (Greiner Labortechnik, Greiner bio one, Germany) and allowed to 
adhere for 2 minutes, before dispensing 5ml of normal fibroblast growth medium (NGM) 
into the flask. NGM consisted of Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, 
UK) supplemented with glutamax (dipeptide L-Alanyl-L-Glutamine), 10% (vol/vol) fetal 
calf serum (FCS), penicillin (lOOU/ml), and streptomycin (lOOpg/ml, all Gibco, UK). The
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flask was incubated in a Heraeus humidified incubator, maintained at 37°C and 5% CO2 . 
After fibroblasts were observed migrating from the specimen, media changes were carried 
out twice weekly.
Cells were passaged successively into T75cm2, then T175cm2 (Greiner Labortechnik, 
Germany) and finally T225cm tissue culture flasks (Coming, New York, USA) just prior 
to confluence. Subsequent routine propagation of cell cultures involved splitting each 
T225cm tissue culture flasks into three. Culture medium was aspirated and the cell 
monolayer washed with 5ml ethylenediaminetetraacetic acid (EDTA) to chelate calcium 
and magnesium ions. Following washing of the monolayer, 2.5ml of 0.25% trypsin (Gibco, 
UK) in versene (Gibco, UK) was dispensed into the flask, and the flask was incubated at 
37°C until all cells had lost contact with the flask surface, forming a single cell suspension. 
The trypsin solution was neutralized with 20ml of NGM, and the resulting cell suspension 
immediately aspirated from the flask into a 50ml centrifuge tube. The suspension was then 
centrifuged at 1000 rpm for 5 minutes to pellet the cells and remove traces of the active 
trypsin. The supernatant was discarded, and the cell pellet resuspended in 12ml of NGM, 
before being evenly distributed between three T225cm cell culture flasks. The flasks were 
returned to the incubator after the final NGM volume had been made up to 35ml. The 
media was changed twice weekly until confluent, at which point the cells were passaged 
again, used for experiments, or prepared for cryostorage. Only cells from passages 3-5 were 
used for experiments as passage number has been shown to influence the efficiency of 
fibroblasts at remodelling matrices (Steinberg et al. 1980).
2.1.5 Cryostorage of cells
A cell suspension was obtained by trypsination of the cell monolayer, as previously 
described, followed by neutralisation and centrifugation at lOOOrpm for 5 minutes to pellet 
the cells. The supernatant was discarded, and the cell pellet resuspended in 3ml of 
cryopreservation medium: 10% DMSO (Dimethyle sulphoxide, Sigma, Poole, Dorset) and 
90% fetal calf serum (FCS, Gibco, Paisley, Scotland). The cell suspension was dispensed 
into 3 labelled cryovials, detailing cell strain, passage number and date. The usual cell 
density for cryopreservation was lx l0 6cells/ml. The cryovials were insulated with paper
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wadding and placed at -80°C, the wadding aids gradual freezing over 24 hours to ensure 
optimal survival during the cryopreservation process. Once frozen, the samples were 
transferred to liquid nitrogen for long-term storage until required.
2.1.6 Propagation of cells from cryostorage
The cryovial was rapidly thawed in a 37°C water bath. The cell suspension was transferred 
to a 15ml centrifuge tube, and 10ml of NGM added drop-wise, slowly, with agitation to 
prevent osmotic stress. The resulting cell suspension was centrifuged at 1000 rpm for 5 
minutes and the supernatant aspirated and discarded to remove traces of DMSO. The cell 
pellet was washed of any remaining cryopreservative with a further 10ml of NGM and then 
recentrifuged. The supernatant was discarded and the cell pellet was resuspended in 13ml 
of NGM, then dispensed into a T75cm flask for incubation.
2.1.7 Cell viability and counting
Cells were stained with Trypan Blue to determine viability and then counted using a 
haemocytometer (improved Neubauer). An aliquot of 20pl of cell suspension was diluted 
1:1 with 20pl of Trypan Blue (0.4%, Sigma, Dorset, UK) and then drawn between the 
haemocytometer (Nebauer) and the cover slip by capillary action. This was examined under 
an inverted phase contrast microscope (Olympus CK2, Olympus Optical Co., Japan.). Live 
cells appeared phase bright, as they retain the ability to pump out the Trypan blue, whereas 
dead cells stained blue, as the dye is not removed. The number of viable cells contained 
within 1 large grid of the haemocytometer was counted and, the count repeated in 3 further 
grids. The cell density of the suspension was then calculated as follows:
Mean cell number of 4 grids x 2 (dilution factor) x 104 = Number of viable cells/ml
2.2 ASSESSMENT OF CELL PROLIFERATION
Ilomastat (GM6001; Calbiochem, UK) and the control peptide (GM6001 negative control, 
Calbiochem, UK) are poorly soluble in aqueous solution and therefore prepared in dimethyl
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sulfoxide (DMSO, Sigma Chemical Co., Dorset, UK) at stock concentrations o f lOOmM. 
Although DMSO is an excellent organic solvent and vehicle for delivery o f ilomastat, it has 
been shown to be cytotoxic to fibroblasts at higher concentrations (Berliner et al. 1967). 
Similarly, synthetic MMP inhibitors have been reported to affect cell proliferation 
(Mannello et al. 2005). Any effect o f ilomastat or DMSO on fibroblast proliferation could 
influence matrix contraction. A proliferation assay was therefore undertaken to determine 
the effect o f ilomastat on proliferation by nodule, cord (unpaired sample) and carpal 
ligament-derived fibroblasts so that an appropriate dose could be selected for subsequent 
experiments that was neither toxic nor a stimulant to proliferation.
2.2.1 Background to the metabolic proliferation assay
Cell proliferation was assessed using a metabolic reagent, WST-1 (Roche Molecular 
Diagnostics and Biochemicals, Lewes, UK). WST-1 is a tetrazolium salt that is cleaved to 
formazan by cellular enzymes (Figure 3). An expansion in the number o f  viable cells 
results in an increase in the overall activity o f  mitochondrial dehydrogenases, which 
increase the amount o f formazan produced. Formazan production directly correlates with 
the number o f metabolically active cells in the culture. The reaction is accompanied by a 
colour change, enabling precise quantification o f the formazan formed, through measuring 
change in absorbance (optical density, OD) spectrophotometrically at 450nm.
n o 2 n o 2
S 02Na
S03Na
S 02Na
SQ3Na
WST-1 Formazan
Figure 3. Cleavage o f  the tetrazolium salt WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]- 
1,3-benzene disulfonate) to formazan was accompanied by a colour change from light red to dark red, which 
was detected spectrophotometrically at 450nm.
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2.2.2 Correlation of cell density with optical density
Initially, the optimal detection limits of the WST-1 proliferation assay were investigated by 
assessing the effect of cell density (number of fibroblasts seeded in each well) on optical 
density.
A single cell suspension of fibroblasts was prepared as described previously and the 
number of viable cells determined using Trypan Blue exclusion. The cell suspension was 
centrifuged at lOOOrpm for 5 minutes and the pellet resuspended in DMEM supplemented 
with 0.5% FCS. This medium is sufficient to promote cellular adhesion whilst retaining 
cells in a quiescent, non-proliferating state over the initial 24-hour culture period. Serial 
dilutions of the cell suspension enabled fibroblasts to be seeded into the central 60 wells 
(4xl03 cells per well) of a 96-well culture plate at a range of cell densities (2-20,000 
fibroblasts in lOOpl/ well). DMEM was dispensed into the outer wells (100pl/ well) to 
reduce evaporative losses within the plate. The plates were incubated at 37°C overnight to 
allow cells to adhere to the well base. After 24 hours, lOpl of WST-1 was added to all cell- 
containing wells. The tissue culture plate was then incubated at 37°C for 2 hours. The 
absorbance, related to the number of viable cells converting WST-1 to coloured formazan 
crystals, was determined at 450nm with a spectrophotometer (Model 550, BioRad, UK) 
using 630nm as a reference wavelength. A graph was plotted of absorbance (optical 
density, OD) against cell density.
2.2.3 Effect of ilomastat on cell proliferation
Four 96-well culture plates were prepared as described above, with cells seeded into the 
central wells at a density of 4xl03 cells per well. A fifth culture plate was prepared with just 
one column of cells. NGM was dispensed into the outer wells (100pl/ well) to reduce 
evaporative losses within the plates. After 24 hours, the low serum culture media in the first 
four plates was aspirated and replaced by serial logarithmic dilutions of ilomastat (lnM- 
lmM) or vehicle control (DMSO lxlO^-1%) in NGM (all n=6 replicates). Meanwhile, 
lOpl of WST-1 was added to the 6 cell-containing wells of the fifth plate, and the plate was 
incubated for 2 hours. The OD value at 450nm provided the t=0 measurement i.e. 
corresponding to cell number at the start of the experiment. The WST-1 assay was
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subsequently performed at 24 or 48 hours on the first four plates to provide a t=24 hr and 
t=48 hr reading for both ilomastat and DMSO dilutions. A graph was plotted of change in 
OD from the initial t=0 value over time, comparing basal conditions with serial dilutions of 
ilomastat or vehicle control (DMSO). Increases in OD above the t=0 value related to 
increases in cell biomass as an indicator of cell proliferation. OD values at 24 and 48 hr 
below the initial t=0 value indicated cell death over the exposure period.
The proliferation assay established the upper limit of ilomastat at which fibroblasts 
remained viable and functional for use in subsequent experiments aimed at investigating the 
effects of ilomastat on matrix contraction.
2.3 MODELS OF MATRIX CONTRACTION
Two models of fibroblast-mediated matrix contraction were employed, the fibroblast- 
populated collagen lattice (FPCL) and the culture force monitor (CFM). The two models 
were used to assess the differential contractile abilities of Dupuytren’s (cord and nodule) 
and control fibroblasts as well as the effects of ilomastat on fibroblast-mediated tissue 
remodelling and contraction.
2.4 FIBROBLAST-POPULATED COLLAGEN LATTICE (FPCL)
Matrix contraction was assessed using a stress-release fibroblast-populated collagen lattice 
(FPCL) model. A single cell suspension of fibroblasts was prepared as previously described 
in section 2.2.1. Cell viability and number were determined using Trypan Blue and a 
Neubauer haemocytometer. The cell suspension was centrifuged at lOOOrpm for 5 minutes. 
The supernatant was aspirated and the pellet washed in phosphate-buffered saline (PBS, 
Gibco, Scotland) to remove traces of FCS. The suspension was recentrifuged, the 
supernatant discarded and the pellet resuspended at 2xl06 cells in 0.6ml GFM (gelatinase- 
free growth medium).
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GFM was used as the main stimulant for matrix contraction to enable accurate assessment 
of gelatinase (MMP-2, -9) production by fibroblasts during the experiment, without 
interference from the gelatinases that occur naturally in fetal-calf serum. Gelatinase-free 
fetal calf serum was prepared as follows: 1ml gelatin sepharose 4B (in 60% ethanol; 
Amersham Biosciences, UK) was dispensed into two 15ml centrifuge tubes. The liquid was 
centrifuged at lOOOrpm for 5 minutes, and the resultant supernatant was discarded. The 
pellet was resuspended in 10ml PBS, to wash away all ethanol remnants, and was then 
recentrifuged. The supernatant was aspirated and discarded. The pellet was resuspended in 
9ml fetal calf serum (Gibco, UK) and incubated at 4°C on a vertical rotary shaker for 2 
hours. During this time, gelatine sepharose binds the gelatinases (mainly MMP-2, MMP-9). 
The mixture was centrifuged at lOOOrpm for 5 minutes, and the supernatant (gelatinase-free 
fetal calf serum) was then aspirated and used to make GFM. All other ingredients of GFM 
were identical to NGM.
2.4.1 Construction of FPCL model
A stress-release FPCL model was constructed as follows. A 1.1ml FPCL lattice mixture 
was prepared by mixing 150pl cell suspension, as prepared above, with 350pl of lOx 
Dulbeccos’ Modification of Eagle’s Medium (DMEM, Sigma, UK) and 600pl of 5mg/ml 
type I collagen (Sigma, UK) in 0.01% acetic acid. The solution was neutralised by drop- 
wise addition of 0.1 M NaOH until a colour change from yellow to just pink was observed, 
indicative of the adjustment of pH from 1.0 to 7-7.5. The liquid lattice was gently agitated 
and 150pl of lattice mixture dispensed per well of a 48-well plate, rotating the plate to 
ensure the lattice was evenly spread throughout the well. The plate was incubated for 1 
hour at 37°C to allow the lattices to polymerise. After 1 hour, test medium (depending on 
individual experiment) was dispensed into wells. FPCLs were allowed to develop 
mechanical tension over 48 hours before being gently released from the well periphery with 
a 200pl Gilson pipette tip and returned to the incubator.
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2.4.2 Assessment of matrix contraction
Lattices were photographed (Figure 4) at point o f release, and then every 24 hours, using a 
camera system (UVP Bioimaging System, Epi Chemi II Darkroom), linked to a computer. 
The lattice area was measured in pixels (ImageTool 3.0) and the degree o f  contraction 
calculated as the change in lattice area was compared to well circumference over time.
2.4.3 Determination of appropriate time course
A stress-release FPCL model was prepared as described above to assess the rate o f lattice 
contraction mediated by cord, nodule (paired, n=4 replicates) and carpal ligament-derived 
fibroblasts (n=4 replicates) over time. After lattice polymerisation, 0.5ml GFM was 
dispensed into each well and the lattices were allowed to develop mechanical tension for 48 
hours before release. The media was changed at point o f release and subsequently every 2 
days. The lattices were photographed at daily intervals over 5 days and the lattice area was 
plotted against time, yielding rate o f lattice contraction from the slope o f the curve. This 
enabled selection o f an appropriate incubation time correlating to the maximal rate o f 
contraction for subsequent FPCL experiments.
Figure 4. Photograph o f  stressed lattices (left), anchored to the well, and contracting lattices (right), 48 hours 
after release from the well periphery.
2.4.4 Optimal ilomastat dose determination
Ilomastat has been shown to suppress FPCL contraction in a dose-dependent manner 
(Daniels et al. 2003). A stress-release FPCL model was employed to determine the dose o f 
ilomastat that yielded maximal suppression o f matrix contraction. FPCLs were prepared as 
described above. After lattice polymerisation, 0.5ml o f  test medium (0, lOOnM, lp,M,
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lOpM or IOOjiM ilomastat) was dispensed into wells in quadruplicate. FPCLs were allowed 
to develop mechanical tension over 48 hours prior to release. Lattice contraction was 
monitored over a further 48 hours enabling selection of the maximum dose of ilomastat that 
suppressed matrix contraction without affecting cell proliferation or viability.
2.4.5 Effect of ilomastat on matrix contraction
A comparison was made between FPCL contraction under basal conditions (GFM) and 
under treatment with ilomastat, control peptide or vehicle control. FPCLs were prepared as 
described above with fibroblasts derived from paired cord and nodule samples (n=5) and 
carpal ligament (n=5). After lattice polymerisation, 0.5ml of test medium (0, lOOpM 
ilomastat, lOOpM control peptide or 0.1% DMSO in GFM) was dispensed into wells in 
quadruplicate. As before, the lattices were released after 48 hours and then allowed to 
contract for a further 48 hours before termination of the experiment. A graph of lattice area 
was plotted against time. The results were pooled for each cell type so that a comparison of 
contractile ability and effect of ilomastat could be made between cord, nodule and carpal 
ligament. Cell-conditioned media samples were collected in quadruplicate to assess MMP 
protein levels and activity both under conditions of mechanical stress (pre-release) and 
lattice contraction (post-release). These were stored at -20°C.
2.4.6 Isolation of membrane-bound and intracellular proteins
At the end of the experiment (section 2.4.5), the lattices were washed in PBS and then cells 
isolated from the matrix by collagenase digestion (0.5% collagenase D, Roche; 0.5% 
Bovine Serum Albumin, Sigma; Phosphate Buffered Saline) at 37°C for 20 minutes or until 
the collagen was completely dissolved. After the lattices had been dissolved, 5ml PBS was 
added to the resultant cell suspension to terminate the reaction. The mixture was 
centrifuged at 1200rpm for 5 minutes, and the supernatant aspirated to remove traces of 
collagenase. The resultant pellet was resuspended in 0.5ml minimal lysis buffer (50mM 
tris-buffered saline pH7.6, 1.5mM NaCl, 0.5mM CaCh, lpM Zn CL, 0.1% Brij-35, 0.25% 
Triton X-100) to isolate membrane-bound and intracellular proteins. The suspension was 
incubated at 4°C for 10 minutes to allow cell lysis, and then centrifuged at 13000rpm for 5 
minutes. The supernatant containing the isolated membrane-bound proteins was aspirated
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and stored at -20°C, prior to determination of protein concentration and type 1 membrane- 
bound MMP (MT1-MMP) activity.
Whilst the FPCL is an efficient model for providing data on fibroblast-mediated matrix 
contraction and allowing media analysis at multiple time points, it is not very sensitive and 
allows only limited analysis of the contraction profile. The culture force monitor was 
therefore introduced to yield accurate kinetic information and enable differentiation of the 
cellular and remodelling components of matrix contraction.
2.5 CULTURE FORCE MONITOR (CFM)
The culture force monitor (Figure 4) is an in vitro kinetic model designed to measure 
contractile forces generated by cells within a three-dimensional matrix in real time 
(Eastwood et al. 1994).
The CFM model involves a fibroblast-seeded collagen lattice that resides within a 
rectangular well filled with growth medium providing a friction-free environment. The well 
was carved out of a single rectangular block of polytetrafluoroethylene (PTFE; RS 
components) and had standard dimensions 7.5 x 2.5 x 1.5cm to a depth of 1.5cm. The 
PTFE ensured a hydrophobic well environment, thus inhibiting cell attachment. The 
collagen lattice was suspended longitudinally between two hydrophilic flotation bars, 
which were connected to the culture force monitor by means of two ‘A’ frames of stainless 
steel suture wire (Figures 5, 6). One frame was attached to a fixed strut and the other, to a 
strain gauge by means of a small hook (Figure 7). The block was positioned on a platform 
with a mounting stage, which enabled fine adjustments to ensure that the lattice was 
accurately aligned between the fixed strut and the strain gauge. The whole apparatus was 
incubated at 37°C, 5% CO2 , with constant humidity within an incubator (Innova CO-48, 
NewBrunswick Scientific Co., NJ, USA).
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The CFM was powered by a 12V power supply, which applied a high input signal, 
increased by a strain gauge amplifier. The output from the amplifier was channelled into a 
voltmeter, and through an analogue digital converter, which provided a force reading every 
800 milliseconds. The data were transferred to a laptop computer (PP01 A, Dell; Windows 
2000) and recorded by a computer software programme (Chart Recorder, Grey Institute, 
UK). As the cell-seeded lattice contracts, the strain gauge lever is deflected horizontally, 
resulting in a positive force reading. Any manual forces on the strain gauge lever or 
transducer, or prolonged time at a temperature different from 37°C can cause inaccuracies 
o f  the transducer’s readings. The force transducer was therefore regularly calibrated against 
a series o f  known weights in order to ensure linearity o f displacement o f  the strain gauge.
A
B 2.2cm
I
1.3cm
1.4cm
D
Figure 5. Components o f  the culture force monitor. Panel A demonstrates a PTFE mould. The depth o f  the 
chamber was 1.5cm. Panel B demonstrates a flotation bar, constructed from plastic canvas squares 
(Haberdashery department, John Lewis Department Store, UK). Four 6 by 3 square rectangles were joined 
together to form each bar using nylon non-absorbable sutures. Panel C shows an ‘A frame’ and panel D 
demonstrates how the flotation bar and ‘A frame’ were connected.
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Figure 6. Demonstration o f  lattice position in well. The cell seeded collagen lattice (a) is suspended between 
two flotation bars (b) attached to ‘A ’ frames. It floats within the well o f  a PTFE mould (c), which is filled 
with test media.
Figure 7. Illustration o f  the culture force monitor positioned in the incubator. The PTFE mould (a) is 
positioned on a platform with a moveable mounting stage (b). One ‘A ’ frame is attached to a fixed strut on the 
platform (c), whilst the other is attached to the strain gauge (d).
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2.5.1 Calibration of the Culture Force Monitor
The transducer was removed from its retaining clamp and placed in a vertical direction on 
top of the mounting stage. The incubator door was shut, and the system was allowed to 
equilibrate for temperature and CO2 levels. The calibration factor on the Chart Recorder 
program was set to 1, and the force reading adjusted to 0. A one-minute recording was then 
made of the measured force by the transducer with no weight applied. A small known 
weight was then applied to the transducer, causing a deflection of the arm and an increase 
in the transmitted force reading. The incubator was allowed to equilibrate before recording 
the force reading for a one-minute period. The process was then repeated for a series of 5 
known weights in total, and the mean reading calculated to provide a mean force for each 
weight. The standard force for each weight was calculated from the equation below and a 
table constructed as illustrated in Table 2. One dyne is equivalent to 10'5 Newtons.
Force (Newtons) = Mass (kg) x  Acceleration (gravity, 9.8)
Weight
number
Actual 
weight (g)
Corresponding 
force (dynes)
Mean force transducer 
reading (dynes)
0 0 0 0
1 0.03 29.4 25
2 0.05 49 43
3 0.2 196 166
4 0.3 294 235
5 0.5 490 403
Table 2. Table illustrating the mean force recorded by the CFM for each known weight and the equivalent 
calculated force.
A scatter graph was then plotted of force recorded by the culture force monitor against the 
standard force for each weight (Figure 8). A line of best fit was drawn, yielding the 
calibration factor from the slope of the graph. The correlation coefficient (R2) was also
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calculated to ensure that a linear relationship was established. The calibration factor was 
then entered directly into the Chart Recorder software.
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Figure 8. Scattergraph o f  calibrating force in dynes plotted against the mean CFM force transducer reading. 
The slope o f  the curve gives the calibration factor (1.22 in this example). The correlation coefficient (R2) was 
also calculated.
2.5.2 Construction of the CFM lattice
A cell suspension of fibroblasts was prepared from two sub-confluent T225cm2 (Coming, 
NY, USA) tissue culture flasks, as described previously. Cell viability and number were 
determined using Trypan Blue and a Neubauer haemocytometer. The cell suspension was 
centrifuged at lOOOrpm for 5 minutes, the supernatant discarded, and the pellet washed in 
PBS, then resuspended in GFM at 10xl06cells/ ml.
Meanwhile the mould and flotation bars were prepared. The flotation bars were attached to 
the ‘A’ frames and checked for symmetry and correct height relative to the mould. They 
were then immersed in 70% IMS to sterilise them, and left on a sterile petri dish to air-dry, 
before being placed at either end of the mould. The mould and ‘A’ frames were autoclaved 
prior to use.
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Lattices were prepared by mixing 700pl of lOx concentrated DMEM (Sigma, Dorset, UK) 
and 6ml Collagen type 1 solution (2.16mg/ml in 0.6% acetic acid, First link, UK). The 
solution was neutralised by drop-wise addition of 5M NaOH, then 1M NaOH, until a 
colour change from yellow to just pink was observed, indicative of the adjustment of pH 
from 1.0 to 7-7.5. Some of the neutralised solution was then pipetted into the flotation bars 
(lm l each) and the rest mixed carefully with 500pl of the cell suspension (5xl06 
fibroblasts). The resultant cell suspension was then dispensed into the well between the two 
flotation bars and the mould, rotated to ensure even lattice distribution throughout the well. 
The mould was placed in an incubator for 30 minutes at 37°C to polymerise the lattice. An 
inverted 9cm Petri dish base placed over the mould was used as a protective lid.
After 30 minutes, the polymerised lattice was released from the well using a sterile green 
needle and 20ml of GFM dispensed into the well. The lattice then floated to the surface 
between the flotation bars. The mould was transferred to the culture force monitor situated 
within a humidified incubator maintained at 37°C, and 5% CO2 . The eye of one ‘A’ frame 
was attached to the fixed strut of the platform and the other was hooked onto the strain 
gauge. The position of the mould on the platform was adjusted to ensure precise 
longitudinal alignment of the flotation bars and platform, to enable frictionless movement 
of the lattice.
2.5.3 Contraction profile determination
The apparatus was allowed to equilibrate in the incubator for 10 minutes before data 
recording commenced. The force at equilibrium was set at zero and subsequent readings 
were recorded every 800ms by a computer software programme (Chart Recorder, Grey 
Institute, UK), which converted the voltage reading into a force measurement in dynes. The 
whole system was maintained at 37°C and 5% CO2 for the duration of the experiment. The 
lattice was allowed to contract for 48 hours, producing a contraction profile over time for 
each cell line and experimental condition investigated. The data for each experiment were 
converted to a mean reading every 15 minutes using the Chart Recorder software and a 
graph of force plotted against time using Microsoft Excel software (Microsoft Corporation).
56
Materials & Methods
2.5.4 Effect of ilomastat on force generation
A comparison was made between force generated by Dupuytren’s (paired cord and nodule, 
n=5) and control fibroblasts (carpal ligament, n=5) under basal conditions (GFM) and 
treatment with ilomastat, control peptide or vehicle control. CFM lattices were prepared as 
described above. After lattice polymerisation, 20ml of test media (0, lOOpM ilomastat, 
lOOpM control peptide or 0.1% DMSO in GFM) was dispensed into the chamber of the 
PTFE mould and force generation recorded over 48 hours.
2.5.5 Effect of ilomastat on matrix remodelling by addition of Cytochalasin-D
After allowing lattices to contract for 48hours, a single dose of cytochalasin-D (Sigma, 
Poole, Dorset, UK), 20pl of 60mM in 0.5ml of GFM, was added to the cell-conditioned test 
media giving an overall concentration of 60pM within the chamber. This was added rapidly 
in order to minimise disruption to the incubator temperature and CO2 levels. Readings were 
recorded for a further 2 hours until the force had reached a plateau, revealing a residual 
force termed ‘residual matrix tension’ (RMT). Cytochalasin-D specifically targets the actin- 
dependent processes required for contraction generated by fibroblasts, but not remodelling 
of the collagen matrix. Therefore, the reduction in force after addition of cytochalasin-D 
was equivalent to the cellular component of contraction. A graph was plotted of force 
against time, yielding maximum force generated as well as differentiation of the cellular 
and matrix components (Figure 9).
The results were pooled for each cell type so that a comparison of the effects of ilomastat 
on maximum force generation and RMT could be made for each cell type (cord, nodule and 
carpal ligament).
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Figure 9. Demonstration o f  force generated by fibroblasts over time in the CFM model. On addition o f  
Cytochalasin-D after 48 hours, the force drastically reduces revealing the separate components o f  residual 
matrix tension (RMT) and cellular contraction.
2.5.6 Removal and processing of lattices from the CFM
At the conclusion o f each experiment, cell-conditioned media samples were collected and 
stored in labelled eppendorfs at -20°C, so that the effect o f  ilomastat on MMP protein 
levels and activity could subsequently be determined. The lattice was removed from the 
CFM mould and examined under light microscopy, to ensure that there was no evidence o f 
contamination or infection. The culture force monitor apparatus is not a closed system, and 
therefore susceptible to contamination, which could cause erroneous results. Any infected 
lattices were therefore discarded and the experiment was rerun.
Lattices were washed in PBS, divided in two (Figure 10) and then cells isolated from the 
matrix by collagenase digestion (0.5% collagenase D, Roche; 0.5% Bovine Serum 
Albumin, Sigma; Phosphate Buffered Saline). PBS (30ml) was added to each cell 
suspension and the two suspensions were centrifuged at 1200rpm for 5 minutes. The 
supernatant was aspirated. One pellet was resuspended in 1ml lysis buffer (50mM tris- 
buffered saline pH7.6, 1.5mM NaCl, 0.5mM CaCl2, lpM  Zn Cl2, 0.1% Brij-35, 0.25%
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Triton X-100) to isolate membrane-bound and intracellular proteins and the other in 1ml 
Tryzol (Invitrogen, UK) for mRNA isolation.
mRNA isolation MT1-MMP
expression
Figure 10. Processing o f CFM lattice at termination o f  experiment. The lattice was divided in two and 
digested by a collagenase solution to isolate cells for determination o f  mRNA profiles and expression o f  
MT1-MMP.
The lysis suspension was incubated at 4°C for 10 minutes to achieve cell lysis, and then 
centrifuged at 13000rpm for 5 minutes. The supernatant was aspirated and stored at -20°C 
prior to determination o f protein concentration and MT1-MMP activity. The Tryzol 
suspension was incubated at room temperature for 5 minutes and then stored at -20°C prior 
to mRNA extraction at a later stage.
2.6 DETERMINATION OF MMP SECRETION AND ACTIVITY
2.6.1 Determination of protein concentration
The total protein concentration o f conditioned media and cell lysate samples was estimated 
using a commercial protein assay reagent based on the Bradford method (BioRad, UK). 
This enabled MMP activity to be normalised against total protein concentration, as protein 
levels affect MMP binding and therefore observed MMP levels and activity.
Cell-conditioned media (CM) samples contained levels o f  protein in excess o f that 
accurately determined by the assay, therefore, samples were diluted 6-fold (40pl CM in 
200pl distilled water). This dilution factor was previously determined by assay validation. 
CM and cell lysate samples were thawed on ice. A 2mg/ml standard protein solution was
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prepared (50mg BSA dissolved in 25ml distilled water). Serial dilutions (0, 0.2, 0.4, 0.6, 
0.8. 1.0, 1.2 mg/ml in 500pl distilled water) of the standard protein solution were prepared. 
The BioRad Protein Assay Reagent was diluted 1:4 with distilled water, and then filtered 
through a Whatman No. 1 filter paper (Whatman International, UK) to remove particulate 
matter. Ten microlitres of each standard was dispensed into labelled replicate tubes (in 
duplicate). Similarly, lOpl of each sample was dispensed into labelled replicate tubes (in 
duplicate). After filtration of the diluted BioRad Protein Assay reagent was complete, 
500pl was dispensed into each tube and mixed thoroughly. After 5 minutes incubation at 
room temperature, the tubes were mixed again to ensure a homogeneous solution and then 
transferred to a 96-well plate (2x100pi of each standard or sample, repeated with each 
replicate). The absorbance at 595nm was determined in a microtitre plate 
spectrophotometer (Model 550, BioRad, UK), and the data transferred to a microsoft excel 
spreadsheet, which enabled calculation of the mean absorbance per standard/sample. 
Absorbance (measured as optical density, OD) was plotted against standard protein 
concentration (mg/ml) and regression analysis used to calculate and plot a line of best fit, 
yielding a regression equation (Figure 11).
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Figure 11. Example o f  protein standard curve. A line o f best fit was plotted, yielding a regression formula, 
allowing the protein concentration in unknown samples to be calculated.
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The regression formula was used to calculate the protein concentration from the OD values 
obtained for each replicate sample. The CM sample concentrations were then multiplied by 
6 to correct for the initial dilution.
2.6.2 Western Blot analysis
The relative expression of specific MMP protein levels was detected in conditioned media 
samples collected from stressed and contracting FPCLs by western blotting. Western 
blotting is a technique that involves the immunochemical detection of a target antigen that 
has been resolved by sodium dodecyl sulphate -  polyacrylamide gel electrophoresis (SDS- 
PAGE). This assay did not yield any information on the enzyme activity levels associated 
with expression of the target MMP.
2.6.2.1 SDS gel formulation
Resolving SDS separating gels were cast into a 1.5mm gel mould (BioRad, UK) with a 15- 
well comb and SDS stacking gel. Generally, the separating gel comprised 10% acrylamide 
(Sigma), 0.4M tris pH8.8, 0.001% SDS, 0.0003% ammonium persulfate (APS) and 0.001% 
tetramethylethylenediamine (TEMED, Invitrogen). However, a 15% acrylamide separating 
gel was used to separate low molecular weight molecules (TIMP-1, -2). The stacking gel 
consisted of 5% acrylamide, 0.125M tris pH6.8, 0.001% SDS, 0.0005% APS and 0.001% 
TEMED.
Once polymerised, the comb was gently removed, and the glass plates assembled within the 
gel running tank with running buffer (25mM tris base, 192mM Glycine, 0.1% SDS). 
Kaleidoscope Marker (lOpl mix of colour-tagged proteins approximately 14.3 -  220kDa, 
BioRad, UK) was dispensed into the first lane of the gel so that the molecular weight of 
bands revealed by western blotting could be estimated. Estimation of protein content in 
each sample, as previously described, enabled loading of equal amounts of protein (lOpg) 
per lane for comparative purposes. Each sample was mixed 1:1 with sample buffer (120mM 
tris pH6.8, 4 %  SDS, 10% glycerol, 0.01% bromophenol blue; 12.5pl per sample) and then 
loaded into successive lanes of the gel. The entire gel tank was connected to a power pack
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(BioRad, UK), and run at 200V for 60 minutes, or until the dye front had reached the base 
of the gel.
After electrophoresis, the gel was briefly soaked in fresh transfer buffer (25mM tris base; 
192mM Glycine; 20% methanol, 70% dFUO). Simultaneously, six pieces of pre-cut filter 
paper (3mm; Whatman, UK) and one pre-cut nitrocellulose membrane (Hybond-ECL; 
Amersham Biosciences, UK) were soaked in transfer buffer. Three filter pads were placed 
onto the base (anode) of the semi-dry blotter, and on top, the nitrocellulose membrane, the 
gel and a further three filter pads. Air bubbles were removed and the protein transferred for 
60mins at 25V. Once the transfer was complete, the nitrocellulose membrane was placed in 
blocking buffer, which consisted of BSA (5%) in TBS (lOmM tris base, 13.8mM NaCl, 
2.7mM KCL), and set for 1 hour on a rotary shaker at room temperature.
2.6.2.2 Antibody detection
Following blocking of non-specific binding, the membrane was washed three times (10 
minutes per wash) in TTBS wash buffer (TBS + 0.1% Tween-20) with shaking. The 
membrane was then incubated in the relevant primary antibody (diluted in blocking buffer, 
Table 3) overnight at room temperature on the rotary shaker.
Following incubation with the primary antibody, the membrane was washed three times (10 
minutes each) in fresh TTBS and incubated with the relevant secondary antibody (diluted in 
blocking buffer, Table 3) for one hour at room temperature on the rotary shaker.
After incubation with the secondary antibody, the membrane was washed again in TTBS as 
previously described. The presence of the protein of interest was then visualised with an 
alkaline phosphatase III substrate kit (Vector Laboratories, SK5300), according to the kit 
instructions. Briefly, 4 drops of each of the three alkaline phosphatase reagents (1 ,2  and 3) 
were diluted in 20ml tris pH8.2 and applied to the membrane. The membrane was placed 
on a rotary shaker and covered to block light. The membrane was checked frequently for 
the appearance of bands. After optimal development of the bands, the reagents were
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removed and the membrane was then placed in df^O  to prevent overexposure, before being 
air-dried and photographed.
M M P Prim ary Antibody A ntibody recognition Dilution Secondary A ntibody Dilution
MMP-1
M ouse monoclonal 
(Calbiochem)
proenzyme (55 kDa) 
active (43 kDa)
1:1000
Rabbit anti-mouse IgG 
(Dako)
1:500
MMP-2
Mouse monoclonal 
(Calbiochem)
proenzyme (72 kDa) 
active (66 kDa)
1:1000
Goat anti-mouse IgG 
(Sigma)
1:1000
MT1-MMP
Rabbit polyclonal 
(Chemicon)
proenzyme (65 kDa) 
active (63 kDa)
1:1000
Goat anti-rabbit IgG 
(Sigma)
1:1000
TIMP-1
Mouse monoclonal 
(Calbiochem)
TIMP-1 protein (30 kDa) 1:1000
Goat anti-mouse IgG 
(Sigma)
1:1000
TIMP-2
Mouse monoclonal 
(Calbiochem)
TIMP-2 protein (21 kDa) 1:400
Goat anti-mouse IgG 
(Sigma)
1:1000
Table 3. Details o f  the primary MMP antibodies and corresponding secondary antibodies used, including 
specific enzyme forms recognised, their respective molecular weights and dilution factors.
2.6.3 Gelatin zymography
Conditioned media samples collected from stressed and contracting FPCLs were analysed 
for MMP activity by gelatin zymography. Gelatin zymography is an electrophoretic 
technique, based on SDS-PAGE, that involves an MMP substrate (gelatin) copolymerised 
with the polyacrylamide gel. Zymography enabled detection of gelatinase (MMP-2, -9) 
activity through digestion of the gelatin substrate.
Resolving SDS separating gels were cast into a 1.5mm gel mould (BioRad, UK) with a 15- 
well comb and SDS stacking gel. The SDS gel comprised 10% acrylamide (Sigma), 0.15% 
gelatine (Type A, Sigma), 0.4M tris pH8.8, 0.001% SDS, 0.0007% ammonium persulfate 
(APS) and 0.003% tetramethylethylenediamine (TEMED, Invitrogen). The separating gel 
consisted of 5% acrylamide, 0.125M tris pH6.8, 0.001% SDS, 0.0005% APS and 0.001% 
TEMED.
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2.6.3.1 Zymographic analysis
The gels were assembled into a running tank with running buffer (2.5mM tris base, 
19.2mM Glycine, 0.01% SDS). After removal of the combs from the separating gel, lOpl of 
Kaleidoscope Marker (mix of colour-tagged proteins approximately 14.3 -  220kDa; 
BioRad, UK) was dispensed into the first lane of the gel, so that the molecular weight of 
bands in the sample lanes could subsequently be determined. Estimation of protein content 
in each sample, as previously described, enabled loading of equal amounts of protein 
(20pg) per lane for comparative purposes. Each sample was mixed 1:1 with sample buffer 
(0.145M tris pH6.8, 4.6% SDS, 23& glycerol, 0.001% bromophenol blue; 12.5pl per 
sample) and then loaded into successive lanes of the gel. The entire gel tank was connected 
to a power pack (BioRad, UK), placed on ice to prevent enzymatic degradation and then 
run at 25mA for 150 minutes.
The gels were then placed in 100ml renaturation buffer (2.5% Triton X-100, lpM zinc 
chloride in distilled water) per gel and incubated at room temperature on an orbital shaker 
for 1 hour. The renaturation process replaces the SDS in the gel with Triton. The 
renaturation buffer was decanted and replaced with 20ml development buffer (50mM TRIS 
base, 200mM sodium chloride, 5mM calcium chloride (anhydrous), 1 pM zinc chloride, in 
distilled water). After 30 minutes, the buffer was decanted and replaced with fresh 
development buffer, and the zymogram was then incubated at 37°C overnight with shaking. 
Incubation with the development buffer allowed the proteins to re-fold and re-establish 
their tertiary structure becoming enzymatically active
The gels were stained with Coomasie Brilliant Blue (0.5% Coomasie Brilliant Blue R-250, 
Sigma; 40% methanol, 10% acetic acid in distilled water) for lhr, and then destained (40% 
methanol, 10% acetic acid in distilled water) by shaking for 30-60 minutes with several 
changes of destain solution. The gels were deemed to have destained sufficiently when 
clear gelatinolytic bands were visible. The gels were then placed in dH20  to prevent further 
destaining before being photographed.
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2.6.4 Enzyme-linked immunosurbent assay (ELISA)
Zym ography demonstrates gelatinolytic activity and so is a poor method o f  quantifying 
non-gelatinolytic MMP activity. It was therefore necessary to assess the activity o f  other 
relevant MMPs. We used an Activity ELISA, which was a m odified ELISA system 
involving activation o f  a detection enzyme by the bound target MMP rather than a 
secondary anti-M MP antibody (Figure 12). This was preformed on conditioned media and 
cell lysate samples using a commercially available ELISA kit (Amersham, UK). The 
instructions provided by the manufacturer were followed precisely.
Pro detection enzyme
SubstrateMMP
Product -  measure 
OD at 405nmActive detection 
enzyme
Anti-MMP
Antibody
Figure 12. Identification o f  active MMP enzymes in CM or cell lysate derived from contracting FPCLs. 
MMPs bind to the anti-MMP antibody, which is adherent to the microplate well. The active MMP complex 
activates a detection enzyme, which in turn, activates a specific chromogenic peptide substrate. The net result 
is a product that can be detected by absorbance at 405nm in a spectrophotometer.
2.6.4.1 Detection of MMP-1 activity
Purified MMP-1 working standards were prepared from stock solutions (0.1-1.56ng/ml), 
then lOOpl o f  each standard and undiluted CM sample was dispensed into a 96-well 
microplate in duplicate. The plate was covered and incubated at 4°C overnight to allow any 
active MMP-1 present to bind to the immobilised antibody. Afterwards, the wells were 
washed and aspirated 4 times with wash buffer, ensuring that all wells were completely
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filled and emptied at each wash. The detection reagent was prepared by mixing lOOpl of 
the detection enzyme with the substrate reconstituted in 5.1ml of assay buffer. Assay buffer 
(50pl) and detection reagent (50pl) were then dispensed into all wells. Absorbance at 
405nm was read by a spectrophotometer to obtain a t=0 value (Model 550, BioRad, UK). 
The plate was then covered and incubated at 4°C for 4 hours again before recording the 
absorbance at 405nm.
The assay was specific for MMP-1 activity so that there was no cross-reactivity with other 
MMPs or TIMPs. As MMP-1 activity is directly proportional to the generation of colour 
through the cleavage of the substrate, it can be represented by the rate of change of 
absorbance at 405nm (i.e. SAbsorbanceW h2, where h is the incubation time in hours). A 
standard curve was generated by plotting 8AbsorbanceW h x 1000 (y axis) against ng/ml 
of MMP-1 standard (x axis, Figure 13). The sample ng/ml MMP-1 values were then read 
directly from the graph. Secreted MMP-1 levels were standardised against the total protein 
content of each sample so that direct comparisons between samples could be made.
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Figure 13. Standard curve for MMP-1 activity.
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2.6.4.2 Detection of MMP-2 activity
Purified MMP-2 working standards were prepared from stock solutions (0.7-12ng/ml), then 
lOOpl of each standard and undiluted CM sample was dispensed into a 96-well microplate 
in duplicate. The assay was specific for MMP-2 activity so that there was no cross­
reactivity with other MMPs or TIMPs. After incubation overnight and thorough washing, 
assay buffer (50pl) and detection reagent (50pl) were dispensed into all wells as previously 
described. Absorbance at 405nm was read by a spectrophotometer to obtain a t=0 value 
(Model 550, BioRad, UK). The plate was then covered and incubated at 4°C for 3 hours 
before recording the absorbance at 405nm again. A standard MMP-2 curve was generated 
as previously described and the sample ng/ml MMP-2 values read directly from the graph 
(Figure 14). Secreted MMP-2 levels were standardised against the total protein content of 
each sample so that direct comparisons between samples could be made.
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Figure 14. Standard curve for MMP-2 activity.
2.6.4.3 Detection of MT1-MMP activity
MT1-MMP working standards were prepared from stock solutions (l-32ng/ml). Cell lysate 
samples required a lOx dilution in order for estimates of activity to fall within the active 
detection range of the assay. The dilution factor was validated in preliminary experiments
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(data not shown). lOOpl of each standard and lOOjil of each diluted lysate sample were 
dispensed into a 96-well microplate in duplicate. After incubation overnight and thorough 
washing, assay buffer (50pl) and detection reagent (50pl) were dispensed into all wells as 
previously described. Absorbance at 405nm was read by a spectrophotometer to obtain a 
t=0 value (Model 550, BioRad, UK). The plate was then covered and incubated at 4°C for 
2.5 hours before again recording the absorbance at 405nm. A standard MT1-MMP curve 
was generated as previously described and the sample ng/ml MT1-MMP values read 
directly from the graph (Figure 15). Values were subsequently normalised against protein 
concentration. MT1-MMP levels were standardised against the total protein content of each 
sample so that direct comparisons between samples could be made.
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Figure 15. Standard curve for MT1-MMP activity.
Western blotting, zymography and ELISA enabled determining of MMP protein and 
activity levels by contracting fibroblasts in both CFM and FPCL models. Subsequently, an 
assessment of MMP gene expression by fibroblasts in the CFM model was undertaken by 
RT-PCR (real time polymerase chain reaction) to determine whether any differences in pre-
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transcriptional control existed between different cell types and in their response to 
ilomastat.
2.7 DETERMINATION OF MMP GENE EXPRESSION
2.7.1 General precautions to prevent contamination
To avoid contamination from RNA degrading enzymes, diethylprocarbonate (DEPC)- 
treated water was used as a solvent for RNA extraction, as it is DNAase and RNAase-free. 
DEPC water was made by adding 2ml DEPC (0.2%; Sigma, UK) to 1 litre of ultra pure 
(18MQ) water and shaking vigorously. The mixture was incubated overnight at 37°C and 
then autoclaved and stored at room temperature until use. Furthermore, all equipment and 
apparatus was designated for RNA use only and pre-incubated with DEPC water before 
autoclaving.
2.7.2 mRNA extraction
After thawing of the cell suspensions (in Tryzol, Gibco), 200pl of chloroform was added to 
each sample and the resultant mixture was shaken vigorously. After incubation at room 
temperature for 3 minutes, the mixture was centrifuged at 11,000 rpm at 4°C for 15 minutes 
to separate the phases. The upper clear phase was transferred carefully to a fresh eppendorf 
and mixed with 0.5ml of 80% isopropanol. After a further 10 minutes incubation at room 
temperature, the mixture was centrifuged at 11,000 rpm for 30 minutes to pellet the RNA. 
The supernatant was aspirated and the pellet resuspended in 1ml of 75% DEPC-ethanol to 
wash the pellet. The RNA suspension was vortexed on low for 10-15 seconds and then 
centrifuged at 4°C for 5 minutes to re-pellet the RNA. The supernatant was discarded and 
the pellet air-dried at room temperature for 10 minutes, then dissolved in 60pl DEPC-water 
by gentle pipetting and finally stored at -80°C in preparation for making cDNA.
2.7.3 Determination of RNA yield and quality
A 1 pi aliquot of the extracted RNA was diluted with 999pl of DEPC water and its 
absorbance determined spectrophotometrically. The spectrophotometer (ComSpec M330)
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was zeroed by making a reference against DEPC water alone, then absorbance readings 
(optical density, OD) were observed at 260nm and at 280nm. One absorbance unit (OD2 6 0) 
represents 40pg of single stranded RNA per ml (Sambrook 1989).
The purity of the extracted RNA was estimated by comparing the ratio of absorbencies 
OD2 6 0 .OD2 8 0, which provided an estimate of contamination due to DNA or protein and 
therefore a measure of the accuracy of the extraction procedures. Pure RNA gives a ratio of 
2.0; however sample ratios between 1.7 and 2.1 were deemed acceptable (Sambrook 1989).
The concentration of RNA isolated pre sample, and subsequently the total yield of RNA 
were calculated from the OD2 60 values as detailed in the equation below. The dilution factor 
accounts for the initial 1:1000 dilution of RNA in DEPC water prior to absorbance 
measurement.
mRNA concentration (pg/pl) = OD2 6 0 X 40 x dilution factor (1000) 
mRNA yield (pg) = mRNA concentration x total volume of isolated RNA
After isolation of mRNA from the cell suspensions, it was necessary to convert RNA into 
cDNA by the reverse transcriptase reaction (RT) as the PCR method involves multiplying 
copies of single-stranded DNA (cDNA) rather than RNA.
2.7.4 Obtaining cDNA from RNA
All reagents were thawed on ice except for reverse transcriptase. The heating block was set 
to 65°C. Five micrograms of RNA from the stock solutions was first diluted in DEPC water 
in fresh sterile PCR grade eppendorf tubes to give a total volume of 8pl. The samples were 
heated at 65°C for 10 minutes and then placed on ice for a further 5 minutes.
The RT working mix was prepared in a separate tube as detailed in Table 4. Ten microlitres 
of working mix was added to each RNA sample and mixed by pipetting. Reverse 
transcriptase (MMLV Reverse transcriptase, 1 pi of 200U/ml, Gibco) was then added fresh
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from the freezer, mixed carefully and the samples were then pulse-spun in a centrifuge for 
60 seconds. Finally, the samples were then incubated at 37°C for one hour.
REAGENTS QUANTITY VOLUM E SOURCE
Oligo-dT primers 200pg/ml 1|U Gibco
0.1M D TT 2pl Gibco
5 x RT buffer 4pl Gibco
DEPC water lpl ”
lOmM dNTPs 2pl Pharmacia (lOOmM kit)
RNAse inhibitor 30U/|il 1|U Pharmacia (porcine)
Table 4. The constituents o f  the reverse transcriptase working mix.
The reaction was terminated by heating samples to 75°C in a heating block (Techne DR I) 
for 10 minutes. cDNA samples were spun at 13,000 rpm for 1 minute at 4°C, then diluted 
1:1 with DEPC water. The samples were then ready to undergo PCR, which enabled 
relative quantification of cDNA and therefore an estimate of the original RNA content of 
each sample.
2.7.5 The polymerase chain reaction (PCR)
Gene expression was determined by quantitative PCR using SYBR Green I (Stratagene, 
USA), a dye that fluoresces when bound non-specifically to double-stranded DNA. The 
following components were added to each well of a 96-well PCR plate: 12.5pl of SYBR 
Green QPCR master mix (Stratagene, USA), 0.375pl reference dye (ROX, 30nM final 
concentration, Stratagene), forward and reverse primers (exact volumes primer-specific as 
determined through preliminary optimisation; data not shown) and DEPC water to make a 
total reaction volume of 25pl. The SYBR Green QPCR master mix included Taq DNA 
polymerase. Aliquots (2pl) of each experimental cDNA sample or negative control were 
dispensed into wells in duplicate. A negative control ( non-template control, DEPC water) 
was used for each primer to screen for contamination of reagents or false amplification
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(primer-dimers). The PCR plate was placed in the PCR machine (MX3000P™, Strategene, 
USA), and the amplification protocol run for a total of 40 cycles.
Each PCR cycle involved 3 stages (Figure 16): denaturing, the solution was heated to 95°C 
to denature the two strands of the target cDNA (SYBR Green I dye remained unbound); 
annealing, the solution was cooled to 60°C to enable the primers to bind to the DNA strand 
ends (fluorescence occurred on binding of the SYBR Green I dye to double-stranded 
DNA), and extension, reheating to 72°C was accompanied by synthesis of complementary 
copies of each DNA strand. Fluorescence, as measured by an amplification plot, increases 
as the double-stranded DNA extends, but remains unchanged in the non-template control 
which is devoid of DNA.
^  Denaturing (95°C): DNA strands separate
A C T G  .. . T C G A  
T G A C A G C T
^  Annealing (60°C): primers bind to DNA strands
Extension (72°C): polymerase 
synthesises new DNA strands
Figure 16. An illustration o f the three stages o f  PCR. Denaturing: solution is heated to 95°C to denature the 
two strands o f  the target DNA. Annealing: solution is cooled to 60°C to allow the primers to anneal to the 
ends o f the DNA strands. Extension: solution is reheated to 72°C to allow polymerase to synthesise 
complementary copies o f each strand.
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2.7.6 Amplification plot
The fluorescence was monitored in real-time and displayed as an amplification plot (Figure 
17), which correlated with the number of copies of DNA synthesised. The initial copy 
number was quantified, based on the threshold cycle, which is defined as the cycle number 
at which fluorescence is determined to be statistically significant above background. The 
threshold cycle has been shown to be inversely proportional to the log of the initial copy 
number (Higuchi et al. 1993). Furthermore, threshold cycle is a more accurate parameter 
than information based on endpoint determinations, which may be influenced by limiting 
reagents. The more template that is initially present, the fewer the number of cycles it takes 
to reach threshold. Ultimately, the threshold cycle value was used to compare RNA 
expression levels between contracting Dupuytren’s and control fibroblasts in the CFM 
model. Responses to ilomastat exposure were compared with responses to basal media 
conditions (GFM) and control peptide.
5
T3
0)0
<5
g
1 
3  O
Template
3
Threshold
cycle Non-
Template2
0
0 5 10 2515 20 30
Number of Cycles Completed
Figure 17. An illustration o f  a PCR amplification plot for a DNA sample (template, blue boxes) and non­
template control (pink boxes). The fluorescence o f  SYBR Green I increases with each cycle as the template 
extends. The threshold cycle is the point at which the fluorescence signal is detectable above a background 
threshold signal (horizontal black line).
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Contamination from primer-dimer formation can result in generation of an amplification 
curve in the absence of cDNA. A dissociation profile was therefore generated to determine 
whether amplification was due to template extension or contamination from primer-dimers 
(Figure 18). The melting of products results in a drop in fluorescence which is recorded on 
the dissociation curve. Primer-dimers generally dissociate at lower temperatures than the 
desired PCR products. Any DNA sample with evidence of primer-dimer formation on the 
dissociation curve was discarded and the PCR repeated.
Template
g  4000
Non-Template
55 60 65 70 75 80 85 90 95
Temperature (C)
Figure 18. An illustration o f  a dissociation curve generated by an uncontaminated DNA template sample and 
contamination in the non-template control. The fluorescence peak due to the amplicon (template curve, blue 
boxes) is distinguishable from the peaks due to primer-dimer formation (non-template curve, pink boxes) 
because dissociation o f  the latter occurs at lower temperatures. Fluorescence is displayed as the first 
derivative.
2.7.7 Oligonucleotide primers
Specific human oligonucleotide primers were used to amplify the variable portions of 
MMP-1, -2, MT1-MMP, TIMP-1 and 2. GAPDH was the housekeeping gene used as an 
internal cellular control. All primers were ordered and synthesised commercially by MWG 
Biotech. An internal control, or housekeeping gene, is required to determine baseline RNA 
expression so that comparisons of MMP expression under different sets of conditions can
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be objectively made. The two main prerequisites of a housekeeping gene in our experiment 
were met by GAPDH; it is expressed by palmar fascia (Beckett 2005) and it does not vary 
with changes in mechanical tension (Mudera et al. 2000; Cheema et al. 2003).
The optimal concentration of each reverse and forward primer pair was established to avoid 
primer-dimer formation, as SYBR Green I will bind to any double-stranded DNA. This was 
determined empirically; serial primer concentrations in the range 50nM to 300nM were run 
with standard cDNA for 40 cycles (data not shown). The optimal concentration was the 
lowest concentration that resulted in the lowest cycle threshold (amplification plot) and an 
adequate fluorescence, with minimal or no primer-dimer formation as determined by the 
dissociation curve.
TA R G E T
PROTEIN
PRIM ER
SEQUENCE
M M P-I F -  5* CGA CTC TAG AAA CAC A AG AGC A AG A 3 ’
R -  5 ’A AG GTT AGC TTA CTG TCA CAC GCT T 3 ’
M M P-2 F -  5 ’ GTG CTG A AG GAC AC A CTA A AG A AG A 3’
R -  5 ’ TTG CCA TCC TTC TCA AAG TTG TAG G 3 ’
M T1-M M P F - 5 ’ GTC TTC AAG GAG CGC TGG TTC TG 3'
R -  5 ’ TAG CCC GGT TCT ACC TTC AG 3’
TIM P-I F -  5 ’ ACC ACC TTA TAC CAG CGT TAT GAG 3 ’
R -  5 ’ GAG GAG CTG GTC CGT CCA CAA GCA 3 ’
TIM P-2 F -  5 ’ CGC TGG ACG TTG GAG GAA AG A AGG 3 ’
R 5 ’ GGG TCC TCG ATG TCG AG A A AC TCC 3 ’
GAPDH F -  5* AAG AAG ATG CGG CTG ACT GTC GAG CCA CAT 3 ’
R -  5 ’ TCT CAT GGT TCA CAC CCA TGA CGA ACA TG 3 ’
Table 5. Table demonstrating primer sequences for the target MMP and TIMP target genes. F denotes forward 
sequences and R reverse sequences. The sequences were designed by previous investigators in our research 
institute (Beckett 2005).
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2.7.8 Data Analysis
The relative expression software tool (REST©) was used for the calculation of relative 
MMP and TIMP gene expression levels in real-time PCR (Pfaffl et al. 2002). This 
mathematical model is based on the mean threshold cycle between the treated and the 
control cells. The target gene expression was normalised against our housekeeping gene, 
GAPDH. Statistical analysis of group differences was performed by Pair Wise Fixed 
Reallocation Randomization Test©, implemented in the REST-XL software (Pfaffl et al. 
2002).
2.8 STATISTICAL ANALYSIS
All data underwent statistical evaluation. Statistical analysis was performed using a 
statistical software package (Sigmastat 2.0). A two-tailed student t-test was used to 
compare treatments between two groups whilst a one-way ANOVA was employed to 
compare results derived from multiple groups. Probabilities with p<0.05 were considered 
statistically significant.
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CHAPTER 3
OPTIMISATION OF CONDITIONS 
FOR MATRIX CONTRACTION IN 
THE FPCL MODEL
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3.1 INTRODUCTION
In this chapter we set out to establish the optimum conditions for use o f ilomastat in 
subsequent models of fibroblast-mediated matrix contraction. Matrix contraction in 
vitro is a complex process that involves numerous cellular processes including 
migration, cellular contraction and matrix reorganisation (Tomasek et al. 2002; Grinnell 
2003). Cell density has been shown to be an additional key parameter that influences 
both the mechanism and extent of lattice contraction (Ehrlich et al. 2000).
As discussed earlier (section 1.15), two of the three variations o f FPCL, the free- 
floating and stress-release models, allow simple quantification of contraction (Grinnell 
2003). In this thesis, we used the stress-release model as it most closely mimics 
Dupuytren’s contracture following surgical release and has been favoured by previous 
investigators studying Dupuytren’s fibroblasts (Howard et al. 2003; Tse et al. 2004).
3.2 AIMS
Initially, our aim was to determine whether ilomastat was cytotoxic or affected 
proliferation and therefore density of Dupuytren’s and carpal ligament-derived 
fibroblasts (section 2.2.3). Secondly, we set out to define an appropriate time course for 
FPCL contraction by Dupuytren’s and control fibroblasts. Finally, we aimed to 
demonstrate a dose-dependent inhibition of fibroblast lattice contraction mediated by 
ilomastat (section 2.4.4). These preliminary experiments were designed so that the 
optimum dose of ilomastat could be selected that suppressed matrix contraction without 
affecting cell proliferation or viability for use in subsequent experiments.
3.3 METHODS
A WST-1 metabolic assay was performed to assess both cytotoxicity and cell 
proliferation. After determining the optimal detection limits o f the WST-1 proliferation 
assay, the effect of serial concentration o f DMSO and ilomastat on fibroblast viability 
and proliferation were investigated. Fibroblast-mediated matrix contraction in a stress-
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release FPCL model was characterised over time and then a dose-response effect of 
ilomastat-mediated suppression of FPCL contraction was established.
3.4 RESULTS
Although 17 Dupuytren’s tissue samples were harvested for explant culture, the number 
of cells available for experiments was limited to five paired sets of cord and nodule due 
to difficulty in delineating cord from nodule, cellular senescence and over-passage of 
cells. Therefore, unpaired nodule and cord cell strains were selected for use in the 
preliminary experiments to test cytotoxicity and establish conditions for the FPCL 
model.
3.4.1 Optimal cell density for proliferation assay
The WST-1 assay is a metabolic proliferation assay that relies on the conversion of a 
tetrazolium salt (WST-1) to formazan by cellular enzymes. The amount of formazan 
produced is related to the number of viable cells present; an increase in cell number is 
estimated by increasing absorbance (or optical density, OD) at 450nm. Conversely, cell 
death is determined as a decrease in OD 450nm at the end-point of the assay compared 
with the t=0 value (section 2.2.3). At higher cell densities, substrate availability may 
become a rate limiting step in the reaction preventing accurate determination of cell 
number from formazan production. Fibroblasts derived from different tissues vary in 
both their size and metabolic activities, which could affect the cell density at which 
substrate availability becomes limiting. It was therefore initially necessary to establish 
an appropriate cell density specific to palmar fascia fibroblasts to use in subsequent 
proliferation experiments.
Nodule-derived fibroblasts were seeded into a 96-well culture plate at a range of 
densities (2-20,000 cells/ well) to determine the optimal limits o f detection of fibroblast 
proliferation by the WST-1 assay (section 2.4.2). The results of the relationship between 
optical density (absorbance at 450nm) and cell number are illustrated in Figure 1.
At lower fibroblast densities (2-12,000 cells/well), there was a linear relationship 
between optical density and number of cells seeded in each well, suggesting that the
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WST-1 reagent could accurately estimate cell number over this range (Figure 2). 
However, at densities greater than 12,000 cells/well, optical density was no longer 
proportional to cell number and would therefore lead to an underestimate o f  cell 
number.
3 i
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Fibroblast Density (xl 000/ well)
Figure 1. An illustration o f  the relationship between optical density (absorbance at 450nm) and cell 
number. Nodule-derived fibroblasts were cultured (n=6 replicates) for 24 hours at various cell 
concentrations (2-20,000/w ell). The absorbance was measured spectrophotometrically using the WST-1 
assay. Mean ± SEM.
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Figure 2. Illustration o f  the relationship between optical density and cell number at lower cell densities. A 
linear regression formula is demonstrated and the correlation coefficient (R2) confirms the linearity o f  the 
relationship.
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From the results, it therefore appeared that the upper limit for accurate determination of 
cell number by the WST-1 assay was 12,000 cells/well. For subsequent proliferation 
assays, it was decided to seed each well with 4,000 cells/well as this density was in the 
lower-middle range of the linear relationship, enabling both a cell loss and up to a three­
fold increase in cell number to be accurately determined by the WST-1 assay.
3.4.2 Effect of ilomastat on fibroblast proliferation
Once the parameters for the WST-1 assay had been established, it was our aim to 
identify any stimulant or toxic effects of the broad-spectrum MMP inhibitor, ilomastat, 
on fibroblast proliferation as this would need to be taken into consideration when 
interpreting subsequent fibroblast contractile activity in our in vitro contraction model. 
Specifically, it would be impossible to separate a proliferative effect (i.e. more cells 
leading to greater contraction) from a genuine effect on the magnitude of matrix 
contraction by a defined number of cells controlled for each set of cell strains (nodule, 
cord) assessed.
Initially, the response of fibroblasts to normal fibroblast growth medium (NGM) was 
determined. Exposure to NGM led to proliferation of Dupuytren’s and control 
fibroblasts as evidenced by the increase in OD values at 48 hours for carpal ligament, 
cord and nodule-derived fibroblasts compared to t=0 values (34 ± 2%, 35 ± 3%, 99 ± 
1% respectively, Figure 3). Under basal conditions, nodule-derived fibroblasts 
demonstrated a significantly greater proliferative response than either cord or carpal 
ligament-derived cells (p<0.001).
Subsequently, the proliferation of fibroblasts exposed to concentrations of ilomastat (0- 
1 mM) was compared with proliferation of cells cultured in the vehicle control (DMSO; 
0-1%), to determine whether any observed effect on proliferation was due to the action 
of the MMP inhibitor or the vehicle control.
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Figure 3. Proliferation o f  Dupuytren’s and control fibroblasts (n=6 replicates) in response to NGM at 24 
hours (filled bars) and 48 hours (open bars). *p<0.001 represents a significantly greater proliferative rate 
for nodule-derived fibroblasts than either cord or carpal ligament-derived cells. Mean ± SEM.
3.4.2.1 Effect of ilomastat on proliferation by cord-derived fibroblasts
The effect o f  serial dilutions o f  ilomastat on proliferation o f  cord-derived fibroblasts is 
illustrated in Figure 4. Following a 48 hour exposure, ilomastat did not affect cell 
proliferation at concentrations o f  InM-lOOpM as OD values were not significantly 
different from exposure to NGM  alone. However, at greater concentrations (Im M ), 
ilomastat induced a 44 ±  1% decrease in absorbance com pared with the t=0 value 
(p<0.001). As we have already shown that OD is proportional to cell number, any 
decrease in OD below the observed t=0 value is indicative o f  cell death over the 48 hour 
exposure period. We therefore conclude that ilomastat appears to be cytotoxic at this 
concentration (Im M ).
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Figure 4. Effect o f  serial dilutions o f  ilomastat on the proliferation o f  cord-derived fibroblast (n=6 
replicates) proliferation over a 48 hour time period. *p<0.001 represents significant reduction in OD 
below the t=0 value (horizontal line, OD 0.78). Mean ± SEM.
However, DMSO is used as a carrier in the preparation of ilomastat and is known to be 
cytotoxic. In order to determine whether concentrations of DMSO used in the 
preparation of ilomastat might influence the efficacy of ilomastat independently, we 
assayed dilutions of DMSO known to be present (lxK f6- ^ )  when ilomastat is tested 
(Figure 5).
Concentrations of 0.1% DSMO and below did not significantly affect cell proliferation. 
Exposure to 1% DMSO led to a reduced proliferative response (OD 0.78 ± 0.02) 
compared to exposure to NGM alone (OD 1.07 ± 0.04, p<0.001) over 48 hours. 
However, the OD values of 1% DMSO were not significantly different from t=0 value 
(OD 0.78 ± 0.01) suggesting that no cell death occurred. The results indicated that 1% 
DMSO induced a cytostatic rather than cytotoxic effect on cord-derived fibroblasts and 
therefore could not account for the cell loss observed on exposure to 1 mM ilomastat.
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Figure 5. Effect o f  serial dilutions o f  DM SO on the proliferation o f  cord-derived fibroblasts (n=6 
replicates) over a 48 hour exposure period. *p<0.001 represents significant reduction in OD below the 
control value (0, NGM exposure alone). The horizontal line depicts the t=0 value (O D 0.78). Mean ±  
SEM.
3.4.2.2 Effect of ilomastat on proliferation by nodule-derived fibroblasts
The effect of serial dilutions of ilomastat and DMSO on proliferation of nodule-derived 
fibroblasts is illustrated in Figure 6. Following a 48hr exposure, ilomastat did not affect 
cell proliferation at concentrations of InM-lOOpM as OD values were not significantly 
different from exposure to NGM alone. Exposure to ImM ilomastat led to a 45 ± 1% 
decrease (p<0.001) in absorbance compared to NGM alone over the 48 hour outcome 
period indicating a suppression of proliferation. However, the cellular absorbance in 
response to ImM ilomastat (0.48 ± 0.02) was not significantly different to the t=0 value 
(0.45 ± 0.01) suggesting that no cell death occurred.
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Figure 6. Effect o f  serial dilutions o f  ilomastat (panel A) and DMSO (panel B) on the proliferation o f  
nodule-derived fibroblasts (n=6 replicates). *p<0.001 represents significant reduction in OD below the 
basal conditions (NGM exposure alone). The horizontal line represents the t=0 value (0.78) for each 
graph. Mean ± SEM.
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DMSO concentrations of 0.1 % and below did not significantly affect cell proliferation, 
whereas, exposure to 1% DMSO led to a reduced proliferative response (OD 0.83 ± 
0.02) compared to exposure to NGM alone (OD 0.92 ± 0.02, p<0.01) over 48 hours. 
However, the OD values in response to 1 % DMSO were not significantly different from 
t=0 value (OD 0.45 ± 0.01) suggesting that no cell death occurred. As 1% DMSO is 
present in ImM ilomastat, the results suggested that the suppression of fibroblast 
proliferation was mediated in part by the concentration of the DMSO in both the vehicle 
control and ilomastat, rather than ilomastat toxicity.
3.4.2.3 Effect of ilomastat on proliferation by carpal ligament-derived fibroblasts
The effect of serial dilutions o f ilomastat and DMSO on proliferation of carpal 
ligament-derived fibroblasts is illustrated in Figure 7. Following a 48hr exposure, OD 
values were not significantly different between basal conditions and ilomastat at 
concentrations InM-lOOpM. However, exposure to ImM ilomastat led to a 11 ± 1% 
decrease (p<0.01) in absorbance compared to NGM alone at 48 hours suggesting an 
inhibition of proliferation. There was no evidence of cell death at any of the 
concentrations o f ilomastat tested as OD values were greater than the t=0 value (0.79 ± 
0 .01).
When the effect o f the vehicle control on proliferation was investigated, there was no 
significant difference demonstrated between the range of DMSO concentrations tested 
( lx l  0"6- 1 %) and basal conditions. The results therefore suggested that the cytostatic 
effect of ilomastat at ImM on carpal ligament-derived fibroblasts was not due to the 
presence o f DMSO in the ilomastat preparation.
In summary, the results o f the proliferation assay suggest that both ilomastat and DMSO 
independently can affect cell proliferation and viability at high concentrations (ImM 
ilomastat, 1% DMSO). Furthermore, the effect appears to be cell-type dependent. 
However, a uniform finding across all cell types was that at lower concentrations of 
DMSO (0.1% or below) and ilomastat (lOOpM or below), fibroblasts remained viable 
and functional.
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Figure 7. Effect o f  serial dilutions o f  ilomastat (panel A) and DMSO (panel B) on the proliferation o f  
carpal ligament-derived fibroblasts (n=6 replicates). *p<0.001 represents significant reduction in OD  
below the basal conditions (NGM exposure alone). The horizontal line represents the t=0 value (0.79) for 
each graph. Mean ± SEM.
Having established that lOOpM ilomastat was the upper limit at which fibroblasts 
remained viable and functional, optimal conditions for investigating fibroblast-mediated 
lattice contraction were determined. Initially, the effect of incubation time was
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investigated by measuring lattice contraction under basal conditions over a 5-day time 
course, aiding establishm ent o f  an optimal time course.
3.4.3 FPCL contraction over 5 days
A stress-release FPCL model was em ployed to assess matrix contraction (see section 
2.6.3). Fibroblast-seeded lattices were allowed to develop mechanical tension for 48 
hours prior to release. D upuytren’s and control fibroblasts all dem onstrated an ability to 
contract collagen lattices in the stress release FPCL model (Figure 8).
A B
C D
Figure 8. An illustration o f  lattice contraction by cord-derived fibroblasts. Panel A illustrates stressed 
lattices (pre-release). Panels B-D illustrate contracting lattices on day 1 (B), day 2 (C) and day 5 (D) 
follow ing release o f  attached lattices from the w ell periphery.
The change in lattice area over time for all three cell types is illustrated in Figure 9. 
O ver the 5-day time course, nodule-derived fibroblasts contracted lattice by 98 ± 0.3% 
o f  their original size, cord by 93 ± 0.5%  and carpal ligament by 81 ± 0.9% .
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Figure 9. A comparison o f  lattice contraction mediated by carpal ligament, cord and nodule-derived 
fibroblasts (n=4 replicates) over time. Mean ±  SEM.
As can be seen in Figure 10, the rate o f  lattice change was not uniform over the 5 days. 
The greatest rate o f  contraction for all three cell types occurred in the day immediately 
following lattice release. After 24 hours, carpal ligament-derived fibroblasts had 
contracted lattices by 63%  ± 1.4%, cord by 72% ± 2.5% and nodule by 80% ± 1.2%. 
This compared with lattice contraction in the final 24 hours o f  4 ± 0.9%, 1 ± 0.5%, 1 ± 
0.3%, respectively.
Although lattices continued to contract over the remaining 4-day tim e course, the rate o f  
contraction was not significantly different between 2 and 5 days post release. Therefore, 
the end point adopted for this assay was determined to be 48 hours post release as this 
initial period is the most sensitive to dynamic changes in lattice contraction. 
Furthermore, a  48 hour incubation time would enable sam pling o f  M M P protein 
production over the dynamic contraction range and reduce the need for additional m edia 
changes and therefore susceptibility to infection.
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Figure 10. A comparison o f  change in lattice contraction over time mediated by carpal ligament, cord and 
nodule-derived fibroblasts (n=4 replicates). Mean + SEM.
FPCLs were subsequently exposed to serial dilutions o f  ilomastat up to lOOpM to 
determine the optimal concentration at which ilomastat was effective in the model o f 
matrix contraction (section 2.6.4).
3.4.4 Effect of ilomastat dose on contraction by cord-derived fibroblasts
The results o f  FPCL contraction by cord-derived Fibroblasts exposed to serial 
concentrations o f  ilomastat (0-100pM ) are illustrated in Figure 11. Following release, 
lattice contraction by fibroblasts exposed to ilomastat (lOOnM-lOpM) was not 
significantly different to exposure to NGM  alone. However, at greater concentrations 
(lOOpM), ilomastat induced a 71 ± 3% suppression (p<0.001) o f  lattice contraction 
compared to basal conditions (NGM ) at 48 hours. The results suggested therefore that 
there was no dose-response effect at the concentrations tested and that ilomastat was 
only efficacious at inhibiting lattice contraction at or around 1OOpM.
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Figure 11. Effect o f ilomastat (lOOnM to lOOpM) on lattice contraction by cord-derived fibroblasts (n=4 
replicates). *p<0.001 represents a significant difference between ilomastat and NGM treatment. Mean ± 
SEM.
3.4.5 Effect of ilomastat dose on contraction by nodule-derived fibroblasts
The results of FPCL contraction by nodule-derived fibroblasts exposed to serial 
concentrations of ilomastat (0-100pM) are illustrated in Figure 12. Following release, 
lattice contraction by fibroblasts exposed to ilomastat (100nM-10pM) was not 
significantly different to exposure to NGM alone. However, at greater concentrations 
(lOOpM), ilomastat induced a 116 ± 2% suppression (p<0.001) of lattice contraction 
compared to basal conditions (NGM) at 48 hours. As with cord-derived fibroblasts, the 
results suggested that the magnitude of response to ilomastat did not vary with the 
concentration of ilomastat tested and that ilomastat was only efficacious at inhibiting 
lattice contraction at lOOpM.
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Figure 12. Effect o f  ilomastat (lOOnM to lOOpM) on lattice contraction by nodule-derived fibroblasts 
(n=4 replicates). *p<0.001 represents a significant difference between ilomastat and NGM treatment. 
Mean ± SEM.
3.4.6 Effect of ilomastat dose on contraction by carpal ligament -derived 
fibroblasts
A graphic illustration of the effect of serial dilutions of ilomastat (0-lOOpM) on lattice 
contraction by carpal ligament-derived fibroblasts is demonstrated in Figure 13. In the 
photograph, lattices exposed to lOOpM ilomastat are visibly larger than those exposed 
to NGM alone. This observation was supported by statistical data based on 
measurements of mean lattice area over time as illustrated in Figure 14.
Exposure to ilomastat at the highest concentration (lOOpM) resulted in a 27 ± 4% 
suppression (p<0.001) of lattice contraction compared to basal conditions (NGM) at 48 
hours. At lOpM, ilomastat induced an apparent 24 ± 3% suppression of lattice 
contraction, although this proved not to be significant. In fact, lattice contraction by 
fibroblasts exposed to all lower doses of ilomastat (lOOnM-lOpM) was not significantly 
different to exposure to NGM alone.
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Figure 13. Digital photograph o f  fibroblast seeded lattices exposed to varying concentrations o f  ilomastat.
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Figure 14. Effect o f  ilomastat (lOOnM to lOOpM) on lattice contraction by carpal ligament-derived 
fibroblasts (n=4 replicates). *p<0.001 represents a significant difference between ilomastat and NGM  
treatment. Mean ±  SEM.
The results of the relative inhibition achieved by different concentrations of ilomastat on 
FPCL contraction for all three cell types is illustrated in Figure 15. Relative inhibition 
was used to described the difference in mean lattice area of ilomastat-exposed lattices
93
Results
relative to GFM exposure. For both Dupuytren’s and control fibroblasts, lOOpM 
ilomastat induced the greatest inhibition in matrix contraction, although for carpal 
ligament-derived cells, the effect at lOpM was almost as effective as at lOOpM, 
although this difference proved not to be significant. Concentrations in excess of 
1 OOpM did not result in a greater magnitude of response (data not shown).
The results of the preliminary proliferation and FPCL experiments suggested therefore 
that 1 OOpM was the optimal dose at which ilomastat suppressed matrix contraction, 
independently o f it’s effects on fibroblast proliferation and was adopted for use in 
subsequent experiments.
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Figure 15. Ilomastat-mediated inhibition in lattice contraction relative to NGM o f  lattices seeded with 
carpal ligament, cord and nodule-derived fibroblasts (n=4 replicates). *p<0.001 represents a significant 
difference between ilomastat lOOpM and NGM treatment at 48 hours. Mean ±  SEM.
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3.5 DISCUSSION
Fibroblast proliferation is a key issue when assessing matrix contraction as cell number 
can influence both the mechanism and extent of lattice contraction (Ehrlich et al. 2000). 
Synthetic MMP inhibitors have been reported to affect cell proliferation through a 
cytostatic (cells are growth-arrested but viable) rather than cytotoxic (cell death is 
induced) effect (Tonn et al. 1999; Coussens et al. 2002). Indeed, the anti-proliferative 
effect is part o f their attraction as anti-cancer agents, although not their principal mode 
of action. Ilomastat has been shown to affect the pattern of cell proliferation in an 
experimental model of heart organogenesis (Linask et al. 2005), although, other 
investigators have found no effect of ilomastat on proliferation of ocular fibroblasts in 
an FPCL model (Daniels et al. 2003) or keratinocyte proliferation in an experimental 
model of wound healing (Mirastschijski et al. 2004). Similarly, DMSO, the carrier that 
ilomastat is prepared in, has been shown to affect cell proliferation. Specifically, 
Berliner and colleagues demonstrated a cytotoxic effect o f DMSO at 5%, but no effect 
at 1%, the maximum dose tested in our experiments (Berliner et al. 1967).
In our investigation, there was no effect o f ilomastat on proliferation of Dupuytren’s 
and control fibroblasts over a wide range of concentrations. However, at the highest 
concentration tested (ImM ), ilomastat appeared to suppress proliferation of nodule and 
carpal ligament-derived fibroblasts, and led to the cell death o f cord-derived cells. It 
must be conceded that this inhibition o f fibroblast proliferation appeared in part to be 
mediated by the concentration of the DMSO used as the vehicle control in the 
preparation o f ilomastat. In addition high concentrations o f ilomastat (ImM) led to cell 
death o f cord derived-cells which appeared to be independent o f the effects o f the 
vehicle control. This latter finding was unexpected as cytotoxicity is not generally 
attributed to MMP inhibitors, although it may have been peculiar to the specific cord 
strain tested. The pattern o f response to ImM ilomastat could be clarified by increasing 
the number o f samples investigated.
When matrix contraction was observed over a long time course (5 days), it was found 
that the greatest rate o f contraction occurred in the first 24 hours. Investigations have 
previously found that cells in the stress-release model develop stress fibres and 
isometric tension during lattice attachment (Grinnell 2003). Once released, lattice
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contraction therefore proceeds rapidly. However, over time, mechanical unloading leads 
to regression of the contractile phenotype slowing of the rate o f contraction, which is 
also compounded by loss o f stimulation from growth factors in the media over time. A 
48 hour post-release time course was therefore selected for subsequent experiments to 
capture the most dynamic period o f lattice contraction and reduce the chance of 
infection from multiple media changes.
Previous investigators have demonstrated a dose-response inhibitory effect of ilomastat 
on FPCL contraction over a similar range o f concentrations (InM-lOOpM) to our 
investigation (Daniels et al. 2003). However, we found that diseased and control palmar 
fascia fibroblasts were only sensitive to ilomastat at the highest concentration tested 
(lOOpM). Therefore, lOOpM ilomastat was selected as the optimal dose for subsequent 
experiments as it induced the greatest inhibition of matrix contraction for all three cell 
types without compromising fibroblast viability or proliferation.
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3.6 SUM M ARY
• The accurate detection limits of the WST-1 assay were established to range from 2- 
12,000 fibroblasts/ well.
• The optimal dose o f ilomastat at which fibroblasts remained viable and functional 
was determined to be lOOpM by the WST-1 assay.
•  Contraction of cord, nodule and carpal ligament fibroblast-seeded lattices was 
greatest in the first 24 hours following lattice release.
•  No dose-response effect for ilomastat (1 OOnM-1 OOpM) was demonstrated.
• The non-toxic dose of ilomastat that achieved the greatest inhibition in lattice 
contraction was determined to be 1 OOpM.
The next chapter was designed to establish the differences in the contractile abilities of
Dupuytren’s and control fibroblasts and to determine the effect of the MMP inhibitor,
ilomastat, on lattice contraction.
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CHAPTER 4
EFFECT OF ILOMASTAT ON MATRIX 
CONTRACTION IN THE FPCL MODEL
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4.1 INTRODUCTION
Contraction is the key pathological component of Dupuytren’s disease. MMP activity has 
been shown to play a critical role in collagen lattice contraction mediated by both ocular 
and dermal fibroblasts in vitro (Scott et al. 1998; Pins et al. 2000; Sheridan et al. 2001; 
Daniels et al. 2003). MMP expression has also been demonstrated in fibroblasts derived 
from normal and diseased palmar fascia (Beckett 2005). Furthermore, there is evidence that 
MMP expression is upregulated in Dupuytren’s tissue (Qian et al. 2004) and that nodule- 
derived fibroblasts respond to changes in their mechanical environment by overexpressing 
MMP-1 and MMP-2 in comparison to control cells (Beckett 2005). We therefore 
determined the importance of MMP activity in matrix contraction by cells derived from 
both early (nodule) and end-stage (cord) Dupuytren’s tissue. Furthermore, we evaluated the 
efficacy of the broad-spectrum MMP inhibitor, ilomastat, in abrogating this activity, and 
hence contraction. A stress-release FPCL model (see section 1.13) was selected to evaluate 
contraction as it provides a good approximation of the mechanical environment of native 
palmar fascia tissue, which is subjected to constant mechanical stress from digital extension 
and relaxation from flexion.
4.2 AIMS
The aims of this chapter were two-fold. Firstly, we set out to assess the effect of ilomastat 
on matrix contraction by Dupuytren’s fibroblasts using a stress-release FPCL model of 
lattice contraction. Secondly, we aimed to determine which MMPs are secreted or 
expressed on the cell surface during contraction and how their protein levels and enzyme 
activity are affected by ilomastat.
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4.3 METHODS
Once the parameters of the in vitro models were established using unpaired cell strains 
(chapter 3), all subsequent experiments were conducted using 5 paired cell strains (nodule 
and cord) with 5 carpal ligament cell strains acting as controls (n=4 replicates/ cell strain/ 
treatment). Stress-release FPCLs were prepared as previously described (section 2.4.5) and 
contraction in response to gelatinase-free media (GFM) was compared with exposure to 
ilomastat (lOOpM), control peptide (lOOpM) or vehicle control (0.1% DMSO). The activity 
and expression of several secreted and membrane-bound MMPs was assessed by western 
blotting, gelatin zymography and ELISA (section 2.6).
4.4 RESULTS
4.4.1 Maximum lattice contraction under basal conditions
A comparison of the maximum lattice contraction achieved by groups of Dupuytren’s (cord 
and nodule) and control (carpal ligament) fibroblasts under basal conditions (GFM) is 
illustrated in Figure 1. After 48 hours, nodule-derived fibroblasts contracted lattices (66 ± 
2%, mean reduction in lattice area) to a significantly greater extent than either cord (57 ± 
2%) or carpal ligament (55 ± 1%). This represented an increase of 20 ± 1% contraction of 
nodule over carpal ligament (p<0.001) and 17 ± 2% over cord (p<0.001). There was no 
significant difference in the extent of contraction between cord and carpal ligament.
As demonstrated in Figure 2, contractile and remodelling activity was greatest in the initial 
24 hours compared with the final 24 hours of incubation for both Dupuytren’s and control 
fibroblasts. After 24 hours, carpal ligament-derived fibroblasts had contracted lattices to 94 
± 1% of their final size, cord to 96 ± 2% and nodule to 98 ± 2%. There were no significant 
differences in the proportion of contraction over the initial or final 24 hours between the 
three different cell types.
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Figure 1. Comparison o f  contractile activity o f  multiple cell strains derived from carpal ligament (n=5), 
Dupuytren’s cord (n=5) and nodule (n=5) in response to GFM. ♦p<0.001 represents a significant difference 
between nodule and cord or carpal ligament. Mean ± SEM.
Although the majority of contraction appeared to occur over the initial 24-hour incubation 
period, significant contraction continued over the remaining 24 hours, the magnitude of 
which depended on the individual cell strains assessed. These results are similar to the 
contraction profiles observed in the preliminary experiments conducted in chapter 3 
(section 3.4.3).
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Figure 2. Comparison o f  contractile activity between fibroblasts (n=5) in the initial 24 hour (closed bars) 
period after lattice release and the final 24 hours (open bars). Mean ±  SEM.
4.4.2 Effect of ilomastat on contraction by cord-derived fibroblasts
A graph illustrating the effect o f  ilomastat on FPCL contraction by cord-derived fibroblasts 
is illustrated in Figure 3. On release, fibroblasts contracted lattices to 43 ± 2% o f  their 
original size under basal conditions (GFM), 41 ± 2% (control peptide) and 46 ± 2% 
(vehicle control) after 48 hours. On exposure to ilomastat, lattice contraction by fibroblasts 
was significantly reduced (69 ± 4%, p<0.001) compared to all three control conditions. No 
significant differences were demonstrated between control groups.
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Figure 3. Graph illustrating change in mean area o f  lattices seeded with cord-derived fibroblasts (n=5) over 
time. *p<0.001 represents a significant difference between ilomastat exposure and all three control conditions 
(GFM, control peptide or vehicle control) at 48 hours. Mean ±  SEM.
4.4.3 Effect of ilomastat on contraction by nodule-derived fibroblasts
A pictorial example o f lattice contraction in response to GFM, ilomastat (100)iM), control 
peptide (100p.M), and vehicle control (DMSO 0.1%) is illustrated in Figure 4. Lattices were 
prepared in quadruplicate and mean lattice area was subsequently calculated as a 
percentage o f  the well base area using image analysis software (ImageTool 3.0).
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Figure 4. A digital photograph o f  lattices seeded with nodule-derived fibroblasts 48 hours after release. Rows 
o f  lattices were exposed to different test conditions as illustrated.
A graph illustrating the effect of ilomastat on FPCL contraction as estimated by lattice size 
in proportion to well base is illustrated in Figure 5. On release, nodule-derived fibroblasts 
contracted lattices to 34 ± 2% (mean ± SEM) of their original size after 48 hours under 
basal conditions (GFM), 33 ± 2% (control peptide) and 40 ± 2% (vehicle control). 
However, when exposed to ilomastat, lattice contraction by fibroblasts was inhibited (60 ± 
3%). A pair-wise Turkey test revealed that the difference between treatment with ilomastat 
and the three control conditions was significant (p<0.001). However, there were no 
significant differences between control growth media, control peptide and vehicle control.
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Figure 5. Graph illustrating change in mean area o f  lattices seeded with nodule-derived fibroblasts (n=5 cell 
strains) overtime. *p<0.001 represents a significant difference between ilomastat exposure and all three 
control conditions (GFM, control peptide or vehicle control) at 48 hours. Mean ± SEM.
4.4.4 Effect of ilomastat on contraction by carpal ligament-derived fibroblasts
A graph illustrating the effect o f ilomastat on FPCL contraction by carpal ligament-derived 
fibroblasts is illustrated in Figure 6. On release, fibroblasts contracted lattices to 45 ± 1% of 
their original size after 48 hours under basal conditions (GFM). A similar extent o f 
contraction was observed between fibroblasts exposed to control peptide (45 ± 2%) and 
vehicle control (50 ± 3%). However, on exposure to ilomastat, fibroblast-mediated lattice 
contraction was significantly reduced (77 ± 2%, p<0.05) compared with the three control 
conditions.
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Figure 6. Graph illustrating change in mean area o f  lattices seeded with carpal ligament-derived fibroblasts 
(n=5) over time. *p<0.001 represents a significant difference between ilomastat exposure and all three control 
conditions (GFM, control peptide or vehicle control) at 48 hours. Mean ± SEM.
4.4.5 Differential effect of ilomastat on carpal ligament, cord and nodule
Exposure to ilomastat significantly inhibited lattice contraction after 48 hours by all cell 
strains assessed compared with exposure to control peptide or vehicle control. Figure 7 
demonstrates the relative inhibition o f lattice contraction, which was calculated as the 
difference in lattice contraction relative to basal conditions (GFM). This relative inhibition 
allowed comparisons in the effectiveness o f  ilomastat to be made between cord, nodule and 
carpal ligament.
The relative inhibition o f lattice contraction mediated by ilomastat was greater for nodule 
(84 ± 8%) than cord-derived fibroblasts (58 ± 7%) or carpal ligament (73 ± 6%). However, 
a one-way ANOVA revealed that there were no significant differences in the extent o f 
inhibition between the different cell types (p=0.097).
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Figure 7. Comparison o f  inhibition o f  FPCL contraction relative to basal conditions (GFM). *p<0.05 
represents a significant difference between ilomastat-mediated inhibition at 48 hours and control peptide or 
vehicle control. Mean ±  SEM.
The relative inhibition in lattice contraction mediated by control peptide was determined to 
be 4 ± 3% for carpal ligament, -5 ± 2% for cord and, 1 ± 4% for nodule-derived fibroblasts. 
This compared to inhibition by the vehicle control o f 18 ± 5%, 18 ± 11% and, 22 ± 11%, 
respectively. We had already demonstrated for each cell type that there were no significant 
differences in lattice contraction between exposure to GFM, control peptide or vehicle 
control. Although the relative inhibition by the vehicle control appeared to be greater than 
control peptide, the differences were not significant as determined by a one-way ANOVA 
confirming our previous findings.
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After establishing the precise effect of ilomastat on matrix contraction mediated by 
Dupuytren’s and control fibroblasts, we subsequently undertook analysis of media collected 
from stressed lattices (pre-release) as well as contracting lattices to determine the protein 
levels and pattern of activity of various secreted MMPs. Similarly, we investigated the 
expression and activity of the membrane-bound MMP, MT1-MMP, in cell lysates. All 
analysis was conducted on samples from three paired Dupuytren’s fibroblasts and three 
carpal ligament samples.
4.4.6 Analysis of MMP protein levels by western blotting
4.4.6.1 MMP-1 production
Two bands were detected by western blot analysis in proximity to the 50kDa marker that 
may have corresponded to both pro (55kDa, apparent as a double band) and active (43kDa) 
forms of MMP-1 (Figure 8). Under conditions of mechanical stress (pre-release), carpal 
ligament, cord and nodule-derived fibroblasts appeared to secrete similar levels of both 
MMP-1 forms on exposure to GFM. Similarly, following release of pre-stressed lattices, all 
three cell types demonstrated similar levels of MMP-1 secretion. Treatment with ilomastat 
or the control peptide (lOOpM) did not appear to significantly affect MMP-1 secretion by 
fibroblasts seeded in either pre-stressed or contracting lattices.
These findings were confirmed objectively by scanning densitometry, which was 
performed on MMP-1 blots of samples collected from contracting lattices (Figure 9). The 
mean band densities of both pro and active MMP-1 forms, which correlate to MMP protein 
level, were calculated. Under basal conditions (GFM), carpal ligament-derived fibroblasts 
produced similar levels of pro and active MMP-1 (6.8 ± 2.8, 9.4 ± 2.5, respectively, mean 
band density) compared to cord (7.5 ± 2.5, 7.7 ± 1.6) and nodule (4.7 ± 1.5, 8.6 ±2.1).
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Figure 8. Sample o f  western blot analysis o f  MMP-1 production by carpal ligament, cord and nodule-derived 
fibroblasts seeded within stressed (pre-release) and contracting (post-release) lattices. Lattices were exposed  
to either GFM (A), ilomastat (B) or control peptide (C). The molecular weight (kDa) o f  kaleidoscope markers 
is listed adjacent to the marker bands in left hand column.
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The results suggested that MMP-1 is an important mediator of matrix contraction by both 
diseased and non-diseased palmar fascial fibroblasts in vitro. However, the similarity 
between the three cell strains also implied that MMP-1 protein levels alone could not 
account for the observed increase in contractile and remodelling ability of nodule-derived 
fibroblasts over cord and carpal ligament.
Treatment with ilomastat or the control peptide did not appear to significantly affect pro- 
MMP-1 secretion compared to basal conditions, as judged by mean band density. This 
finding implied that ilomastat did not affect MMP-1 protein at the translational level, 
although an effect on transcription could not be excluded by western blot analysis.
It is important to emphasise that equal amounts of protein were loaded into each lane o f the 
western blot. Therefore, MMP-1 protein levels were standardised against total protein 
enabling direct comparisons to be made o f  mean band densities between different cell types 
and different conditions.
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Figure 9. Quantification o f  MMP-1 protein production o f  fibroblasts (n=5) seeded in contracting lattices. 
Panel A demonstrates pro-MMP-1 and panel B active MMP-1 production as determined by mean band 
density o f  western blots for fibroblasts exposed to GFM, ilomastat or control peptide. Mean ± SEM.
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4.4.6.2 MMP-2 production
A typical western blot analysis of MMP-2 is illustrated in Figure 10. The antibody used to 
detect MMP-2 is specific to both pro (72kDa) and active (66kDa) forms of the protein. We 
detected bands most likely corresponding to the active form suggesting that cells seeded in 
both stressed and contracting lattices secreted active MMP-2. However, the width of the 
bands suggested the presence of additional MMP-2 species between pro and active form 
that were being processed. Furthermore, faint bands were present around the 50kDa marker 
suggestive of MMP-1 (pro and active forms) that pointed to overlap in the specificity of the 
primary anti-MMP-2 antibody used.
Western blots of samples from contracting lattices were assessed objectively by scanning 
densitometry (Figure 11). Under basal conditions, carpal ligament-derived fibroblasts 
produced similar levels of MMP-2 (18.5 ± 2.7 mean band density) compared to cord (14.6 
± 4.6) and nodule (18.1 ± 3.4). Treatment with ilomastat or the control peptide did not 
appear to significantly affect pro-MMP-2 secretion, as there was no significant difference 
in mean band densities between GFM, ilomastat or control peptides for all three cell types. 
The results suggested that exposure to ilomastat did not affect regulation of MMP-2 
production at the translational level.
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Figure 10. Sample o f  western blot analysis o f  MMP-2 production by carpal ligament, cord and nodule-derived 
fibroblasts seeded within stressed (pre-release) and contracting (post-release) lattices. Lattices were exposed 
to either GFM (A), ilomastat (B) or control peptide (C). The molecular weight (kDa) o f  kaleidoscope markers 
is listed adjacent to the marker bands in left hand column.
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Figure 11. MMP-2 protein production as determined by mean band density o f  western blots. Fibroblasts (n=3) 
seeded in contracting lattices were exposed to GFM, ilomastat or control peptide. Mean ± SEM.
4.4.6.3 MT1-MMP
Carpal ligament, cord and nodule-derived fibroblasts expressed both pro (65kDa) and 
active (63kDa) forms of MT1-MMP, a membrane bound MMP, following release of pre­
stressed lattices (Figure 12). A double band is present, which may correlate to both pro 
(65kDa) and active (63kDa) forms of MT1-MMP. Exposure to ilomastat resulted in the 
presence of more prominent bands for carpal ligament, cord and nodule-derived fibroblasts 
suggesting an upregulation of active MT1-MMP compared to basal conditions. This finding 
was confirmed by analysis of mean active MT1-MMP band densities (Figure 13).
Under basal conditions, mean band densities of active MT1-MMP expression were similar 
for carpal ligament (7.4 ± 0.8) and cord (5.8 ± 1.4). Although nodule-derived fibroblasts 
appeared to express far higher levels of active MT1-MMP (10.7 ± 1.4) compared with
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either cord or carpal ligament, the difference was not statistically significant (p=0.063).
However, on exposure to ilomastat, mean band densities increased significantly for all three 
cell types (21 ±  2.2, 20.2 ± 4.2 and 30.7 ± 4.6, respectively), confirm ing an upregulation o f  
M T1-M M P expression. Treatm ent with control peptide did not appear to significantly 
affect M T1-M M P expression.
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Figure 12. Western blot analysis o f  MT1-MMP production by carpal ligament, cord and nodule-derived 
fibroblasts. Lattices were exposed to either GFM (A), ilomastat (B) or control peptide (C). The molecular 
weight (kDa) o f  kaleidoscope markers is listed adjacent to the marker bands in left hand column.
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Figure 13. Active MT1-MMP protein production as determined by mean band density o f  western blots (n=3). 
*p<0.05 represents a significant increase in mean band density o f  fibroblasts exposed to ilomastat compared 
to GFM or control peptide. Mean ± SEM.
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W estern blot analysis is a m ethod for determ ining the presence and com parative abundance 
o f  proteins, how ever, it does not yield inform ation on enzym e activity levels associated 
with M M P expression. Furtherm ore, w estern blot analysis proved too insensitive to detect 
both pro and active form s o f  M M P-2. By contrast, zym ography enables detection o f  actual 
gelatinase enzym e activity (M M P-2, M M P-9) through digestion o f  a gelatin substrate. 
Zym ography w as therefore selected to establish levels o f  M M P-2 enzym e activity.
4.4.7 Gelatin zymography
U nder conditions o f  m echanical stress (pre-release), carpal ligament, cord and nodule- 
derived fibroblasts released sim ilar levels o f  a gelatinolytic species into the m edia that was 
com patible w ith proM M P-2 (72kD a; Figure 14). T reatm ent w ith ilomastat or the control 
peptide did not appear to significantly affect proM M P-2 activity.
Follow ing release o f  stressed lattices, all D upuytren’s and non-D upuytren’s-derived 
fibroblasts secreted both proM M P-2 and an additional gelatinolytic species com patible with 
active M M P-2 (66kD a). The presence o f  active M M P-2 in m edia collected from  lattices 
post-release suggested that M M P-2 activation was concom itant w ith lattice contraction 
under basal conditions. H ow ever, bands corresponding to active M MP-2 w ere absent in 
lattices exposed to ilom astat for all three cell types, suggesting that ilom astat significantly 
suppressed M M P-2 enzym e activity. In addition, the results further highlighted the role o f  
active M M P-2 in fibroblast rem odelling and contractile behaviour, as lattices exposed to 
ilom astat produced no detectable active M M P-2 and contracted less than control conditions.
114
Results
Carpal Ligament Cord Nodule
A B C A B C A B C
Pre-release
Pro
Post-release Pro
Active
Figure 14. Analysis o f  gelatinolytic activity produced in conditioned media collected from stressed (pre­
release) and contracting (post-release) collagen lattices. Carpal ligament, cord and nodule-derived fibroblasts 
were exposed to either GFM (A), ilomastat (B) or control peptide (C).
MMP-9, another important gelatinase, was also detected by zymography. However, not all 
cord, nodule and carpal ligament-derived cell strains appeared to secrete MMP-9 
consistently under the same conditions. Furthermore, where present, gelatinolytic bands 
corresponding to MMP-9 (92kDa) were small indicating less active enzyme in comparison 
to MMP-2 (Figure 15). Therefore no precise pattern o f MMP-9 activity relating to cell type 
or culture conditions could be identified. The results therefore implied that MMP-9 has a 
less significant role in contractile behaviour by palmar fascial fibroblasts than MMP-2, 
which was abundant in all cell lines tested.
Zymography specificajly detects gelatinase activity (MMP-2, MMP-9), therefore further 
analysis by Activity ELISA was required to determine the activity levels o f MMP-1 in 
conditioned media samples, and MT1-MMP in cell lysates derived from contracting 
lattices.
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Figure 15. Analysis o f  gelatinolytic activity produced in conditioned media collected from contracting (post­
release) collagen lattices. Carpal ligament, cord and nodule-derived fibroblasts were exposed to either GFM 
(A), ilomastat (B) or control peptide (C).
4.4.8 Enzyme-Linked Immunosorbent Assay (ELISA)
4.4.8.1 MMP-1 Activity
The results for MMP-1 activity in cell-conditioned media are illustrated in Figure 16. 
Enzyme activity (panel A) was standardised against sample protein concentration so that 
direct comparisons between different treatments and cell strains could be made.
Carpal ligament and cord-derived fibroblasts secreted similar levels o f  active MMP-1 (0.4 
± 0.06ng/mg and 0.39 ± 0.02ng/mg respectively) in post-release contracting lattices. By 
contrast, nodule-derived fibroblasts appeared to secrete levels o f  active MMP-1 in excess o f 
double the levels secreted by all other cell strains (1.25 ± 0.18ng/mg; p<0.05) o f active 
enzyme.
MMP-9
Pro MMP-2
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Figure 16. Quantification o f  MMP-1 activity (ng/ml conditioned media, panel A) and activity standardised 
against media protein content (ng/mg, panel B). Exposure to ilomastat resulted in a significant (*p<0.05) 
inhibition o f  MMP-1 activity to compared to GFM or control peptide. fp<0.05 represents a significant 
difference between nodule (n=3) and cord (n=3) or carpal ligament (n=3). Mean ± SEM.
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MMP-1 activity secreted by nodule-derived fibroblasts was significantly inhibited by 
exposure to ilomastat, leading to a 55% reduction in active MMP-1, compared with MMP-1 
secreted in response to GFM alone (p<0.01). Ilomastat also suppressed MMP-1 activity 
from cord-derived fibroblasts (0.27 ± 0.02ng/mg, p<0.01) but not carpal ligament (0.41 ± 
0.02ng/mg). Ilomastat-mediated suppression of lattice contraction by Dupuytren’s 
fibroblasts was therefore concomitant with inhibition of MMP-1 activity, suggesting an 
important role for active MMP-1 in remodelling and contractile behaviour. MMP-1 activity 
was not significantly inhibited by exposure to the control peptide for carpal ligament, cord 
or nodule-derived fibroblasts.
4.4.8.2 MT1-MMP Activity
Activity of MT1-MMP in cell lysates is illustrated in Figure 17. Panel A demonstrates 
uncorrected enzyme activity, whereas, panel B represents activity standardised against 
protein concentration. All cells assessed demonstrated measurable amounts of MT1-MMP 
in response to GFM basal media. Cord and nodule-derived cells appeared to express higher 
basal levels (220 ± 44, 212 ± 9ng/mg cell lysate, respectively) than carpal ligament (122 ± 
lOng/mg cell lysate), although the difference proved not to be significant (p=0.051).
In contrast to MMP-1, ilomastat treatment appeared to increase MT1-MMP expression in 
cells where lattice contraction had been suppressed. Nodule-derived fibroblasts exhibited 
the greatest increase in MT1-MMP expression, with levels rising threefold to 630 ± 
40ng/mg (p<0.001). Greater MT1-MMP activity was also demonstrated for carpal ligament 
(358 ± 38ng/mg, p<0.001). Treatment with control peptide did not significantly alter MT1- 
MMP activity. There was no significant difference in MT1-MMP activity for cord-derived 
fibroblasts exposed to GFM, ilomastat (430 ± 109ng/mg) or control peptide (188 ± 
38ng/mg) as determined by a one-way ANOVA.
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Figure 17. Quantification o f  MT1-MMP activity (ng/ml cell lysate, n=5, panel A) and activity standardised 
against lysate protein content (ng/mg cell lysate, n=3, panel B). Exposure to ilomastat resulted in a significant 
(*p<0.05) upregulation o f  MT1-MMP activity to compared to GFM or control peptide. Mean ±  SEM.
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4.5 DISCUSSION
In our stress-release FPCL model, nodule-derived fibroblasts (derived from the 
proliferative stage of disease) demonstrated a greater contractile ability compared with cord 
(derived from the ECM deposition stage) or carpal ligament under basal conditions. This 
was an interesting finding as few studies have compared cord-derived fibroblasts directly 
with nodule in the FPCL model. Our findings further define the distinction between these 
two clinical phenotypes, which represent different stages of disease and also appear to be 
distinguishable at the cellular level in terms of fibroblast contractile and remodelling 
behaviour.
Although some studies have shown a greater contractile capacity of cord-derived cells 
compared to cells derived from the normal palmar fascia (Howard et al. 2003), we found no 
difference in our model. Selection of cord from nodule is undoubtedly a key issue and it is 
unclear how Howard and colleagues accurately made the distinction in their study. Our 
method of distinguishing the two types of diseased fascia was robust, as it required clinical 
evaluation to be supported by histological findings before tissue could be delineated 
confidently as either cord or nodule.
In our model, treatment with ilomastat significantly reduced collagen lattice contraction by 
Dupuytren’s and non-Dupuytren’s fibroblasts. As established in Chapter 3, this was 
unrelated to cytotoxicity and therefore attributable to one of the many roles performed by 
MMPs that may influence contractile behaviour including migration (Ehrlich et al. 1990; 
Grinnell 2003), remodelling through removal of matrix molecules, growth, signalling and 
differentiation (Koike et al. 2002; Visse et al. 2003). Inhibition by ilomastat appeared to be 
greatest for nodule although statistically no difference was found between the different cell 
types. Increasing the number of samples assessed might have established whether nodule- 
derived fibroblasts were indeed more sensitive to inhibition by ilomastat was outside the 
scope of the present study.
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Analysis of media samples collected during lattice contraction demonstrated involvement 
of several MMPs in this process. Fibroblasts seeded in contracting lattices (post-release) 
produced MMP-1, MMP-2 and MT1-MMP. The primary substrate of MMP-1 is collagen 
type 1 and similar to the findings of previous investigators, MMP-1 activity was detected in 
the media collected from contracting FPCLs (Scott et al. 1998; Derderian et al. 2005). In 
our study, MMP-1 activity was greatest for nodule-derived fibroblasts, which also 
contracted lattices to the greatest extent. Treatment with ilomastat inhibited enzymic 
activity of MMP-1 in Dupuytren’s-derived fibroblasts (both nodule and cord) but not the 
levels of MMP-1 protein secreted. Surprisingly, ilomastat did not affect MMP-1 activity in 
control carpal ligament fibroblasts as a group, although some individual carpal ligament 
strains demonstrated a small but significant inhibition in response to ilomastat.
Activation of MMP-2 occurred concomitantly with lattice contraction and ilomastat 
inhibited MMP-2 at the level of enzyme-substrate interaction in all fibroblasts. MMP-9, 
which has been shown to be involved in contraction (Defawe et al. 2005), was not 
consistently detected in our study suggesting that MMP-2 is the dominant gelatinase 
mediating lattice contraction by palmar fascial fibroblasts. Our results imply utilisation of 
both MMP-1 and MMP-2 in processing and remodelling of the collagen lattice by 
Dupuytren’s fibroblasts during contraction. Furthermore, regulation of MMPs at the level 
of activation appears to be a crucial step in determining fibroblast contractile behaviour.
MT1-MMP, a membrane-bound MMP known to mediate activation of proMMP-2 
(Deryugina et al. 2001; Visse et al. 2003) was expressed in contracting lattices. Most of the 
MT1-MMP appeared to be expressed in the active form. Exposure of Dupuytren’s 
fibroblasts to ilomastat resulted in an upregulation of MT1-MMP protein expression and 
enzymic activity. This may have been the result of a local feedback mechanism -  
fibroblasts responding to reduced MMP-2 activity by upregulating MT1-MMP expression 
to increase proMMP-2 activation. These results reinforce the dynamic nature of cell-matrix 
interactions: even after MMP secretion has occurred, fibroblasts retain the ability to 
influence their activity in response to matrix signals through membrane-bound enzymes 
such as MT1-MMP.
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4.6 SUMMARY
• Nodule-derived fibroblasts contracted lattices to a significantly greater extent than 
either cord or carpal ligament.
• Inhibition of MMP activity by ilomastat resulted in a significant suppression of lattice 
contraction by Dupuytren’s and control fibroblasts.
• All cell types secreted similar levels of MMP-1 and MMP-2 under basal conditions.
• Ilomastat suppressed activation of MMP-1 and MMP-2.
• Ilomastat exposure induced an increase in expression and activity of MT1-MMP.
In the next chapter, we investigated fibroblast-mediated contraction using the culture force 
model to enable precise quantification of force generation by fibroblasts and to establish 
whether ilomastat had a differential effect on the two components of contraction, namely 
fibroblast contraction and matrix remodelling. Furthermore, a more in depth analysis of 
MMP regulation was performed involving assessment of gene expression, protein levels 
and enzyme activity of both MMPs and their endogenous inhibitors, the TIMPs.
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CHAPTER 5
GENERATION OF CONTRACTILE 
FORCE, MATRIX REMODELLING 
MMP GENE EXPRESSION AND 
ACTIVITY: MODULATION BY 
ILOMASTAT
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5.1 INTRODUCTION
It has been postulated that permanent tissue contracture is the result of two distinct 
processes working in parallel, namely cell-mediated matrix contraction and matrix 
remodelling (Flint et al. 1990; Tomasek et al. 2002). Although the stress-release FPCL 
model provides information on overall collagen contraction, it does not allow delineation of 
the cellular and remodelling components. The culture force monitor was developed to 
provide actual kinetic information on force generation by fibroblasts embedded in a 
collagen matrix (Eastwood et al. 1994). However, more recently, modifications to the 
model have also enabled quantification of the remodelling component, therefore, providing 
further insight into the mechanics of tissue contracture (Marenzana et al. 2006). The precise 
role of MMP activity in the two processes of cell-mediated contraction and matrix 
remodelling has yet to be determined. MMP activity can be regulated at several different 
levels, therefore, understanding key links in the regulatory chain is an essential pre­
requisite to successful development of drugs for therapeutic intervention.
5.2 AIMS
Initially, we set out to determine the effect of ilomastat on force generation by Dupuytren’s 
fibroblasts in the CFM model. We also intended to differentiate the influence of MMP 
activity on cellular contraction and matrix remodelling. Finally, we aimed to establish how 
the pattern of MMP and TIMP expression and activity was affected by ilomastat during the 
process of force generation.
5.3 METHODS
All experiments were conducted using 5 paired Dupuytren’s cell strains (nodule and cord) 
with 5 carpal ligament cell strains acting as controls. Collagen lattices were prepared in the 
CFM model as previously described (section 2.5) and force generation in response to
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gelatinase-free media (GFM) was compared with exposure to ilomastat (lOOpM) or control 
peptide (lOOpM). Addition of Cytochalasin-D (60pM final concentration) allowed 
differentiation of the cellular and remodelling components. The activity and expression of 
several secreted and membrane-bound MMPs was assessed by RT-PCR, western blotting 
and ELISA (sections 2.6-2.7).
5.4 RESULTS
Initially, the model was prepared using acellular collagen lattices to determine whether any 
force was generated in the system in the absence of fibroblasts. Similarly, cytochalasin-D 
was added after 48 hours to demonstrate that it did not affect the collagen lattice structure.
5.4.1 Force generation in acellular lattices
A typical contraction profile of an acellular collagen lattice is demonstrated in Figure 1. As 
can be seen, a small amount of force generation (7 dynes) was observed despite the absence 
of fibroblasts. This inherent mechanical tension has been demonstrated previously and may 
have occurred as a result of a humidity imbalance in the system brought about by 
evaporative losses in the media or lattice (Beckett 2005).
On addition of cytochalasin-D at 48 hours, an initial reduction in measured force was 
demonstrated. However, this was short-lived and may have been due to the sensitivity of 
the force transducer to the addition of fluid to the system. The force quickly recovered to 
it’s prior level implying that any effect of cytochalasin-D subsequently observed was the 
result of a specific effect on cellular processes and not due to an alteration of collagen 
matrix structure or stiffness.
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Figure 1. Contraction profile o f  an acellular collagen lattice. Cytochalasin-D was added to the system after 48 
hours (red arrow).
5.4.2 Effect of ilomastat on contraction and remodelling by cord-derived fibroblasts
A graph illustrating the effect o f  ilomastat on force generation by cord-derived fibroblasts 
is illustrated in Figure 2. Although, force readings were plotted at 15-minute intervals, the 
SEM was only displayed at 6-hour intervals to avoid data clutter. Over the first 48 hours, 
cord-derived fibroblasts exposed to GFM appeared to generate much greater forces than 
fibroblasts exposed to ilomastat. However, the difference only reached statistical 
significance at 42 and 48 hours. After 48 hours, fibroblasts developed a significantly 
greater force both under basal conditions (143 ±  18 dynes, mean ± SEM) and in response to 
control peptide (141 ± 2 3  dynes) compared with ilomastat (71 ±  10 dynes, p=0.023). This 
difference represented a 100% reduction in force generation by fibroblasts exposed to 
ilomastat.
Although there appears to be a distinct pattern o f inhibition by ilomastat, the fact that 
statistical significance occurred at just two time intervals underlies the considerable inter­
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patient variability encountered in contractile responses of cord-derived fibroblasts. This is 
highlighted by the wide ranges of force generation observed at 48 hours for fibroblasts 
exposed to GFM (97 -  197 dynes), control peptide (90 -  221 dynes) and ilomastat (47 -  
100 dynes). However, all cell strains tested individually demonstrated the same pattern of 
inhibition by ilomastat that was present throughout the majority of the 48-hour contraction 
profile.
After addition of cytochalasin-D at 48 hours, which specifically disrupts actin-dependent 
processes, the level of force sharply reduced leaving a residual matrix tension (RMT) of 44 
± 11 dynes for fibroblasts under basal conditions (GFM). Similar levels of RMT were 
observed on exposure to ilomastat (26 ± 7 dynes) and control peptide (57 ± 9 dynes). 
Further interpretation and analysis of this remodelling component will be made in 
subsequent results sections.
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Figure 2. Force generation by cord-derived fibroblasts (n=5) over time. Cytochalasin-D was added to the 
system after 48 hours. *p<0.05 represents a significant difference between ilomastat exposure and control 
conditions (GFM or control peptide). Mean ± SEM.
127
Results
5.4.3 Effect of ilomastat on contraction and remodelling by nodule-derived 
fibroblasts
A graph illustrating the effect o f  ilomastat on force generation by nodule-derived 
fibroblasts is illustrated in Figure 3. After 48 hours, nodule-derived fibroblasts generated 
forces o f  176 ±  15 dynes under basal conditions (GFM). However, exposure to ilomastat 
significantly reduced their ability to generate contractile force (80 ± 8 dynes, p<0.001). In 
fact, a significant difference was first observed at 12 hours (p=0.03) and maintained until 
addition o f  cytochalasin-D at 48 hours. Exposure to control peptide did not significantly 
affect maximum force generation (178 ± 1 7  dynes) compared to basal conditions.
After addition o f cytochalasin-D, the level o f  force maintained by fibroblasts sharply 
reduced leaving a residual matrix tension (RMT) o f 60 ± 11 dynes under basal conditions 
(GFM). Similar levels o f  RMT were observed for fibroblasts exposed to ilomastat (40 ± 4 
dynes) and control peptide (56 ± 5 dynes).
Control Media 
Ilomastat 
Control Peptide
« 120
Time (hours)
Figure 3. Force generation by nodule-derived fibroblasts (n=5 cell strains) over time. Cytochalasin-D was 
added to the system after 48 hours. *p<0.05 represents a significant difference between ilomastat exposure 
and control conditions (GFM or control peptide). Mean ±  SEM.
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5.4.4 Effect of ilomastat on contraction and remodelling by carpal ligament-derived 
fibroblasts
A graph illustrating the effect of ilomastat on force generation by carpal ligament-derived 
fibroblasts is illustrated in Figure 4. At 48 hours, fibroblasts generated similar levels of 
contractile force on exposure to GFM (72 ± 10 dynes) compared to control peptide (78 ± 17 
dynes) or ilomastat (51 ± 10 dynes). In fact, throughout the first 48 hours of monitoring, no 
significant differences were observed between ilomastat and the two control conditions 
although a pattern of inhibition was evident from the graph. As with cord-derived 
fibroblasts, all individual carpal ligament strains demonstrated the same pattern of reduced 
force generation on exposure to ilomastat but collectively, interpatient variability prevented 
emergence of an overall pattern in the group. This is borne out in the wide standard error 
bars of individual data points on the graph. Force generation at 48 hours ranged from 48 -  
100 dynes in fibroblasts exposed to GFM, 35 -  126 dynes (control peptide) and 22 -  73 
dynes (ilomastat).
Addition of cytochalasin-D at 48 hours resulted in a sharp reduction in force level for 
fibroblasts exposed to GFM, leaving a residual matrix tension of 30 ± 5 dynes. Similar 
levels of RMT were observed for exposure to ilomastat (22 ± 6 dynes) and control peptide 
(28 ± 7 dynes).
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Figure 4. Force generation by carpal ligament-derived fibroblasts (11=5) over time. Fibroblasts were exposed 
to GFM, control peptide or ilomastat. Cytochalasin-D was added to the system after 48 hours. Mean ± SEM.
The information derived from the use o f  the culture force monitor lattice contraction model 
was subsequently analysed further to enable comparisons to be made between the response 
o f Dupuytren’s and control fibroblasts to ilomastat in terms o f  maximum force generation 
and rate o f  force development. Similarly, the relative importance o f  cell-mediated matrix 
contraction and matrix remodelling between different cell types was investigated.
5.4.5 Comparison between responses of cord, nodule and carpal ligament
5.4.5.1 Maximum force generation
A comparison o f  the maximum force generated by different cell strains in response to 
ilomastat and control conditions is illustrated in Figure 5. Under basal conditions (GFM), 
Dupuytren’s-derived fibroblasts generated significantly greater contractile forces than 
control cells (p<0.001), representing an increase over carpal ligament o f  246 ± 21% for 
nodule and 197 ± 25% for cord-derived fibroblasts.
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Exposure to ilomastat resulted in a significant (p<0.05) reduction in the maximum force 
generated by nodule and cord-derived fibroblasts but not carpal ligament. Inhibition by 
ilomastat was greatest for nodule, resulting in a 53 ± 7% (relative to GFM) reduction in 
force compared with a 49 ± 5% relative reduction for cord, although the difference was not 
statistically significant. Exposure to the control peptide did not significantly affect force 
generation between cell strains derived from different stages of Dupuytren’s disease 
compared to GFM.
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Figure 5. Maximum force generated over a 48-hour time period by carpal ligament (n=5), cord (n=5) and 
nodule-derived fibroblasts (n=5) in response to GFM, ilomastat or control peptide. tP<0-05 represents a 
significant difference between ilomastat and GFM or control peptide. *p<0.01 represents a significant 
difference in response to GFM between Dupuytren’s and carpal ligament fibroblasts. Mean ± SEM.
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5.4.5.2 Rate of contraction
The greatest rate of force generation by all three cell strains occurred over the first 24 
hours. To further establish the precise relationship between time and force development, we 
analysed the rate of increase in force at 2 hourly intervals over the first 24 hours. The 
results of this analysis are demonstrated in Figure 6.
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Figure 6. Rate o f  increase in force development over the first 24 hours for carpal ligament (CL), cord and 
nodule-derived fibroblasts (n=5). *p<0.05 represents a significant increase by cord compared with CL. 
tp<0.05 represents a significant difference between nodule and cord or CL. }p<0.05 represents a significant 
increase by nodule compared with CL. Mean ± SEM.
Over the first 2-hour period, cord-derived fibroblasts demonstrated the greatest rate of force 
generation (11 ± 3 dynes/ hour), contracting to a significantly greater extent than carpal 
ligament (1 ± 1 dynes/ hour; p<0.05), and nodule (4 ± 1 dynes/ hour). Conversely, over the 
proceeding three 2-hour intervals, nodule-derived fibroblasts developed force at the greatest 
rate. During the 4-6 hour and 6-8 hour intervals, force generation by nodule-derived
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fibroblasts (25 ± 7, 11 ± 1 dynes/ hour, respectively) occurred at a faster rate (p<0.05) than 
carpal ligament (3 ± 1, 2 ± 1 dynes/ hour, respectively), but was not significantly different 
from cord (8 ± 4, 5 ± 2 dynes/ hour, respectively). After 8 hours, the rate o f force 
generation was reduced and similar for all three cell types.
5.4.5.3 Effect of ilomastat on matrix remodelling
The histogram in Figure 7 demonstrates the residual force within the CFM system (residual 
matrix tension or RMT) after disruption o f  the actin cytoskeleton with cytochalasin-D. The 
RMT represents the amount o f permanent matrix remodelling that has occurred within the 
collagen lattice.
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Figure 7. Histogram demonstrating the residual matrix tension o f  Dupuytren’s and control lattices (n=5). 
Fibroblasts were exposed to either GFM, ilomastat or control peptide. *p<0.05 represents a significant 
increase o f  nodule over carpal ligament in response to GFM. Mean ± SEM.
Under basal conditions, there were significant differences in the mean RMT values o f 
Dupuytren’s and control fibroblasts (p<0.05) as revealed by a one-way ANOVA. Nodule-
133
Results
derived fibroblasts demonstrated an RMT of 69 ± 11 dynes, representing a 127 ± 36% 
increase over carpal ligament. Further analysis revealed that the RMT of cord-derived 
fibroblasts (44 ± 11 dynes) was not significantly different from either nodule or carpal 
ligament (30 ± 5 dynes). The results suggested that nodule-derived fibroblasts were able to 
mediate greater permanent remodelling of the collagen lattice than carpal ligament. 
Although exposure to ilomastat tended to result in a lower RMT for all three cell strains, 
the differences were not significant when compared to either GFM or control peptide. 
These findings led to the conclusion that whilst ilomastat treatment resulted in a reduction 
in force generated by cells derived from each different tissue; treatment did not affect 
permanent matrix remodelling.
The cellular component of force generation can similarly be calculated from the collected 
data as the drop in force following addition of cytochalasin-D, in other words, the 
difference between force generated at 48 hours and residual matrix tension. The cellular 
component for each fibroblast type is displayed in Figure 8.
Under basal conditions, the mean cellular component for cord and nodule-derived 
fibroblasts (98 ± 11 dynes, 108 ± 12 dynes, respectively) was significantly greater 
(p<0.001) than for carpal ligament (42 ± 8 dynes). Exposure to ilomastat resulted in a 
significant decrease in the cell-mediated contractile force component for cord and nodule 
(46 ± 6 dynes, 39 ± 8 dynes, respectively) compared to GFM, but not for carpal ligament 
(28 ± 8 dynes). The results therefore appeared to suggest that ilomastat specifically targeted 
cell-mediated force development rather than spatial reorganisation of the matrix.
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Figure 8. Histogram demonstrating cell-mediated contractile force generated by Dupuytren’s and control 
fibroblasts (n=5). Fibroblasts were exposed to either GFM, ilomastat or control peptide. *p<0.05 represents a 
significant increase by nodule and cord-derived cells compared with carpal ligament in response to GFM. 
fp<0.001 represents a significant difference between treatment with ilomastat and GFM. Mean ± SEM.
As determined by Marenzana and colleagues (Marenzana et al. 2006), the reduction in 
force following addition of cytochalasin-D is a result of both the disruption of the actin 
cytoskeleton as well as a recoil force due to the spring-like action of the strain gauge being 
released. They also demonstrated that the greater the final cell-generated force, the greater 
the recoil force and therefore total force reduction. This observation implies that the 
observed RMT is in fact an underestimate of the full extent of matrix remodelling. 
Furthermore, it suggests that both the remodelling and cellular components might more 
accurately be expressed as a proportion of the total force generated rather than raw force 
readings as illustrated in Figure 9.
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When the data was analysed in terms of proportions, it was shown that ilomastat exposure 
resulted in a significant reduction in the cellular component of force generation by nodule- 
derived fibroblasts (48 ± 6%) compared with either GFM (62 ± 5%) or control peptide (68 
± 2%; p<0.05). However, no significant difference between cellular and remodelling 
components was encountered between ilomastat and control conditions for cord or carpal 
ligament. Furthermore, both Dupuytren’s and control fibroblasts demonstrated similar 
proportions of cellular and remodelling components under basal conditions (GFM).
The force generation data derived from the CFM therefore suggested that MMP activity is 
important in both cell-mediated contraction as well as spatial remodelling of the matrix, 
although the relative influence on these two aspects of force development appears to 
depend on fibroblast origin.
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Figure 9. Histogram demonstrating proportion o f  maximum force generated in terms o f  RMT (filled) and 
cellular (dashed) components. *p<0.05 represents a significant difference in response to GFM, ilomastat and 
control peptide (n=5). Mean ± SEM.
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The next set of experiments was designed to assess whether changes in mechanical tension 
in the CFM model were concomitant with changes in MMP expression and activity. 
Initially, gene expression was determined by RT-PCR to establish whether ilomastat 
affected MMP and TIMP mRNA levels either directly or indirectly through a feedback 
mechanism.
5.4.6 RT-PCR: MMP and TIMP gene expression
5.4.6.1 Comparison of gene expression by cord, nodule and carpal ligament
We initially analysed baseline gene expression to determine whether any differences 
existed between Dupuytren’s and control fibroblasts that might correlate with the observed 
differences in force generation described previously in this chapter. MMP and TIMP gene 
expression by cord and nodule-derived fibroblasts relative to control carpal ligament cells 
under basal conditions (GFM) is demonstrated in Figure 10. This relative gene expression 
was expressed as a logarithmic value (refer to section 2.9.8). Therefore, a value greater than 
zero represented gene upregulation, whereas, values less than zero were indicative of 
downregulation. Furthermore, the data was normalised to GAPDH, the housekeeping gene, 
which is not sensitive to changes in the mechanical environment.
Under basal conditions, nodule-derived fibroblasts expressed significantly greater levels of 
MMP-1 (6.3 ± 30, p<0.05) relative to carpal ligament. Similarly, fibroblasts derived from 
cord also expressed relatively greater levels of MMP-1 (1.8 ± 10), although this proved not 
to be significant. MMP-1 expression therefore correlated with the increase in force 
generated by nodule compared to carpal ligament, suggesting that transcription is an 
important level at which regulation of MMP activity occurs. The levels of other MMP and 
TIMP genes investigated were similar between cord, nodule and carpal ligament.
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Figure 10. Comparison o f  MMP and TIMP gene expression by cord (n=5) and nodule (n=5) relative to carpal 
ligament-derived fibroblasts (n=5) under basal conditions (GFM). *p<0.05 represents a significant increase o f  
nodule over carpal ligament. Mean ±  SEM.
A direct comparison between gene expression by nodule relative to cord-derived fibroblasts 
was similarly made to establish whether any differences in baseline gene expression existed 
between the two Dupuytren’s phenotypes. As illustrated in the results in Figure 11, no 
significant differences were demonstrated in MMP and TIMP gene expression profiles 
between cord and nodule-derived cells, which mirrored the findings that contractile and 
remodelling behaviour was similar between the two.
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Figure 11. Comparison o f  MMP and TIMP gene expression profiles by nodule (n=5) relative to cord-derived 
fibroblasts under basal conditions (GFM). Mean ± SEM.
5.4.6.2 Effect of ilomastat on gene expression by cord-derived fibroblasts
The expression by cord-derived fibroblasts o f secreted (MMP-1 and MMP-2) and 
membrane-bound MMPs (MT1-MMP) as well as TIMPs (TIMP-1 and TIMP-2) is 
illustrated in Figure 12. Gene expression o f  cord-derived fibroblasts exposed to ilomastat 
and control peptide was calculated relative to basal conditions (GFM).
Treatment with ilomastat appeared to result in an upregulation o f MMP-1 and MMP-2 (2.3 
± 24.4, 2.4 ± 50, log expression ratios, respectively), although this proved not to be 
statistically significantly. Similarly, MT1-MMP and the TIMP genes assayed were not 
affected by exposure to ilomastat. No difference in relative gene expression was observed 
with exposure to the control peptide.
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Figure 12. Comparison o f  MMP and TIMP gene expression by cord-derived fibroblasts (n=5) exposed to 
either ilomastat or control peptide relative to basal conditions (GFM). Mean ±  SEM.
The large variability associated with MMP-1 and MMP-2 expression determined by RT- 
PCR is notable and mirrors the variability observed in the force generation profiles o f cord- 
derived fibroblasts. This variability reflects underlying differences between patients. 
Furthermore, it may additionally suggest that although all cord tissue appears superficially 
homogeneous, it may vary considerably in terms o f  expression and contractile behaviour 
with stage o f  disease.
S.4.6.3 Effect of ilomastat on gene expression by nodule-derived fibroblasts
The expression by nodule-derived fibroblasts o f various secreted and expressed MMPs and 
TIMPs is illustrated in Figure 13. Exposure to ilomastat resulted in a downregulation o f 
MMP-1 and MMP-2 (-1.3 ± 1.6, -0.9 ± 0.5) relative to GFM, although this proved not to be 
significant. MT1-MMP appeared to be upregulated (0.4 ± 1.4) in response to ilomastat 
although this too was not significant. Likewise, TIMP gene expression was unaffected by 
ilomastat and there was no effect o f control peptide on any gene. It is notable that the gene 
expression profiles derived from nodule-derived fibroblasts was associated with less inter­
patient variability compared with cord-derived fibroblasts.
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Figure 13. Comparison o f  MMP and TIMP gene expression by nodule-derived fibroblasts (n=5) exposed to 
either ilomastat or control peptide relative to basal conditions (GFM). Mean ±  SEM.
5.4.6.4 Effect of ilomastat on gene expression by carpal ligament-derived fibroblasts
MMP and TIMP gene expression by carpal ligament-derived fibroblasts is illustrated in 
Figure 14. Neither ilomastat nor control peptide appeared to affect gene expression relative 
to basal conditions (GFM). This was borne out statistically as log expression ratios o f 
ilomastat and control peptide treatment proved to be not significantly different from each 
other.
The results o f  RT-PCR provided some interesting insights into MMP regulation, suggesting 
that ilomastat exposure did not affect MMP-1 and MMP-2 at the level o f transcription 
either through a direct inhibitory effect or a feedback mechanism within the 48 hour 
experimental window. Furthermore, ilomastat-mediated inhibition o f MMP activity did not 
result in a feedback downregulation o f TIMP-1 an TIMP-2 gene expression at 48 hours.
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Figure 14. Comparison o f  MMP and TIMP gene expression by carpal ligament-derived fibroblasts (n=5) 
exposed to either ilomastat or control peptide relative to basal conditions (GFM). Mean ± SEM.
The results o f  the RT-PCR established that only nodule-derived fibroblasts exhibited 
elevated MMP-1 expression corresponding to force generation. Conversely, the gene 
expression profiles o f  MMP-2, MT1-MMP, TIMP-1 and TIMP-2 were not significantly 
different between the three cell strains and not affected by exposure to ilomastat. We 
subsequently performed western blot analysis to determine whether ilomastat affected 
MMP and TIMP activity at the protein level.
5.4.7 Western Blot analysis: estimation of MMP and TIMP protein levels
5.4.7.1 MMP-1
Cord, nodule and carpal ligament-derived fibroblasts appeared to secrete similar levels o f 
both pro and active MMP-1 on exposure to GFM (Figure 15). Furthermore, MMP-1 
secretion did not appear to be significantly affected by treatment with ilomastat or the
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control peptide. The findings suggested that modulation of MMP-1 activity did not occur at 
the level of translation or was beyond the sensitivity of detection by western blot analysis.
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Figure 15. Western blot analysis o f  pro and active MMP-1 production by carpal ligament, cord and nodule- 
derived fibroblasts. Lattices were exposed to either GFM (A), ilomastat (B) or control peptide (C). The 
molecular weight (kDa) o f  kaleidoscope markers is listed adjacent to the marker bands in left hand column.
S.4.7.2 MMP-2
Only the latent form of MMP-2 (proMMP-2, 72kDa) was detected by western blotting as 
demonstrated by a sample blot in Figure 16. Some variation was observed in band intensity 
between different fibroblast types. Therefore, scanning densitometry was performed on all 
blots to objectively assess proMMP-2 protein levels (Figure 17).
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Figure 16. Western blot analysis o f  MMP-2 production by carpal ligament, cord and nodule-derived 
fibroblasts. Lattices were exposed to either GFM (A), ilomastat (B) or control peptide (C). The molecular 
weight (kDa) o f  kaleidoscope markers is listed adjacent to the marker bands in left hand column.
As determ ined by scanning densitom etry, carpal ligament-derived fibroblasts produced 
similar levels o f  proM M P-2 (14.6 ± 0.6 mean band density) com pared to cord (17.0 ± 2.3) 
and nodule-derived cells (19.4 ± 2.1) under basal conditions. Treatment with ilomastat or 
the control peptide did not appear to significantly affect proM M P-2 secretion, as there was 
no significant difference in mean band densities between GFM, ilomastat or control 
peptides by D upuytren’s and control fibroblasts. The results therefore suggested that 
exposure to ilom astat did not affect regulation o f  MMP-2 production at the translational 
level.
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Figure 17. MMP-2'protein production as determined by mean band density o f  western blots (n=5). Fibroblasts 
seeded in contracting lattices were exposed to GFM, ilomastat or control peptide. Mean ± SEM.
5.4.7.3 MT1-MMP
M T1-M M P was detected in cell lysates isolated from cord, nodule and carpal ligament- 
derived fibroblasts as demonstrated in Figure 18. Two prom inent bands were detected. The 
upper one was a double band probably corresponding to pro-M Tl-M M P (65kDa) and 
active M T1-M M P species (63kDa). The lower band (around 55kDa) was not anticipated 
and may have been due to the primary antibody reacting with MMP-1 species in addition to 
M T1-M M P. M T1-M M P is expressed on the surface o f  all cells. Exposure to ilomastat 
appeared to result in an upregulation o f  the am ount o f  active M T1-M MP by all three 
fibroblast strains, but did not affect the levels o f  pro-enzyme. The findings were confirmed 
by scanning densitometry as dem onstrated in Figure 19.
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Figure 18. Western blot analysis o f  pro and active MT1-MMP expression by carpal ligament, cord and 
nodule-derived fibroblasts in cell lysates. Lattices were exposed to either GFM (A), ilomastat (B) or control 
peptide (C). The molecular weight (kDa) o f  kaleidoscope markers is listed adjacent to the marker bands in left 
hand column.
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Figure 19. A ctive MT1-M MP protein production as determined by mean band density o f  western blots (n=5). 
*p<0.05 represents a significant increase in mean band density o f  fibroblasts exposed to ilomastat compared 
to GFM or control peptide. Mean ± SEM.
Under basal conditions, mean band densities o f  active M T1-M M P expression were similar 
for carpal ligam ent (5.6 ± 1.5), cord (2.6 ± 0.8) and nodule-derived fibroblasts (1.8 ± 0.5). 
However, on exposure to ilomastat, mean band densities were increased significantly for all 
three cell types (41 ± 10.2, 47 ± 10.0 and 32 ±  2.9, respectively), confirm ing an 
upregulation o f  M T1-M M P expression. Furthermore, the extent o f  ilomastat-mediated 
M T1-M M P upregulation was similar between all three cell strains. Treatment with control 
peptide did not appear to significantly affect M T1-M M P expression.
5.4.7.4 TIMP-1
A protein corresponding to TIMP-1 (25kDa) was detected in m edia collected from 
contracting lattices seeded with both D upuytren’s and control fibroblasts as illustrated in 
Figure 20. Low er molecular weight markers were more prominent than in previous blots 
due to the use o f  a 15% acrylamide separating gel. Similar amounts o f  TIMP-1 protein 
appeared to be produced by all three cell strains under basal conditions. Furthermore,
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TIMP-1 production did not appear to be influenced by exposure to ilomastat or control 
peptide. Scanning densitometry was not performed. As with some previous blots, cross­
reactivity between the primary antibody and other M MP species resulted in additional 
bands (possibly pro and active MMP-1).
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Figure 20. Western blot analysis o f  TIMP-1 production by carpal ligament, cord and nodule-derived 
fibroblasts. Lattices were exposed to either GFM (A), ilomastat (B) or control peptide (C). The molecular 
weight (kDa) o f  kaleidoscope markers is listed adjacent to the marker bands in left hand column.
5.4.7.5 TIMP-2
Cord, nodule and carpal ligament-derived fibroblasts did not appear to secrete significant 
levels o f  TIM P-2 (21 kDa) on exposure to either GFM, ilomastat or control peptide as no 
bands corresponding to TIMP-2 were reliably detected by western blotting.
The results o f  the western blot analysis implied that exposure to ilomastat does not 
modulate M MP or TIMP activity at the level o f translation. The exception being MT1- 
M MP, which was found to be m odulated at the level o f  translation but not transcription. We
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subsequently performed an activity ELISA to establish the pattern of MT1-MMP and 
MMP-2 activity by fibroblasts exposed to ilomastat.
5.4.8 Effect of ilomastat on MMP activity
5.4.8.1 MMP-2 activity
Activity of MMP-2 secreted in cell-conditioned media (CM) is illustrated in Figure 22. 
Panel A demonstrates levels of active enzyme activity. Under basal conditions, MMP-2 
activity produced by carpal ligament-derived fibroblasts (53 ± 1.3ng/ml CM) was similar to 
both cord (55 ± 0.6ng/ml CM) and nodule (53 ± 1.3ng/ml CM). Exposure to ilomastat 
resulted in a significant reduction in activity of secreted MMP-2 by carpal ligament, cord 
and nodule cells (53 ± 4.5%, 42 ± 4.7% and 46 ± 5.4%, respectively; p<0.001). Control 
peptide did not significantly affect MMP-2 activity. The protein concentration of 
conditioned media samples did not vary significantly between different cell strains or 
treatment groups and so the same pattern of inhibition of MMP-2 activity by ilomastat was 
observed once activity had been standardised against protein concentration (panel B).
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Figure 22. Quantification o f  MMP-2 activity (ng/ml conditioned media, panel A) and activity standardised 
against protein content (ng/mg conditioned media, panel B). *p<0.001 represents a significant inhibition o f  
MMP-2 activity following ilomastat exposure compared to GFM or control peptide (n=5). Mean ± SEM.
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5.4.8.2 MT1-MMP activity
Activity of cell-surface bound MT1-MMP in cell lysates is illustrated in Figure 23. Panel A 
demonstrates levels of enzyme activity, whereas, panel B represents activity standardised 
against protein concentration. All cells assessed demonstrated measurable amounts of 
MT1-MMP activity in response to GFM basal media. Cord and nodule ligament-derived 
cells appeared to express similar basal levels of MT1-MMP (132 ± 17, 156 ± 18ng/mg cell 
lysate, respectively) compared to carpal ligament (148 ± 27ng/mg cell lysate).
Ilomastat treatment resulted in a significant upregulation of MT1-MMP expression in cells 
where lattice contraction had been suppressed. Nodule and cord-derived fibroblasts 
appeared to exhibit the greatest increase in MT1-MMP expression, with levels rising 
threefold to 486 ± 140ng/mg (p<0.05) and 497 ± 23ng/mg, respectively (p<0.001). Carpal 
ligament-derived cells also demonstrated an increase in MT1-MMP activity on exposure to 
ilomastat (405 ± 113ng/mg), although this proved to be not significant. Treatment with 
control peptide did not significantly alter activity of MT1-MMP of either Dupuytren’s or 
control fibroblasts.
149
Results
350
IGFM 
I Ilomastat 
I Control peptide
300
8  250
6
'5bc
•S' 150 
>
<
0-i
S
sI
H
200
100
50
Carpal Ligament Cord Nodule
B
700 -|
.5‘5  ■*—> 600
2
O h
o n 500
E
'5b
Vh
N—^ 400
£
o 300
<
Oh
s 200§1
f—« 100
£
Carpal Ligament Cord Nodule
Figure 23. Quantification o f  levels o f  MT1-MMP activity (ng/ml cell lysate, panel A) and activity 
standardised against lysate protein content (ng/mg protein, panel B). *p<0.05 represents a significant 
upregulation o f  MT1-MMP activity following ilomastat exposure compared to GFM or control peptide (n=5). 
Mean ± SEM.
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5.5 DISCUSSION
Mechanical tension and tissue contracture are two related facets of tissue biology that are 
important in Dupuytren’s disease and can be investigated in vitro using a culture force 
monitor (CFM). In the CFM model, force generated by contracting fibroblasts is transferred 
into a force maintained by permanent matrix shortening (Marenzana et al. 2006). This latter 
process requires spatial reorganisation of the matrix, or matrix remodelling, to achieve 
actual shortening, which is facilitated by MMP activity.
In our model, nodule and cord-derived fibroblasts generated a significantly greater force 
than control cells under basal conditions, a finding supported by previous researchers using 
a culture force monitor (Bisson et al. 2004). Exposure to ilomastat significantly inhibited 
the maximum force obtained by Dupuytren’s fibroblasts (both cord and nodule), suggesting 
that MMP activity influences the ability of fibroblasts to generate contractile force. 
However, our results also imply that MMP activity is not critical to force development, as 
ilomastat did not significantly affect the force generated by carpal ligament-derived 
fibroblasts. The findings suggest that MMP activity is more influential in fibroblast- 
mediated contractile force generation in diseased tissue than normal palmar fascia.
Of particular interest to our investigation was in establishing how MMP activity influences 
the transfer of force from contracting fibroblasts to the collagen lattice. This was 
determined by the effect of ilomastat on residual matrix tension. In absolute terms, 
ilomastat did not affect the RMT of either disease or control fibroblasts. However, when 
analysed as a proportion of maximum force generation, ilomastat specifically reduced the 
cell-mediated rather than remodelling component by nodule-derived fibroblasts. This was 
an unexpected finding pointing to a more significant role played by MMP activity in force 
generation dependent on function of the actin cytoskeleton rather than spatial 
reorganisation of the matrix. However, with cord and carpal ligament-derived cells, 
ilomastat appeared to reduce the remodelling component in line with the overall reduction 
in force generation.
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Nodule-derived fibroblasts were found to express higher levels of MMP-1 under normal 
growth conditions compared to control cells, which correlated with their increased force 
generation. However, no similar increase in MMP-1 was detected in cord-derived 
fibroblasts suggesting that force generation is mediated by other MMPs in addition to 
MMP-1.
Regulation of MMPs has been shown to occur at the level of gene expression (Reuben et al. 
2006). Through feedback mechanisms, we might have expected a decrease in TIMP gene 
expression as a result of the presence of an exogenous inhibitor (ilomastat). Furthermore, 
an increase in MMP-1 and MMP-2 gene expression in response to inhibition at the level of 
enzyme activity by ilomastat may have also been anticipated. However, in our experimental 
models, no difference in gene expression was demonstrated between treatment with 
ilomastat and control conditions. Due to the nature of the CFM models, only endpoint 
sampling was feasible, therefore dynamic changes in gene expression may have been 
missed. This seems a distinct possibility as the most dynamic changes in force generation 
occurred in the first 10 hours, whereas, gene expression was assessed at 50 hours. 
Conversely, the 50-hour time course may have been too short to enable differences in 
transcription to be detected.
Exposure to ilomastat did not influence the secretion of the MMP or TIMP proteins under 
investigation. However, as demonstrated in the FPCL model of contraction in Chapter 4, 
treatment with ilomastat resulted in an inhibition of MMP-2 activity, whereas MT1-MMP 
expression and activity were upregulated, a finding that could relate to the role of MT1- 
MMP as an activator of proMMP-2. In general, the findings of the MMP and TIMP 
analysis suggest that within the CFM time course used in our model, regulation of activity 
was predominantly directed at the level of protein activation rather than transcription or 
translation.
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5.6 SUMMARY
• Nodule and cord-derived fibroblasts demonstrated a greater ability to generate force 
than carpal ligament in the CFM model.
• The rate of force development was significantly different between Dupuytren’s and 
control cells over the first 8 hours of contraction, but not after 8 hours.
• Ilomastat significantly inhibited force development by Dupuytren’s but not control 
cells.
• Ilomastat did not affect the absolute residual matrix tension values of cord, nodule or 
carpal ligament-derived fibroblasts. However, in terms of proportion, ilomastat 
preferentially inhibited cell-mediated contraction compared with matrix remodelling for 
nodule-derived fibroblasts.
• Nodule-derived fibroblasts expressed greater levels of MMP-1 gene than carpal 
ligament. However, no difference in gene expression was observed in response to 
different experimental conditions.
• Ilomastat resulted in an inhibition of MMP-2 activity at the level of enzyme activation.
• Ilomastat resulted in an upregulation of MT1-MMP protein expression and activity but 
did not affect MMP-1, MMP-2, TIMP-1 or -2 protein levels.
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CHAPTER 6 
GENERAL DISCUSSION
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6.1 OVERVIEW
Dupuytren’s disease is a fibrocontractile condition that causes disability through 
progressive digital contracture. It is a condition that naturally lends itself to scientific 
research because it is common, accounts for significant morbidity and gives rise to a 
discrete clinical problem that remains unsolved; namely, the high recurrence rates seen 
after surgery. In addition, diseased tissue samples are in abundance and readily available 
for analysis. Looking at the broader perspective, tissue contracture and fibroblast 
proliferation are common features of many related conditions that are not bound by 
anatomy or tissue type. The findings from our research may therefore contribute to the 
wider understanding of these related fibrocontractile disorders, further defining the 
underlying disease processes and helping to establish solutions.
Our decision to focus our research on the influence of MMP activity in Dupuytren’s 
disease is similarly pertinent. Collectively, the family of MMP enzymes have been the 
source of much interest and speculation over recent years, as an appreciation of their 
corollary role in tissue remodelling has unfolded. The precise influence of MMPs in 
disease processes is undoubtedly more complicated than at first anticipated, but many 
and varied research initiatives into their therapeutic potential continue.
The problem of recurrence in Dupuytren’s following corrective surgery is long-standing. 
However, in assessing the influence of MMPs, we have selected a novel avenue of 
research aimed at generating a new solution to an old riddle.
In this chapter, we aim to tie in the various threads that have been investigated in this 
thesis. Specifically, we will look to clarify differences between cellular activity observed 
from cord and nodule-derived tissue and seek to correlate these with disease progression. 
We will also seek to determine the role of MMP activity in remodelling of collagen 
lattices and generation of contractile force and, discuss the influence of an MMP 
inhibitor on regulation of MMP activity. We hope to demonstrate how these studies 
contribute to the greater body of knowledge about Dupuytren’s and what further
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research it points up. Some of the limitations of this present study have already been 
acknowledged at various points in the results chapters, however, a few general points 
will be made at the end of each section.
6.2 CORD AND NODULE -  TWINS OR SIBLINGS?
The distinction between cord and nodule is very relevant to the study of Dupuytren’s 
disease. Many researchers have sought to characterise the differences between the two 
clinical phenotypes, in order more specifically to define their respective roles in the 
disease’s progression. Compared to cord, nodules are often associated with an earlier, 
active stage of disease in which fibroblasts are more proliferative (Luck 1959), contract 
collagen lattices to a greater extent (Bisson et al. 2003), express more a-SMA (Dave et 
al. 2001; Bisson et al. 2003) and demonstrate less intercellular communication (Moyer et 
al. 2002). However, nodule-derived fibroblasts have also been shown to demonstrate 
reduced metabolic activity compared to cord (Seyhan et al. 2006), which contradicts the 
postulation that they form a focus of active disease.
Clearly, selection of cord from nodule is a key issue. We chose a robust method for 
distinguishing the two phenotypes, in that it relied on clinical appearance to correlate 
with histological evaluation before a positive identification could be made. However, 
some researchers have been less stringent in their selection process, often relying purely 
on macroscopic appearance (Seyhan et al. 2006). Others have grouped all Dupuytren’s- 
derived fibroblasts together in their investigations (Rayan et al. 1994; Tomasek et al. 
1995; Wong et al. 2006) or looked at either just cord or nodule respectively (Hurst et al. 
1986; Tarpila et al. 1996; Kuhn et al. 2002). Even with a rigorous assessment, the 
distinction may not be so black and white as cord and nodule often co-occur. Therefore, 
it is conceivable that pockets of nodule-like fibroblasts may reside within cord tissue and 
vice versa. Nevertheless, it was important to investigate the two Dupuytren’s tissue 
types separately, to establish whether previously ascribed differences were prevalent in 
our model and whether a differential sensitivity to MMP inhibition existed.
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In support of the findings of previous researchers, we found that fibroblasts derived from 
nodules demonstrated an increased proliferative response compared to cord and 
contracted lattices to a greater extent in the FPCL model. However, the differences in 
contractile ability were not apparent in the CFM model: although nodule-derived 
fibroblasts generated greater forces on average, the responses were not significantly 
different from cord, a similar finding to Beckett (Beckett 2005). The wide range of cord- 
mediated CFM responses suggested that cord tissue is not in fact a distinct entity, but is 
responsible for a spectrum of fibroblast behaviour that overlaps considerably with 
nodule tissue. Similarly, the interpatient variability highlighted the difficulty in selecting 
tissue samples from patients at the same stage of disease and may have masked some 
important findings.
As well as differences in contractile behaviour, discrepancies between cord and nodule 
were noted at the molecular level. Specifically, under basal conditions, MMP-1 activity 
was greater in nodule-derived fibroblasts than cord, which was concurrent with 
increased lattice contraction. Our findings support the notion that differences between 
cord and nodule are significant enough to warrant investigation of each in isolation. 
However, by increasing the number of samples tested and endeavouring to control for 
disease stage, we may have been able to reduce interpatient variability and further 
delineate differences between cord and nodule. Such an approach might establish or 
refute some of the underlying trends that did not reach statistical significance and further 
illuminate the specific roles of cord and nodule in the development and progression of 
the disease.
6.3 INFLUENCE OF MMP ACTIVITY ON CONTRACTION, FORCE 
GENERATION AND REMODELLING
It is well established that MMPs are involved in collagen contraction, matrix 
organisation and tissue scarring. Furthermore, MMPs are found in normal and diseased 
palmar fascia, where, it has been speculated they play a role in the development of
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contracture (Beckett 2005). Therefore, we sought to assess the efficacy of an MMP 
inhibitor on Dupuytren’s fibroblasts in vitro, as a preliminary investigation into the 
influence of MMPs on remodelling, and to outline their role in disease pathogenesis.
Ilomastat is a broad-spectrum inhibitor therefore making it a good interventional 
candidate. This is an important attribute, since as overlapping substrate specificity 
among MMP family members has been well documented (Stemlicht et al. 2001) and 
individually, specific MMP-blocking agents have been shown to have little effect on 
lattice contraction (Sheridan et al. 2001). Furthermore, ilomastat has been found to 
inhibit matrix contraction by ocular fibroblasts (Daniels et al. 2003), reduce scarring in 
an experimental model of glaucoma filtration surgery (Wong et al. 2003) and prevent 
human lens capsular contracture (Wong et al. 2004). In their study, Daniels and 
colleagues (Daniels et al. 2003) looked at the effect of various MMP inhibitors on 
collagen contraction, among them ilomastat, BB-94 and CellTech. Whilst all inhibitors 
reduced contraction, ilomastat was deemed most beneficial, being effective over the 
widest concentration range, further evidence of its suitability for our investigation.
Of all three FPCL models, the stress-release model was chosen to investigate contraction 
initially as it is thought to closely mimic the late granulation tissue remodelling phase of 
wound healing, which has many parallels with Dupuytren’s disease (section 1.9.2). 
Furthermore, as discussed earlier, it provides a good approximation of the mechanical 
environment of palmar fascia tissue.
In our study, treatment with ilomastat significantly reduced collagen lattice contraction 
by all tissue-derived fibroblasts in the stress-release FPCL model. As discussed, this was 
unrelated to cytotoxicity as cells were able to proliferate normally and remain viable at 
the concentration of ilomastat investigated: lOOpM. Furthermore, treatment with the 
control peptide or vehicle control did not significantly affect matrix contraction 
compared to basal conditions (GFM). The results suggested that contraction and lattice 
remodelling by Dupuytren’s fibroblasts are highly MMP-dependent processes. However, 
the fact that ilomastat did not mediate complete inhibition of lattice contraction also
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indicates that MMP activity may not be essential for matrix contraction. Conversely, 
ilomastat, despite conferring broad-spectrum inhibition, may not abrogate activity of 
some MMPs with overlapping substrate specificities (e.g. MT1-MMP) that assume 
greater importance once key MMPs are blocked (e.g. MMP-1).
MMP activity was greatest for nodule-derived fibroblasts, correlating with both the 
increased contractile ability of nodule relative to cord as well as with an apparent 
increased sensitivity of nodules to inhibition by ilomastat, although the latter finding did 
not achieve statistical significance. These observations support the postulation that 
nodules form an active focus of disease, being more involved than cord in the processes 
leading to contracture.
The CFM model was subsequently selected for investigation of contractile processes to 
provide actual kinetic information on force generation and to define more narrowly the 
individual components of cell-mediated contraction and matrix remodelling. 
Interestingly, the effects of ilomastat on tissue-derived fibroblasts in the CFM model 
were not uniform. Whilst a clear pattern of inhibition of force generation was 
demonstrated for cord and nodule, exposure to ilomastat did not significantly affect 
tension development by carpal ligament-derived fibroblasts.
The results for carpal ligament-derived fibroblasts mirrored findings by a previous 
investigator using dermal fibroblasts (Phillips et al. 2003). Phillips and colleagues 
demonstrated that ilomastat (lOpM) inhibited lattice contraction by dermal fibroblasts in 
a free-floating FPCL model, but did not significantly reduce force generation as 
determined through use of a CFM model. The authors concluded that MMP activity 
facilitates three-dimensional remodelling, but does not influence cellular force output. 
Based on our own observations in the two models, it could be similarly argued that 
MMP activity influences spatial remodelling of the matrix by carpal ligament-derived 
fibroblasts, but does not affect the generation of tensile strength. A key difference is that 
in their investigation, Phillips and colleagues used a lower dose of ilomastat (lOpM
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compared to lOOpM). They too may have encountered an inhibition of force 
development at the higher dose of ilomastat selected for our study.
Ilomastat did, however, reduce force development by cord and nodule-derived 
fibroblasts suggesting that abnormal MMP activity may be an important feature in the 
pathogenesis of Dupuytren’s disease. Specifically, the findings imply that regulation of 
tensile force is mediated by MMP activity in diseased, but not in normal palmar fascia. 
This notion supports the rationale for the therapeutic use of an MMP inhibitor in 
Dupuytren’s disease.
Further insight regarding the influence of MMP activity on both remodelling and force 
generation can be gleaned through the addition of cytochalasin-D to the CFM system, as 
established by Marenzana and colleagues (Marenzana et al. 2006). In their seminal 
paper, they elegantly demonstrated how cytochalasin-D, which specifically targets actin- 
dependent cellular processes, enables quantification of remodelling processes in the 
CFM model and, by extension, evaluation of cell-mediated tensile force generation. 
Specifically, they established that the addition of cytochalasin-D leads to a rapid 
reduction in force, leaving a residual matrix tension (RMT), which is an approximation 
of matrix shortening and therefore of remodelling.
In our study, although exposure to ilomastat reduced overall force development by 
Dupuytren’s fibroblasts, it did not affect the magnitude of RMT by either cord or 
nodule-derived fibroblasts. These findings imply that MMP activity does not directly 
influence force attributable to spatial reorganisation or shortening of the matrix. 
Conversely, ilomastat was shown significantly to reduce the cell-mediated contractile 
force by both cord and nodule-derived fibroblasts, suggesting that MMP activity is 
directly involved in the generation of tensile strength by fibroblasts.
When the data for cord-derived fibroblasts were analysed in terms of proportion of 
overall force generation rather than absolute numbers, ilomastat exposure did not affect 
either the proportion of the remodelling or cellular components. In other words, the two
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components reduced in line with the overall decrease in maximum force generation. In 
summary, the results derived from the CFM imply that MMP activity is an important 
mediator of both cell-dependent force generation and force retained in the matrix as a 
result of spatial remodelling. However, the findings also suggest that the relative 
influence of MMP activity on the two processes depends on fibroblast type or possibly 
the mechanical environment of the tissue from which the cells are derived. Several 
investigators have demonstrated that the compliance of tissue from which cells derive 
affects cellular behaviour including force generation (Wrobel et al. 2002; Peyton et al.
2005). The difference in tissue compliance between normal and diseased palmar fascia 
may therefore additionally be an important issue.
Interpreting the force generation plot in terms of two components is schematic and 
practical; however, it does not allow characterisation of all underlying processes. As 
illustrated in Figure 1, some researchers have considered the development of force in the 
CFM model to occur in three different phases (Tomasek et al. 2002; Marenzana et al.
2006), an assumption that allows further postulations to be made about the possible role 
of MMPs.
The initial phase follows cell-seeding and correlates with cell migration, the latter 
having been associated with force generation by traction (Harris et al. 1981; Ehrlich et 
al. 1990; Tranquillo 1999). Through matrix softening, MMPs can facilitate the migration 
of cells through the matrix. The importance of MMP activity on migration has been 
demonstrated in an experimental model of wound healing (Mirastschijski et al. 2004) 
and in culture keloid fibroblasts (Fujiwara et al. 2005), thus supporting a role for MMPs 
in force generated by traction.
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Figure 1. The three phases o f  force generation in the culture force monitor. The actual beginning and end 
o f  each phase is uncertain and not clearly defined. Addition o f  Cytochalasin-D is marked by an arrow.
As mechanical stress develops at the beginning of the second phase (contraction phase), 
fibroblasts differentiate into proto-myofibroblasts and myofibroblasts, which can exert 
contractile force on the extracellular matrix. Cell force during this phase is relatively 
constant, representing a form of tensional homeostasis (Brown et al. 1998). As well as 
simple matrix destruction, MMPs have a profound influence on fundamental cellular 
processes such as proliferation, growth, signalling and differentiation (Koike et al. 2002; 
Visse et al. 2003), which could indirectly influence contractile force generation. 
Furthermore, by reducing the mechanical tension generated through traction, an MMP 
inhibitor would reduce the stimulus for differentiation. In fact, ilomastat has been shown 
to mediate a reduction in both a-SMA expression and lattice contraction by dermal 
fibroblasts that was independent of TGF-p, a profibrotic mediator (Mirastschijski et al.
2004).
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The final phase, characterised by the RMT, is due to irreversible shortening and 
remodelling of the collagen lattice such as occur in tissue contracture. Any remodelling 
process necessarily depends on the removal of matrix molecules and is therefore likely 
to be highly dependent on MMPs.
Although, the CFM model does not allow the precise differentiation of traction from 
contraction, our work suggests a role for MMP activity in all phases of force 
development by Dupuytren’s fibroblasts. In contrast to our hypothesis, ilomastat did not 
just specifically target remodelling behaviour, but it also resulted in an inhibition of the 
force generated through fibroblast locomotion and contraction. The fact that ilomastat 
did not affect the force generated by control fibroblasts suggests that MMP-dependent 
force development is more prominent in diseased tissue and may be a contributing factor 
to tissue contracture in vivo. As previously discussed, this may relate to the 
‘conditioning’ of fibroblasts dependent on the mechanical environment of the tissue 
from which the cells were derived. Figure 2 is a schematic illustration of how an MMP 
inhibitor might target different steps in the process of matrix contraction, based on a 
synthesis of our own findings, current knowledge about Dupuytren’s pathogenesis, and 
postulations regarding contracture development (Tomasek et al. 2002; Marenzana et al.
2006).
A limitation to our study is that changes in cell number in the two lattice models were 
not formally assessed. Instead, it was assumed that the results of the proliferation assay 
on fibroblasts cultured in monolayer would be applicable to fibroblasts seeded in 
collagen lattices. However, it is feasible that ilomastat may have mediated a different 
effect, with respect to viability and proliferation, on fibroblasts cultured in two- 
dimensions as opposed to three-dimensional lattices. In addition, cell number may have 
varied over the period of mechanical strain. Any such difference may have influenced 
the contraction and force generation profiles elicited in the two models.
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Figure 2. A schematic diagram illustrating the points at which an MMP inhibitor might interrupt the 
sequence o f  events leading to permanent matrix shortening.
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6.4 PATTERN OF EXPRESSION AND ACTIVITY OF SPECIFIC MMPS
Our results demonstrated the involvement of several MMPs in the processes of matrix 
contraction and generation of tensile force including, among them MMP-1, MMP-2 and 
MT1-MMP. Furthermore, the endogenous inhibitors, TIMP-1 and TIMP-2, were 
expressed concomitantly with MMP expression. Figure 3 provides a brief overview of 
the interaction between collagen and the relevant MMPs.
Figure 3. Schematic representation o f  the involvement o f  MMPs in the degradation o f  collagen type I.
Similar to the findings of previous investigators (Scott et al. 1998; Derderian et al.
2005), we demonstrated that MMP-1, was associated with lattice contraction and 
remodelling. In our study, nodule-derived fibroblasts expressed greater levels of MMP-1 
mRNA and demonstrated greater MMP-1 activity, compared with carpal ligament- 
derived cells under basal conditions. These baseline MMP-1 changes correlated with 
greater FPCL contraction and force development by nodule compared with those by 
carpal ligament. Furthermore, treatment with ilomastat inhibited both MMP-1 activity 
and contraction in Dupuytren’s-derived fibroblasts (both nodule and cord). These results
Collagi
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Collagen I is the primary substrate o f  
MMP-1, although MT1-MMP (membrane- 
bound) will also cleave it under certain 
conditions.
The gelatinases (MMP-2, MMP-9) only 
degrade collagen I after initial cleavage by 
MMP-1, unless they are in sufficiently high 
concentration in the absence o f  MMP-1.
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imply utilisation of MMP-1 during matrix contraction and remodelling by Dupuytren’s 
fibroblasts.
The role of MMP-1 in the processing of lattices by control fibroblasts is less clear. 
Ilomastat did not affect MMP-1 activity by carpal ligament-derived fibroblasts, despite 
inhibiting FPCL contraction. The possibility that this finding could have been 
attributable to patient variability and insufficient sampling has already been discussed 
(Chapter 4). This eventuality is particularly likely, as ilomastat is known to be a potent 
inhibitor of MMP-1 (Ki 400pMa www.merckbisciences.co.uk). It is worth noting that 
although ilomastat confers broad-spectrum MMP inhibition, it has different affinities for 
each of the MMPs with which it interacts (e.g. MMP-2 - K* 500pM, MMP-3 - 27nM).
The results may also suggest that the balance of collagen type I cleavage by carpal 
ligament-derived fibroblasts is fundamentally different from Dupuytren’s-derived cells, 
favouring a more prominent role for collagenases such as MT1-MMP and MMP-8 than 
MMP-1. This is conceivable since tissue-specific MMP activity has been documented to 
vary between physiological and diseased states (Tchetverikov et al. 2005). As MMP-1 
levels were increased in nodule-derived cells, the reduction in MMP activity may have 
been more pronounced due to the specificity of ilomastat for this mediator compared 
with other MMP species. Further analysis to identify the role of other collagenases in 
matrix remodelling by control fibroblasts was beyond the scope of this study but is the 
subject of ongoing investigations.
ProMMP-2, a gelatinase, was detected in FPCLs under stress (pre-release) in 
Dupuytren’s and in control fibroblasts. By contrast, both pro and active forms were 
detected in post-release lattices suggesting that activation of MMP-2 was concomitant 
with lattice contraction. Ilomastat inhibited MMP-2 in all fibroblasts at the level of 
activation. MMP-1 is involved in proteolytic cleavage of the triple helical structure of 
type 1 collagen, exposing fragments that are susceptible to gelatinases including MMP- 
2. Our results imply a role for MMP-2 in processing and remodelling of the collagen 
lattice by Dupuytren’s fibroblasts during contraction.
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The importance of MMP-2 in mediating lattice contraction and remodelling by oral 
mucosal and dermal fibroblasts has been demonstrated in previous studies (Mudera et al. 
2000; Stephens et al. 2001). Furthermore, Tarlton and colleagues found a direct 
relationship between mechanical stress and release of MMP-2 by Dupuytren’s tissue in 
vitro (Tarlton et al. 1998). MMP-9, another gelatinase, has been shown to be upregulated 
by tendon fibroblasts in response to mechanical loading (Prajapati et al. 2000) and 
attachment to collagen type 1 (Ritty et al. 2003). However, MMP-9 was not consistently 
detected in our study, suggesting that MMP-2 is the dominant gelatinase involved in 
mediating lattice contraction by palmar fascial fibroblasts.
The main pathway for proMMP-2 activation occurs on the cell surface and is mediated 
by MT1-MMP in association with TIMP-2 (Butler et al. 1998; Wang et al. 2000). 
Exposure of Dupuytren’s fibroblasts to ilomastat resulted in an upregulation of MT1- 
MMP protein expression and enzymic activity. The results suggest that fibroblasts may 
have upregulated MT1-MMP expression at the cell surface in response to detection of 
reduced MMP-2 activity, thereby enhancing proMMP-2 activation. Previous work has 
demonstratied increased MTl-MMP-dependent activation of proMMP-2 in the presence 
of marimastat, another synthetic MMP inhibitor (Toth et al. 2000). By contrast, TIMP-2 
levels were not affected by treatment with ilomastat. TIMP-2 is a known inhibitor of 
MT1-MMP, and although essential for proMMP-2 activation, an excess of TIMP-2 can 
actually prevent the activation process (Nagase et al. 2006). A further possibility is that 
MT1-MMP was upregulated in response to reduced MMP-1 activity, as MT1-MMP has 
the capacity to digest interstitial collagens (Ohuchi et al. 1997) and has been shown to 
influence cellular migration through collagen lattices (Koike et al. 2002).
The net balance between MMP and TIMP activity has been identified as an important 
determinant of tissue homeostasis (Stephens et al. 2001; Nakatani et al. 2006) and 
therefore, modulation of MMP activity by an exogenous inhibitor might have been 
expected to result in changes in TIMP levels. However, the expression and protein levels 
of the two endogenous inhibitors, TIMP-1 and TIMP-2, were not affected by treatment
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with ilomastat in either Dupuytren’s or control fibroblasts. Our investigation, however, 
did not rule out changes at the level of TIMP-1 and TIMP-2 enzyme activity. This is 
especially pertinent as our analysis of the various points in the regulatory chain from 
transcription to protein activation suggested that, with the exception of MT1-MMP, 
changes in MMP activity mediated by ilomastat exposure were predominantly 
manifested at the level of extracellular proteolytic activation. Analysis of TIMP-1 and 
TIMP-2 activity was beyond the scope of our study, but may have further illuminated 
the nature of cel 1-matrix interactions, especially with regard to proMMP-2 activation and 
the net balance between MMP and TIMP activity.
The differences between TIMP-1 and TIMP-2 levels in Dupuytren’s and in control 
patients have been investigated previously. Ulrich and colleagues demonstrated elevated 
TIMP-1 serum levels in Dupuytren’s patients compared to controls (Ulrich et al. 2003). 
However, a limitation to Ulrich’s study is that snapshot systemic enzyme levels may be 
a poor correlate of localised tissue activity, since many external factors can influence 
MMP expression (Parsons et al. 1997; Meisser et al. 2005). In our model, Dupuytren’s- 
derived fibroblasts exhibited similar levels of both TIMP-1 and TIMP-2, compared to 
controls.
In another study, the effect of mechanical tension on MMP and TIMP expression was 
investigated using a CFM model (Beckett 2005). Introduction of a mechanical load to 
the system resulted in an upregulation of TIMP-1 gene expression by carpal ligament, 
but not by Dupuytren’s-derived fibroblasts. Conversely, nodule-derived fibroblasts 
responded by upregulating MMP-1 and MMP-2 expression. The results suggested that 
the net balance between MMP and TIMP activity was modified in response to a 
mechanical stimulus, favouring an increase in matrix turnover by Dupuytren’s 
fibroblasts. Interestingly, when a static load was applied in Beckett’s study, no 
differences in either TIMP-1 or TIMP-2 expression were encountered between 
Dupuytren’s and control fibroblasts, which corroborated with our findings.
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Mechanical load has also previously been identified as an important mediator of MMP 
and TIMP gene expression by dermal fibroblasts (Mudera et al. 2000) and by osteoblasts 
(Jansen et al. 2006). A limitation to the CFM model is that only endpoint sampling is 
possible due to the sensitive nature of the equipment. In essence, analysis of gene 
expression, protein levels and enzyme activity were therefore only possible at the 
termination of the experiment. However, our investigation demonstrated that force 
development by Dupuytren’s fibroblasts occurred at a significantly greater rate than 
control carpal ligament cells only for the first ten hours. Differences in expression and 
activity of MMPs may therefore have only been apparent during the most dynamic 
period of development of mechanical tension (0 -1 0  hours) in the CFM model.
6.5 ILOMASTAT -  THERAPEUTIC POTENTIAL?
The past decade has seen the accumulation of a body of evidence pointing to a central 
role for MMPs in both biological and pathological processes (Lemaitre et al. 2006; 
Nagase et al. 2006). Based on some of this early work, the therapeutic potential of 
targeting MMP activity has been investigated in several diseases, notably cancer and 
rheumatoid arthritis (Egeblad et al. 2002; Mengshol et al. 2002). However, clinical trials 
have not yet demonstrated any clear benefit of MMP inhibitors in improving patient 
outcomes (Baker et al. 2002; Coussens et al. 2002). As discussed in the introduction, this 
relates partly to trial design, and partly to the complex and diverse roles performed by 
MMPs in vivo. It is anticipated that an understanding of the precise MMP abnormality 
involved in disease progression, as well as the selection of an inhibitor with appropriate 
specificity, will yield successful results.
With regard to Dupuytren’s, the use of synthetic MMP inhibitors aimed at preventing 
disease recurrence and progression constitutes an attractive strategy. Dupuytren’s 
fibroblasts demonstrate abnormal contractile and remodelling behaviour compared to 
controls in vitro (Bisson et al. 2004; Beckett et al. 2005). This behaviour has, in turn, 
been associated with an abnormal pattern of MMP expression (Beckett et al. 2005). In
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our study, inhibition of MMP-1 and MMP-2 activity by ilomastat accompanied a 
reduction in lattice contraction and in force generation mediated by Dupuytren’s 
fibroblasts.
Clinically, nodules precede cords, and some have conjectured that the nodule is the 
initial trigger for contracture development (Chiu et al. 1978). Our results demonstrate 
that nodule-derived fibroblasts mediate greater lattice contraction than cord and were 
more sensitive to inhibition by ilomastat. These findings imply that intervention with an 
MMP inhibitor might be best directed at an early stage of the disease when nodules 
predominate. By specifically targeting nodules, it may be possible to prevent the 
progression to contracture and thus avoid the need for surgery.
Critics will draw attention to circumstantial evidence derived from the observations of 
Hutchinson of patients enrolled in a clinical trial investigating the effects on advanced 
gastric adenocarcinoma of marimastat, a hydroxamate MMP inhibitor with specificity 
against MMP- and MMP-9 (Hutchinson et al. 1998). Three out of twelve patients were 
noted to develop a Dupuytren’s-like condition. However, the evidence is at best 
anecdotal. In particular, it is unclear whether patients were screened for Dupuytren’s 
prior to the beginning of the trial: Dupuytren’s would not be an uncommon finding in 
such an elderly cohort of patients. Furthermore, the condition described in the trial 
resolved on withdrawal of marimastat, which suggests a fundamental difference from 
Dupuytren’s, which by definition results in permanent tissue contracture. Nonetheless, 
the findings are intriguing and highlight the fact that we do not yet fully comprehend the 
complete diversity of roles performed by MMPs in tissue homeostasis.
Our results suggest a critical role for MMP activity in matrix processing and 
organisation by Dupuytren’s fibroblasts in vitro, suggesting that inhibition of MMP 
activity may well reduce contracture in vivo, by reducing fibroblast-mediated matrix 
contraction and remodelling. Obviously, the step from in-vitro results to proven clinical 
benefit is not insignificant. The importance of selecting an inhibitor with appropriate
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specificity has already been highlighted and might require further work to establish more 
precisely the MMP and TIMP abnormalities underlying Dupuytren’s.
Of critical importance, ilomastat, or the chosen MMP inhibitor, must be shown to be 
safe when administered in vivo. Unfortunately, an experimental model of Dupuytren’s 
disease does not exist. However, MMP inhibitors (MPI) are in general thought to induce 
few serious complications. In particular, ilomastat has been shown to be safe in vivo in 
an experimental model of otitis media (Antonelli et al. 2003) and glaucoma filtration 
surgery (Wong et al. 2003). Minor side effects such as arthritis and myalgia are 
commonly described for MPIs (Wall et al. 2004) and are often attributed to the 
inhibition of sheddases. It may therefore be useful to evaluate and make comparisons 
with newer MPIs, such as BMS-275291, that lack antisheddase activity and have been 
shown to be well tolerated by patients enrolled in clinical trials (Lara et al. 2006).
6.6 CONCLUDING REMARKS
As suggested by its numerous associations and putative causes, Dupuytren’s contracture 
may be the final pathway for several different aetiologies. Therefore, a broad approach 
to investigating the molecular basis of this condition is indicated. Previous work by 
other researchers has been directed towards abnormalities in growth factors, 
extracellular matrix proteins, and even free radicals. In carrying out this study, we have 
achieved what we set out to do: we have completed another piece of the puzzle and 
outlined a new strategy for tackling disease progression and recurrence. Specifically, we 
have made a rigorous assessment of the influence of MMP activity on matrix 
organisation by Dupuytren’s fibroblasts, through the use of two distinct models of 
collagen lattice contraction.
The supposition that MMP activity may play a pivotal role in the development of 
contracture has been made previously (Tomasek et al. 2002; Beckett 2005). We have 
now delivered some robust experimental evidence to suggest that inhibition of MMP
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activity can reduce matrix contraction and remodelling by Dupuytren’s fibroblasts. It 
may therefore be effective in reducing contracture in vivo.
6.7 PROPOSAL FOR FUTURE WORK
Our study yielded interesting results that merited further investigation. However, the 
scope of the project was inevitably limited by time constraints. Based on an analysis of 
our findings, there are several experimental threads that could be picked up and pursued 
in further studies. They include further in-vitro work as a basis for another MD project, 
as well as the progressing to a clinical model.
Future work might take a more searching look at the role of MMP activity in force 
development by Dupuytren’s fibroblasts. As mentioned previously, force is thought to 
be initially generated through fibroblast locomotion and contraction, but it was not 
possible to differentiate respective responsibility through the model we used in our 
project. It would, however, be possible to determine the effect of ilomastat on the 
movement of Dupuytren’s fibroblasts through the matrix by means of migration assays 
using a confocal microscope. This would enable an assessment to be made of force 
generated by traction. Furthermore, an examination of a-SMA expression by contracting 
fibroblasts exposed to ilomastat might indicate whether any effect on cell-mediated 
contraction was independent of myofibroblast differentiation. This could be established 
through a combination of PCR, western blotting and immunohistochemical staining.
As alluded to earlier, MMP expression has been shown to be mechano-sensitive 
(Mudera et al. 2000). In our model, fibroblast contractile activity and changes in rate of 
force development were greatest early on. It would therefore be interesting to sample 
lattices and media at an early stage, perhaps after 6 or 8 hours. This would permit an 
investigation of the transient differences in mRNA expression and in intracellular 
signalling proteins such as protein kinases, arising between different cell strains and in 
response to ilomastat.
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Ultimately, the goal is to assess the effect of an MMP inhibitor in preventing recurrence 
in patients undergoing surgery for Dupuytren’s contracture. This could be established by 
a randomised controlled trial. However, before undertaking a clinical trial, several 
considerations must be addressed. First and foremost, the MMP inhibitor must be shown 
to be safe when administered in vivo. Subsequently, a suitable dosage regime, point of 
intervention and mode of delivery will need to be worked out, so that diseased tissue can 
be targeted effectively with minimal systemic impact.
173
REFERENCES
Adams, J. C. and F. M. Watt (1993). "Regulation of development and differentiation by 
the extracellular matrix." Development 117(4): 1183-98.
Alioto, R. J., R. N. Rosier, R. I. Burton and J. E. Puzas (1994). "Comparative effects of 
growth factors on fibroblasts of Dupuytren's tissue and normal palmar fascia." J 
Hand Sure \Ami 19(3): 442-52.
Antonelli, P. J., G. S. Schultz, D. J. Sundin, P. A. Pemberton and P. J. Barr (2003). 
"Protease inhibitors alpha 1-antitrypsin and ilomastat are not ototoxic in the 
chinchilla." Laryngoscope 113(10): 1764-9.
Arafa, M., J. Noble, S. G. Royle, I. A. Trail and J. Allen (1992). "Dupuytren's and 
epilepsy revisited." J Hand Sure TBrl 17(2): 221-4.
Armstrong, J. R., J. S. Hurren and A. M. Logan (2000). "Dermofasciectomy in the 
management of Dupuytren’s disease." J Bone Joint Surg Br 82(1): 90-4.
Amoczky, S. P., T. Tian, M. Lavagnino and K. Gardner (2004). "Ex vivo static tensile 
loading inhibits MMP-1 expression in rat tail tendon cells through a 
cytoskeletally based mechanotransduction mechanism." J Orthop Res 22(2): 
328-33.
Attali, P., O. Ink, G. Pelletier, C. Vernier, F. Jean, L. Moulton and J. P. Etienne (1987). 
"Dupuytren's contracture, alcohol consumption, and chronic liver disease." Arch 
Intern Med 147(6): 1065-7.
Augoff, K., J. Kula, J. Gosk and R. Rutowski (2005). "Epidermal growth factor in 
Dupuytren's disease." Plast Reconstr Surg 115(1): 128-33.
Badalamente, M. A. and L. C. Hurst (1999). "The biochemistry o f Dupuytren's disease." 
Hand Clin 15(1): 35-42, v-vi.
Badalamente, M. A., L. C. Hurst and V. R. Hentz (2002). "Collagen as a clinical target: 
nonoperative treatment of Dupuytren's disease." J Hand Surg [Am] 27(5): 788- 
98.
Badalamente, M. A., S. P. Sampson, L. C. Hurst, A. Dowd and K. Miyasaka (1996). 
"The role of transforming growth factor beta in Dupuytren's disease." J Hand 
SurgJAml 21(2): 210-5.
Bailey, A. J., S. Bazin, T. J. Sims, M. Le Lous, C. Nicoletis and A. Delaunay (1975). 
"Characterization of the collagen o f human hypertrophic and normal scars." 
Biochim Biophvs Acta 405(2): 412-21.
Bailey, A. J., J. F. Tarlton, J. Van der Stappen, T. J. Sims and A. Messina (1994). "The 
continuous elongation technique for severe Dupuytren's disease. A biochemical 
mechanism." J Hand Sure TBrl 19(4): 522-7.
Baird, K. S., J. F. Crossan and S. H. Ralston (1993). "Abnormal growth factor and 
cytokine expression in Dupuytren's contracture." J Clin Pathol 46(5): 425-8.
Baker, A. H., D. R. Edwards and G. Murphy (2002). "Metalloproteinase inhibitors: 
biological actions and therapeutic opportunities." J Cell Sci 115(Pt 19): 3719-27.
Bayat, A., J. S. Watson, J. K. Stanley, M. W. Ferguson and W. E. Oilier (2003). 
"Genetic susceptibility to dupuytren disease: association o f Zf9 transcription 
factor gene." Plast Reconstr Sure 111(7): 2133-9.
Beckett, K. (2005). "The Progression from Contraction to Contracture in Dupuytren's 
Derived Fibroblasts: a Study of the Cellular and Molecular Events." MD thesis, 
UCL.
Beckett, K., M. Bisson, V. Mudera, D. A. McGrouther and A. O. Grobbelaar (2005). "A 
hypothesis for the progression of Dupuytren's Contracture [abstract]." J Hand 
Surg [Brl 30 (Suppl 1): 28.
Bell, E., B. Ivarsson and C. Merrill (1979). "Production of a tissue-like structure by 
contraction o f collagen lattices by human fibroblasts of different proliferative 
potential in vitro." Proc Natl Acad Sci U S A 76(3): 1274-8.
Berliner, D. L. and A. G. Ruhmann (1967). "The influence of dimethyl sulfoxide on 
fibroblastic proliferation." Ann N Y Acad Sci 141(1): 159-64.
Bisson, M. A., D. A. McGrouther, V. Mudera and A. O. Grobbelaar (2003). "The 
different characteristics of Dupuytren's disease fibroblasts derived from either 
nodule or cord: expression o f alpha-smooth muscle actin and the response to 
stimulation by TGF-betal." J Hand Sure (Brl 28(4): 351-6.
Bisson, M. A., V. Mudera, D. A. McGrouther and A. O. Grobbelaar (2004). "The 
contractile properties and responses to tensional loading of Dupuytren's disease- 
derived fibroblasts are altered: a cause of the contracture?" Plast Reconstr Sure 
113(2): 611-21; discussion 622-4.
Bramhall, S. R., A. Rosemurgy, P. D. Brown, C. Bowry and J. A. Buckels (2001). 
"Marimastat as first-line therapy for patients with unresectable pancreatic 
cancer: a randomized trial." J Clin Oncol 19(15): 3447-55.
175
Brickley-Parsons, D., M. J. Glimcher, R. J. Smith, R. Albin and J. P. Adams (1981). 
"Biochemical changes in the collagen of the palmar fascia in patients with 
Dupuytren's disease." J Bone Joint Sure Am 63(5): 787-97.
Brown, P. D. (2000). "Ongoing trials with matrix metalloproteinase inhibitors." Expert 
Opin Investig Drugs 9(9): 2167-77.
Brown, R. A., R. Prajapati, D. A. McGrouther, I. V. Yannas and M. Eastwood (1998). 
"Tensional homeostasis in dermal fibroblasts: mechanical responses to 
mechanical loading in three-dimensional substrates." J Cell Phvsiol 175(3): 323- 
32.
Bulstrode, N. W., M. Bisson, B. Jemec, A. L. Pratt, D. A. McGrouther and A. O. 
Grobbelaar (2004). "A prospective randomised clinical trial of the intra­
operative use of 5-fluorouracil on the outcome of dupuytren's disease." J Hand 
Sure fBrl 29(11: 18-21.
Bulstrode, N. W., B. Jemec and P. J. Smith (2005). "The complications of Dupuytren's 
contracture surgery." J Hand Sure TAm] 30(5): 1021-5.
Butler, G. S., M. J. Butler, S. J. Atkinson, H. Will, T. Tamura, S. Schade van Westrum, 
T. Crabbe, J. Clements, M. P. d'Ortho and G. Murphy (1998). "The TIMP2 
membrane type 1 metalloproteinase "receptor" regulates the concentration and 
efficient activation of progelatinase A. A kinetic study." J Biol Chem 273(2): 
871-80.
Cheema, U., S. Y. Yang, V. Mudera, G. G. Goldspink and R. A. Brown (2003). "3-D in 
vitro model of early skeletal muscle development." Cell Motil Cvtoskeleton 
54(3): 226-36.
Chiquet, M., M. Matthisson, M. Koch, M. Tannheimer and R. Chiquet-Ehrismann
(1996). "Regulation of extracellular matrix synthesis by mechanical stress." 
Biochem Cell Biol 74(6): 737-44.
Chiquet, M., A. S. Renedo, F. Huber and M. Fluck (2003). "How do fibroblasts translate 
mechanical signals into changes in extracellular matrix production?" Matrix Biol 
22(1): 73-80.
Chiu, H. F. and R. M. McFarlane (1978). "Pathogenesis of Dupuytren's contracture: a 
correlative clinical-pathological study." J Hand Sure fAml 3(1): 1-10.
Choquet, D., D. P. Felsenfeld and M. P. Sheetz (1997). "Extracellular matrix rigidity 
causes strengthening o f integrin-cytoskeleton linkages." Cell 88(1): 39-48.
176
Citron, N. and A. Heamden (2003). "Skin tension in the aetiology of Dupuytren's 
disease; a prospective trial." J Hand Sure [Br] 28(6): 528-30.
Citron, N. D. and V. Nunez (2005). "Recurrence after surgery for Dupuytren's disease: a 
randomized trial of two skin incisions." J Hand Sure IBrl 30(6): 563-6.
Conway, J. G., J. A. Wakefield, R. H. Brown, B. E. Matron, L. Sekut, S. A. Stimpson, 
A. McElroy, J. A. Menius, J. J. Jeffreys, R. L. Clark and et al. (1995). 
"Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a 
matrix metalloproteinase inhibitor." J Exp Med 182(2): 449-57.
Cordova, A., M. Tripoli, B. Corradino, P. Napoli and F. Moschella (2005). "Dupuytren's 
contracture: an update of biomolecular aspects and therapeutic perspectives." J 
Hand Sum [Brl 30(61: 557-62.
Coussens, L. M., B. Fingleton and L. M. Matrisian (2002). "Matrix metalloproteinase 
inhibitors and cancer: trials and tribulations." Science 295(5564): 2387-92.
Critchley, E. M., S. D. Vakil, H. W. Hayward and V. M. Owen (1976). "Dupuytren's 
disease in epilepsy: result of prolonged administration of anticonvulsants." J 
Neurol Neurosurg Psychiatry 39(5): 498-503.
Daniels, J. T., A. D. Cambrey, N. L. Occleston, Q. Garrett, R. W. Tamuzzer, G. S. 
Schultz and P. T. Khaw (2003). "Matrix metalloproteinase inhibition modulates 
fibroblast-mediated matrix contraction and collagen production in vitro." Invest 
Ophthalmol Vis Sci 44(31: 1104-10.
Darby, I., O. Skalli and G. Gabbiani (1990). "Alpha-smooth muscle actin is transiently 
expressed by myofibroblasts during experimental wound healing." Lab Invest 
63(1): 21-9.
Dave, S. A., D. R. Banducci, W. P. Graham, 3rd, G. M. Allison and H. P. Ehrlich 
(2001). "Differences in alpha smooth muscle actin expression between 
fibroblasts derived from Dupuytren's nodules or cords." Exp Mol Pathol 71(2): 
147-55.
Defawe, O. D., R. D. Kenagy, C. Choi, S. Y. Wan, C. Deroanne, B. Nusgens, N. 
Sakalihasan, A. Colige and A. W. Clowes (2005). "MMP-9 regulates both 
positively and negatively collagen gel contraction: a nonproteolytic function of 
MMP-9." Cardiovasc Res 66(2): 402-9.
Derderian, C. A., N. Bastidas, O. Z. Lerman, K. A. Bhatt, S. E. Lin, J. Voss, J. W. 
Holmes, J. P. Levine and G. C. Gurtner (2005). "Mechanical strain alters gene
177
expression in an in vitro model of hypertrophic scarring." Ann Plast Sure 55(1): 
69-75; discussion 75.
Deryugina, E. I., B. Ratnikov, E. Monosov, T. I. Postnova, R. DiScipio, J. W. Smith and
A. Y. Strongin (2001). "MTl-MMP initiates activation of pro-MMP-2 and 
integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells." 
Exp Cell Res 263(2T 209-23.
Eastwood, M., D. A. McGrouther and R. A. Brown (1994). "A culture force monitor for 
measurement of contraction forces generated in human dermal fibroblast 
cultures: evidence for cell-matrix mechanical signalling." Biochim Biophvs Acta 
1201(2): 186-92.
Eastwood, M., V. C. Mudera, D. A. McGrouther and R. A. Brown (1998). "Effect of 
precise mechanical loading on fibroblast populated collagen lattices: 
morphological changes." Cell Motil Cvtoskeleton 4001: 13-21.
Eastwood, M., R. Porter, U. Khan, G. McGrouther and R. Brown (1996). "Quantitative 
analysis of collagen gel contractile forces generated by dermal fibroblasts and 
the relationship to cell morphology." J Cell Physiol 166(1): 33-42.
Egeblad, M. and Z. Werb (2002). "New functions for the matrix metalloproteinases in 
cancer progression." Nat Rev Cancer 2(3): 161-74.
Ehrlich, H. P., A. Desmouliere, R. F. Diegelmann, I. K. Cohen, C. C. Compton, W. L. 
Gamer, Y. Kapanci and G. Gabbiani (1994). "Morphological and 
immunochemical differences between keloid and hypertrophic scar." Am J 
Pathol 145(1): 105-13.
Ehrlich, H. P. and J. B. Rajaratnam (1990). "Cell locomotion forces versus cell 
contraction forces for collagen lattice contraction: an in vitro model of wound 
contraction." Tissue Cell 22(4): 407-17.
Ehrlich, H. P. and T. Rittenberg (2000). "Differences in the mechanism for high- versus 
moderate-density fibroblast-populated collagen lattice contraction." J Cell 
Physiol 185(3): 432-9.
Elsdale, T. and J. Bard (1972). "Collagen substrata for studies on cell behavior." J Cell 
Biol 54(3): 626-37.
Fitzgerald, A. M., J. J. Kirkpatrick and I. L. Naylor (1999). "Dupuytren's disease. The 
way forward?" J Hand Sure TBrl 24(4): 395-9.
178
Flint, M. H. and C. A. Poole (1990). "Contraction and contracture, in Me Farlane RM, 
Me Grouther DA, Flint MH (eds): Dupuytren's Disease. Edinburgh, Churchill 
Livingstone." (104-16).
Foucher, G., C. Comil and E. Lenoble (1992). "Open palm technique for Dupuytren's 
disease. A five-year follow-up." Ann Chir Main Memb Super 11(5): 362-6.
Foucher, G., J. Medina and R. Navarro (2003). "Percutaneous needle aponeurotomy: 
complications and results." J Hand Sure [Brl 28(5): 427-31.
Fujiwara, M., Y. Muragaki and A. Ooshima (2005). "Keloid-derived fibroblasts show 
increased secretion of factors involved in collagen turnover and depend on 
matrix metalloproteinase for migration." Br J Dermatol 153(2): 295-300.
Gabbiani, G. (2003). "The myofibroblast in wound healing and fibrocontractive 
diseases." J Pathol 200(4): 500-3.
Gabbiani, G., C. Chaponnier and I. Huttner (1978). "Cytoplasmic filaments and gap 
junctions in epithelial cells and myofibroblasts during wound healing." J Cell 
Biol 76(3): 561-8.
Gabbiani, G., B. J. Hirschel, G. B. Ryan, P. R. Statkov and G. Majno (1972). 
"Granulation tissue as a contractile organ. A study of structure and function." J 
Exp Med 135(4): 719-34.
Gabbiani, G. and G. Majno (1972). "Dupuytren's contracture: fibroblast contraction? An 
ultrastructural study." Am J Pathol 66(1): 131-46.
Gabbiani, G., G. B. Ryan and G. Majne (1971). "Presence o f modified fibroblasts in 
granulation tissue and their possible role in wound contraction." Experientia 
27(5): 549-50.
Garbisa, S., G. Scagliotti, L. Masiero, C. Di Francesco, C. Caenazzo, M. Onisto, M. 
Micela, W. G. Stetler-Stevenson and L. A. Liotta (1992). "Correlation of serum 
metalloproteinase levels with lung cancer metastasis and response to therapy." 
Cancer Res 52(16): 4548-9.
Gelberman, R. H., D. Amiel, R. M. Rudolph and R. M. Vance (1980). "Dupuytren's 
contracture. An electron microscopic, biochemical, and clinical correlative 
study." J Bone Joint Sure Am 62(3): 425-32.
Giannelli, G., J. Falk-Marzillier, O. Schiraldi, W. G. Stetler-Stevenson and V. Quaranta
(1997). "Induction of cell migration by matrix metalloprotease-2 cleavage of 
laminin-5." Science 277(5323): 225-8.
179
Glimcher, M. J. and H. M. Peabody (1990). "Collagen organization, in Me Farlane RM, 
Me Grouther DA, Flint MH (eds): Dupuytren’s Disease. Edinburgh, Churchill 
Livingstone." 72-85.
Godtfredsen, N. S., H. Lucht, E. Prescott, T. I. Sorensen and M. Gronbaek (2004). "A 
prospective study linked both alcohol and tobacco to Dupuytren's disease." J 
Clin Epidemiol 57(8): 858-63.
Gonzalez, A. M., M. Buscaglia, R. Fox, A. Isacchi, P. Sarmientos, J. Farris, M. Ong, D. 
Martineau, D. A. Lappi and A. Baird (1992). "Basic fibroblast growth factor in 
Dupuytren's contracture." Am J Pathol 141(3): 661-71.
Grinnell, F. (1994). "Fibroblasts, myofibroblasts, and wound contraction." J Cell Biol 
124(4): 401-4.
Grinnell, F. (1999). "Signal transduction pathways activated during fibroblast 
contraction of collagen matrices." Curr Top Pathol 93: 61-73.
Grinnell, F. (2000). "Fibroblast-collagen-matrix contraction: growth-factor signalling 
and mechanical loading." Trends Cell Biol 10(9): 362-5.
Grinnell, F. (2003). "Fibroblast biology in three-dimensional collagen matrices." Trends 
Cell Biol 13(5): 264-9.
Grinnell, F. and C. H. Ho (2002). "Transforming growth factor beta stimulates 
fibroblast-collagen matrix contraction by different mechanisms in mechanically 
loaded and unloaded matrices." Exp Cell Res 273(2): 248-55.
Guidry, C. and F. Grinnell (1987). "Contraction of hydrated collagen gels by 
fibroblasts: evidence for two mechanisms by which collagen fibrils are 
stabilized." Coll Relat Res 6(6): 515-29.
Hande, K. R., M. Collier, L. Paradiso, J. Stuart-Smith, M. Dixon, N. Clendeninn, G. 
Yeun, D. Alberti, K. Binger and G. Wilding (2004). "Phase I and 
pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor." Clin 
Cancer Res 10(3): 909-15.
Haralson, M. A. and J. R. Hassell (1995). "The Extracellular matrix - an overview. In 
The extracellular matrix - a practical approach. Edited by Haralson and Hassell, 
IRL Oxford University Press." (1-30).
Haro, H., H. C. Crawford, B. Fingleton, K. Shinomiya, D. M. Spengler and L. M. 
Matrisian (2000). "Matrix metalloproteinase-7-dependent release of tumor 
necrosis factor-alpha in a model of herniated disc resorption." J Clin Invest 
105(2): 143-50.
Harris, A. K., D. Stopak and P. Wild (1981). "Fibroblast traction as a mechanism for 
collagen morphogenesis." Nature 290(5803): 249-51.
Harter, L. V., K. A. Hruska and R. L. Duncan (1995). "Human osteoblast-like cells 
respond to mechanical strain with increased bone matrix protein production 
independent of hormonal regulation." Endocrinology 136(2): 528-35.
Higuchi, R., C. Fockler, G. Dollinger and R. Watson (1993). "Kinetic PCR analysis: 
real-time monitoring of DNA amplification reactions." Biotechnology (N Y) 
11(9): 1026-30.
Hinz, B., G. Celetta, J. J. Tomasek, G. Gabbiani and C. Chaponnier (2001). "Alpha- 
smooth muscle actin expression upregulates fibroblast contractile activity." Mol 
Biol Cell 12(9): 2730-41.
Holmbeck, K., P. Bianco, J. Caterina, S. Yamada, M. Kromer, S. A. Kuznetsov, M. 
Mankani, P. G. Robey, A. R. Poole, I. Pidoux, J. M. Ward and H. Birkedal- 
Hansen (1999). "MTl-MMP-deficient mice develop dwarfism, osteopenia, 
arthritis, and connective tissue disease due to inadequate collagen turnover." 
Cell 99(1): 81-92.
Howard, J. C., V. M. Varallo, D. C. Ross, J. H. Roth, K. J. Faber, B. Alman and B. S. 
Gan (2003). "Elevated levels of beta-catenin and fibronectin in three- 
dimensional collagen cultures of Dupuytren's disease cells are regulated by 
tension in vitro." BMC Musculoskelet Disord 4: 16.
Hu, F. Z., A. Nystrom, A. Ahmed, M. Palmquist, R. Dopico, I. Mossberg, J. Gladitz, M. 
Rayner, J. C. Post, G. D. Ehrlich and R. A. Preston (2005). "Mapping of an 
autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a 
Swedish family." Clin Genet 68(5): 424-9.
Hueston, J. T. (1962). "Further studies on the incidence of Dupuytren's contracture." 
Med J Aust 49(1): 586-8.
Hueston, J. T. (1963). "Recurrent Dupuytren's contracture." Plast Reconstr Surg 31: 66- 
9.
Hueston, J. T., J. V. Hurley and S. Whittingham (1976). "The contracting fibroblast as a 
clue to Dupuytren's contracture." Hand 8(1): 10-2.
Hurst, L. C., M. A. Badalamente and J. Makowski (1986). "The pathobiology of 
Dupuytren's contracture: effects of prostaglandins on myofibroblasts." J Hand 
Surg TAml 11(1): 18-23.
181
Hutchinson, J. W., G. M. Tiemey, S. L. Parsons and T. R. Davis (1998). "Dupuytren's 
disease and frozen shoulder induced by treatment with a matrix 
metalloproteinase inhibitor." J Bone Joint Surg Br 80(5): 907-8.
Itoh, T., H. Matsuda, M. Tanioka, K. Kuwabara, S. Itohara and R. Suzuki (2002). "The 
role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody- 
induced arthritis." J Immunol 169(5): 2643-7.
Jain, A., F. Brennan and J. Nanchahal (2002). "Treatment of rheumatoid tenosynovitis 
with cytokine inhibitors." Lancet 360(9345): 1565-6.
Jansen, J. H., H. Jahr, J. A. Verhaar, H. A. Pols, H. Chiba, H. Weinans and J. P. van 
Leeuwen (2006). "Stretch-induced modulation of matrix metalloproteinases in 
mineralizing osteoblasts via extracellular signal-regulated kinase-1/2." J Orthop 
Res 24(7): 1480-8.
Jemec, B., A. O. Grobbelaar, G. D. Wilson, P. J. Smith, R. Sanders and D. A. 
McGrouther (1999). "Is Dupuytren's disease caused by an imbalance between 
proliferation and cell death?" J Hand Surg TBrl 24(5): 511-4.
Jones, G. C., A. N. Corps, C. J. Pennington, I. M. Clark, D. R. Edwards, M. M. Bradley,
B. L. Hazleman and G. P. Riley (2006). "Expression profiling of 
metalloproteinases and tissue inhibitors of metalloproteinases in normal and 
degenerate human achilles tendon." Arthritis Rheum 54(3): 832-42.
Jones, G. E. and J. A. Witkowski (1979). "Reduced adhesiveness between skin 
fibroblasts from patients with Duchenne muscular dystrophy." J Neurol Sci 
43(3): 465-70.
Keilholz, L., M. H. Seegenschmiedt and R. Sauer (1996). "Radiotherapy for prevention 
of disease progression in early-stage Dupuytren's contracture: initial and long­
term results." Int J Radiat Oncol Biol Phvs 36(4): 891-7.
Ketchum, L. D. and T. K. Donahue (2000). "The injection of nodules of Dupuytren's 
disease with triamcinolone acetonide." J Hand Surg TAml 25(6): 1157-62.
Koike, T., R. B. Vernon, M. A. Hamner, E. Sadoun and M. J. Reed (2002). "MT1- 
MMP, but not secreted MMPs, influences the migration of human microvascular 
endothelial cells in 3-dimensional collagen gels." J Cell Biochem 86(4): 748-58.
Kozma, E. M., K. Olczyk, G. Wisowski, A. Glowacki and R. Bobinski (2005). 
"Alterations in the extracellular matrix proteoglycan profile in Dupuytren's 
contracture affect the palmar fascia." J Biochem (Tokyo) 137(4): 463-76.
182
Kuhn, M. A., X. Wang, W. G. Payne, F. Ko and M. C. Robson (2002). "Tamoxifen 
decreases fibroblast function and downregulates TGF(beta2) in dupuytren's 
affected palmar fascia." J Surg Res 103(2): 146-52.
Lambert, C. A., A. C. Colige, C. Munaut, C. M. Lapiere and B. V. Nusgens (2001). 
"Distinct pathways in the over-expression of matrix metalloproteinases in human 
fibroblasts by relaxation of mechanical tension." Matrix Biol 20(7): 397-408.
Lara, P. N., Jr., W. M. Stadler, J. Longmate, D. I. Quinn, J. Wexler, M. Van Loan, P. 
Twardowski, P. H. Gumerlock, N. J. Vogelzang, E. E. Vokes, H. J. Lenz, J. H. 
Doroshow and D. R. Gandara (2006). "A randomized phase II trial of the matrix 
metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer 
patients with bone metastases." Clin Cancer Res 12(5): 1556-63.
Lemaitre, V. and J. D'Armiento (2006). "Matrix metalloproteinases in development and 
disease." Birth Defects Res C Embryo Today 78(1): 1-10.
Li, B. H., P. Zhao, S. Z. Liu, Y. M. Yu, M. Han and J. K. Wen (2005). "Matrix 
metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal 
carcinoma invasion and metastasis." World J Gastroenterol 11(20): 3046-50.
Lin, C. Q. and M. J. Bissell (1993). "Multi-faceted regulation of cell differentiation by 
extracellular matrix." Faseb J 7(9): 737-43.
Linask, K. K., M. Han, D. H. Cai, P. R. Brauer and S. M. Maisastry (2005). "Cardiac 
morphogenesis: matrix metalloproteinase coordination of cellular mechanisms 
underlying heart tube formation and directionality of looping." Dev Dvn 233(3): 
739-53.
Lindahl, G. E., R. C. Chambers, J. Papakrivopoulou, S. J. Dawson, M. C. Jacobsen, J. 
E. Bishop and G. J. Laurent (2002). "Activation of fibroblast procollagen alpha 
1(1) transcription by mechanical strain is transforming growth factor-beta- 
dependent and involves increased binding of CCAAT-binding factor (CBF/NF- 
Y) at the proximal promoter." J Biol Chem 277(8): 6153-61.
Ling, R. S. (1963). "The Genetic Factor in Dupuytren's Disease." J Bone Joint Surg Br 
45: 709-18.
Luck, J. V. (1959). "Dupuytren's contracture; a new concept o f the pathogenesis 
correlated with surgical management." J Bone Joint Surg Am 41-A(4): 635-64.
Makela, E. A., H. Jaroma, A. Haiju, S. Anttila and J. Vainio (1991). "Dupuytren's 
contracture: the long-term results after day surgery." J Hand Surg TBrl 16(3): 
272-4.
183
Malemud, C. J. (2006). "Matrix metalloproteinases (MMPs) in health and disease: an 
overview." Front Biosci 11: 1696-701.
Mannello, F., G. Tonti and S. Papa (2005). "Matrix metalloproteinase inhibitors as 
anticancer therapeutics." Curr Cancer Drug Targets 5(4): 285-98.
Marenzana, M., N. Wilson-Jones, V. Mudera and R. A. Brown (2006). "The origins and 
regulation of tissue tension: Identification of collagen tension-fixation process in 
vitro." Exp Cell Res 312(4): 423-33.
Matthews, P. (1979). "Familial Dupuytren's contracture with predominantly female 
expression." Br J Plast Surg 32(2): 120-3.
McCann, B. G., A. Logan, H. Belcher, A. Warn and R. M. Warn (1993). "The presence 
of myofibroblasts in the dermis of patients with Dupuytren's contracture. A 
possible source for recurrence." J Hand Surg [Br] 18(5): 656-61.
McFarlane, R. M. (1983). "The current status of Dupuytren's disease." J Hand Surg 
[Am] 8(5 Pt 2): 703-8.
McFarlane, R. M. (1990). "Is Dupuytren's disease a neoplasm? In McFarlane RM, 
McGrouther DA, Flint MH (eds): Dupuytren's Disease: Biology and Treatment, 
Vol 5, The Hand and Upper Limb Series. Edinburgh, Churchill Livingstone." 
229-290.
McFarlane, R. M. (1991). "Dupuytren's disease: relation to work and injury." J Hand 
Surg lAml 16(5): 775-9.
McGrouther, D. A. (1982). "The microanatomy of Dupuytren's contracture." Hand 
14(3): 215-36.
Meisser, A., M. Cohen and P. Bischof (2005). "Concentrations of circulating gelatinases 
(matrix metalloproteinase-2 and -9) are dependent on the conditions of blood 
collection." Clin Chem 51(1): 274-6.
Meister, P., J. M. Gokel and K. Remberger (1979). "Palmar fibromatosis-"Dupuytren's 
contracture". A comparison of light electron and immunofluorescence 
microscopic findings." Pathol Res Pract 164(4): 402-12.
Mengshol, J. A., K. S. Mix and C. E. Brinckerhoff (2002). "Matrix metalloproteinases 
as therapeutic targets in arthritic diseases: bull’s-eye or missing the mark?" 
Arthritis Rheum 46(1): 13-20.
Menzel, E. J., H. Piza, C. Zielinski, A. T. Endler, C. Steffen and H. Millesi (1979). 
"Collagen types and anticollagen-antibodies in Dupuytren's disease." Hand 
11(3): 243-8.
184
Messina, A. and J. Messina (1993). "The continuous elongation treatment by the TEC 
device for severe Dupuytren's contracture of the fingers." Plast Reconstr Surg 
92(1): 84-90.
Meyer, M. and D. A. McGrouther (1991). "A study relating wound tension to scar 
morphology in the pre-stemal scar using Langers technique." Br J Plast Surg 
44(4): 291-4.
Mirastschijski, U., C. J. Haaksma, J. J. Tomasek and M. S. Agren (2004). "Matrix 
metalloproteinase inhibitor GM 6001 attenuates keratinocyte migration, 
contraction and myofibroblast formation in skin wounds." Exp Cell Res 299(2): 
465-75.
Moermans, J. P. (1996). "Long-term results after segmental aponeurectomy for 
Dupuytren's disease." J Hand Surg [Brl 21(6): 797-800.
Moyer, K. E., D. R. Banducci, W. P. Graham, 3rd and H. P. Ehrlich (2002). 
"Dupuytren's disease: physiologic changes in nodule and cord fibroblasts 
through aging in vitro." Plast Reconstr Surg 110(1): 187-93; discussion 194-6.
Mudera, V. C., R. Pleass, M. Eastwood, R. Tamuzzer, G. Schultz, P. Khaw, D. A. 
McGrouther and R. A. Brown (2000). "Molecular responses of human dermal 
fibroblasts to dual cues: contact guidance and mechanical load." Cell Motil 
Cytoskeleton 45(1): 1-9.
Mudgett, J. S., N. I. Hutchinson, N. A. Chartrain, A. J. Forsyth, J. McDonnell, Singer, 
II, E. K. Bayne, J. Flanagan, D. Kawka, C. F. Shen, K. Stevens, H. Chen, M. 
Trumbauer and D. M. Visco (1998). "Susceptibility o f stromelysin 1-deficient 
mice to collagen-induced arthritis and cartilage destruction." Arthritis Rheum 
41(1): 110-21.
Murrell, G. A., M. J. Francis and L. Bromley (1987). "Free radicals and Dupuytren's 
contracture." Br Med J fClin Res Ed) 295(66101: 1373-5.
Murrell, G. A., M. J. Francis and L. Bromley (1991). "The collagen changes of 
Dupuytren's contracture." J Hand Surg [Br] 16(3): 263-6.
Nagase, H., R. Visse and G. Murphy (2006). "Structure and function of matrix 
metalloproteinases and TIMPs." Cardiovasc Res 69(3): 562-73.
Nagase, H. and J. F. Woessner (1999). "Matrix Metalloproteinases." The Journal of 
Biological Chemistry 274(311: 21491-21494.
Nakatani, S., M. Ikura, S. Yamamoto, Y. Nishita, S. Itadani, H. Habashita, T. Sugiura, 
K. Ogawa, H. Ohno, K. Takahashi, H. Nakai and M. Toda (2006). "Design and
185
synthesis of novel metalloproteinase inhibitors." Bioorg Med Chem 14(15): 
5402-22.
Neely, A. N., C. E. Clendening, J. Gardner, D. G. Greenhalgh and G. D. Warden
(1999). "Gelatinase activity in keloids and hypertrophic scars." Wound Repair 
Regen 7(3): 166-71.
Ohuchi, E., K. Imai, Y. Fujii, H. Sato, M. Seiki and Y. Okada (1997). "Membrane type 
1 matrix metalloproteinase digests interstitial collagens and other extracellular 
matrix macromolecules." J Biol Chem 272(4): 2446-51.
Parsons, M., E. Kessler, G. J. Laurent, R. A. Brown and J. E. Bishop (1999). 
"Mechanical load enhances procollagen processing in dermal fibroblasts by 
regulating levels of procollagen C-proteinase." Exp Cell Res 252(2): 319-31. 
Parsons, S. L., S. A. Watson, P. D. Brown, H. M. Collins and R. J. Steele (1997).
"Matrix metalloproteinases." Br J Surg 84(2): 160-6.
Peyton, S. R. and A. J. Putnam (2005). "Extracellular matrix rigidity governs smooth 
muscle cell motility in a biphasic fashion." J Cell Physiol 204(1): 198-209.
Pfaffl, M. W., G. W. Horgan and L. Dempfle (2002). "Relative expression software tool 
(REST) for group-wise comparison and statistical analysis of relative expression 
results in real-time PCR." Nucleic Acids Res 30(9): e36.
Phillips, J. A., C. A. Vacanti and L. J. Bonassar (2003). "Fibroblasts regulate contractile 
force independent of MMP activity in 3D-collagen." Biochem Biophvs Res 
Commun 312(3): 725-32.
Pins, G. D., M. E. Collins-Pavao, L. Van De Water, M. L. Yarmush and J. R. Morgan
(2000). "Plasmin triggers rapid contraction and degradation of fibroblast- 
populated collagen lattices." J Invest Dermatol 114(4): 647-53.
Pittet, B., L. Rubbia-Brandt, A. Desmouliere, A. P. Sappino, P. Roggero, S. Guerret, J. 
A. Grimaud, R. Lacher, D. Montandon and G. Gabbiani (1994). "Effect of 
gamma-interferon on the clinical and biologic evolution o f hypertrophic scars 
and Dupuytren’s disease: an open pilot study." Plast Reconstr Surg 93(6): 1224- 
35.
Prajapati, R. T., B. Chavally-Mis, D. Herbage, M. Eastwood and R. A. Brown (2000). 
"Mechanical loading regulates protease production by fibroblasts in three- 
dimensional collagen substrates." Wound Repair Regen 8(3): 226-37.
186
Qian, A., R. A. Meals, J. Rajfer and N. F. Gonzalez-Cadavid (2004). "Comparison of 
gene expression profiles between Peyronie's disease and Dupuytren's 
contracture." Urology 64(2): 399-404.
Rayan, G. M. (1999). "Clinical presentation and types of Dupuytren's disease." Hand 
CUn 15(1): 87-96, vii.
Rayan, G. M. and J. J. Tomasek (1994). "Generation of contractile force by cultured 
Dupuytren's disease and normal palmar fibroblasts." Tissue Cell 26(5): 747-56.
Reuben, P. M. and H. S. Cheung (2006). "Regulation of matrix metalloproteinase 
(MMP) gene expression by protein kinases." Front Biosci 11: 1199-215.
Riley, G. P., V. Curry, J. DeGroot, B. van El, N. Verzijl, B. L. Hazleman and R. A. 
Bank (2002). "Matrix metalloproteinase activities and their relationship with 
collagen remodelling in tendon pathology." Matrix Biol 21(2): 185-95.
Ritter. M. A. (1973). "The anatomy and function of the palmar fascia." Hand 5(3): 263- 
7.
Ritty, T. M. and J. Herzog (2003). "Tendon cells produce gelatinases in response to type 
I collagen attachment." J Orthop Res 21(3): 442-50.
Rodrigo, J. J., J. J. Niebauer, R. L. Brown and J. R. Doyle (1976). "Treatment of 
Dupuytren's contracture. Long-term results after fasciotomy and fascial 
excision." J Bone Joint Surg Am 58(3): 380-7.
Rombouts, J. J., H. Noel, Y. Legrain and E. Munting (1989). "Prediction of recurrence 
in the treatment of Dupuytren's disease: evaluation of a histologic 
classification." J Hand Surg TAml 14(4): 644-52.
Rosemurgy, A., J. Harris, A. Langleben, E. Casper, S. Goode and H. Rasmussen (1999). 
"Marimastat in patients with advanced pancreatic cancer: a dose-finding study." 
Am J Clin Oncol 22(3): 247-52.
Rosenbaum, E., M. Zahurak, V. Sinibaldi, M. A. Carducci, R. Pili, M. Laufer, T. L. 
DeWeese and M. A. Eisenberger (2005). "Marimastat in the treatment of 
patients with biochemically relapsed prostate cancer: a prospective randomized, 
double-blind, phase I/II trial." Clin Cancer Res 11(12): 4437-43.
Ross, D. C. (1999). "Epidemiology of Dupuytren's disease." Hand Clin 15(1): 53-62, vi.
Sambrook, J. (1989). "Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a 
laboratory manual. 2nd Ed Cold Spring Harbor Laboratory press volume 3 pp 
E5."
187
Schmalfeldt, B., D. Prechtel, K. Harting, K. Spathe, S. Rutke, E. Konik, R. Fridman, U. 
Berger, M. Schmitt, W. Kuhn and E. Lengyel (2001). "Increased expression of 
matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type 
plasminogen activator is associated with progression from benign to advanced 
ovarian cancer." Clin Cancer Res 7(8): 2396-404.
Scott, K. A., E. J. Wood and E. H. Karran (1998). "A matrix metalloproteinase inhibitor 
which prevents fibroblast-mediated collagen lattice contraction." FEBS Lett 
441(1): 137-40.
Serini, G. and G. Gabbiani (1999). "Mechanisms of myofibroblast activity and 
phenotypic modulation." Exp Cell Res 250(2): 273-83.
Seyhan, H., J. Kopp, S. Schultze-Mosgau and R. E. FLorch (2006). "Increased metabolic 
activity of fibroblasts derived from cords compared with nodule fibroblasts 
sampling from patients with Dupuytren's contracture." Plast Reconstr Surg 
117(4): 1248-52.
Sheetz, M. P., D. P. Felsenfeld and C. G. Galbraith (1998). "Cell migration: regulation 
of force on extracellular-matrix-integrin complexes." Trends Cell Biol 8(2): 51- 
4.
Shelley, W. B. and E. D. Shelley (1993). "Response of Dupuytren's contracture to high- 
potency topical steroid." Lancet 342(8867): 366.
Sheridan, C. M., N. L. Occleston, P. Hiscott, C. H. Kon, P. T. Khaw and I. Grierson
(2001). "Matrix metalloproteinases: a role in the contraction of vitreo-retinal 
scar tissue." Am J Pathol 159(41: 1555-66.
Sier, C. F., F. J. Kubben, S. Ganesh, M. M. Heerding, G. Griffioen, R. Hanemaaijer, J. 
H. van Krieken, C. B. Lamers and H. W. Verspaget (1996). "Tissue levels of 
matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival 
of patients with gastric carcinoma." Br J Cancer 74(3): 413-7.
Skiles, J. W., N. C. Gonnella and A. Y. Jeng (2004). "The design, structure, and clinical 
update of small molecular weight matrix metalloproteinase inhibitors." Curr 
Med Chem 11(22): 2911-77.
Smith, M. R., H. Kung, S. K. Durum, N. H. Colburn and Y. Sun (1997). "TIMP-3 
induces cell death by stabilizing TNF-alpha receptors on the surface o f human 
colon carcinoma cells." Cytokine 9(10): 770-80.
188
Steinberg, B. M., K. Smith, M. Colozzo and R. Pollack (1980). "Establishment and 
transformation diminish the ability of fibroblasts to contract a native collagen 
gel." J Cell Biol 87(1): 304-8.
Stephens, P., K. J. Davies, N. Occleston, R. D. Pleass, C. Kon, J. Daniels, P. T. Khaw 
and D. W. Thomas (2001). "Skin and oral fibroblasts exhibit phenotypic 
differences in extracellular matrix reorganization and matrix metalloproteinase 
activity." Br J Dermatol 144(2): 229-37.
Stemlicht, M. D. and Z. Werb (2001). "How matrix metalloproteinases regulate cell 
behavior." Annu Rev Cell Dev Biol 17: 463-516.
Stiles, P. J. (1966). "Ultrasonic therapy in Dupuytren's contracture." J Bone Joint Surg 
Br 48(3): 452-4.
Streuli, C. (1999). "Extracellular matrix remodelling and cellular differentiation." Curr 
Opin Cell Biol 11(5): 634-40.
Tarlton, J. F., P. Meagher, R. A. Brown, D. A. McGrouther, A. J. Bailey and A. Afoke
(1998). "Mechanical stress in vitro induces increased expression of MMPs 2 and 
9 in excised Dupuytren's disease tissue." J Hand Surg [Br] 23(3): 297-302.
Tarpila, E., M. R. Ghassemifar, S. Wingren, M. Agren and L. Franzen (1996). 
"Contraction of collagen lattices by cells from Dupuytren's nodules." J Hand 
SurgJBr] 21(6): 801-5.
Tchetverikov, I., L. S. Lohmander, N. Verzijl, T. W. Huizinga, J. M. TeKoppele, R. 
Hanemaaijer and J. DeGroot (2005). "MMP protein and activity levels in 
synovial fluid from patients with joint injury, inflammatory arthritis, and 
osteoarthritis." Ann Rheum Pis 64(5): 694-8.
Terek, R. M., W. A. Jiranek, M. J. Goldberg, H. J. Wolfe and B. A. Alman (1995). "The 
expression of platelet-derived growth-factor gene in Dupuytren contracture." J 
Bone Joint Surg Am 7701: 1-9.
Thannickal, V. J., G. B. Toews, E. S. White, J. P. Lynch, 3rd and F. J. Martinez (2004). 
"Mechanisms of pulmonary fibrosis." Annu Rev Med 55: 395-417.
Tomasek, J. and G. M. Rayan (1995). "Correlation o f alpha-smooth muscle actin 
expression and contraction in Dupuytren's disease fibroblasts." J Hand Surg 
[Am] 20(3): 450-5.
Tomasek, J. J., G. Gabbiani, B. Hinz, C. Chaponnier and R. A. Brown (2002). 
"Myofibroblasts and mechano-regulation o f connective tissue remodelling." Nat 
Rev Mol Cell Biol 3(5): 349-63.
189
Tonn, J. C., S. Kerkau, A. Hanke, H. Bouterfa, J. G. Mueller, S. Wagner, G. H. Vince 
and K. Roosen (1999). "Effect of synthetic matrix-metalloproteinase inhibitors 
on invasive capacity and proliferation of human malignant gliomas in vitro." Int 
J Cancer 80(5): 764-72.
Toth, M., M. M. Bernardo, C.M. Overall, Y.A. DeClerck, H.Tschesche, M.L. Cher, S. 
Brown, S. Mobashery, R. Fridman, R. (2000). "Tissue inhibitor of 
metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix 
metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the 
(Membrane type l)-MMP-dependent activation of pro-MMP-2." J Biol Chem 
275(52): 41415-23.
Tranquillo, R. T. (1999). "Self-organization of tissue-equivalents: the nature and role of 
contact guidance." Biochem Soc Svmp 65: 27-42.
Tse, R., J. Howard, Y. Wu and B. S. Gan (2004). "Enhanced Dupuytren's disease 
fibroblast populated collagen lattice contraction is independent of endogenous 
active TGF-beta2." BMC Musculoskelet Disord 5(1): 41.
Ulrich, D., K. Hrynyschyn and N. Pallua (2003). "Matrix metalloproteinases and tissue 
inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's 
disease." Plast Reconstr Surg 112(5): 1279-86.
van der Rest, M. and R. Garrone (1991). "Collagen family of proteins." Faseb J 5(13): 
2814-23.
Vande Berg, J. S., R. H. Gelberman, R. Rudolph, D. Johnson and P. Sicurello (1984). 
"Dupuytren's disease: comparative growth dynamics and morphology between 
cultured myofibroblasts (nodule) and fibroblasts (cord)." J Orthop Res 2(3): 247- 
56.
Visse, R. and H. Nagase (2003). "Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases: structure, function, and biochemistry." Circ Res 92(8): 827- 
39.
Wall, L., D. C. Talbot, P. Bradbury and D. I. Jodrell (2004). "A phase I and 
pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in 
patients with solid tumours." Br J Cancer 90(4): 800-4.
Wang, Z., R. Juttermann and P. D. Soloway (2000). "TIMP-2 is required for efficient 
activation of proMMP-2 in vivo." J Biol Chem 275(34): 26411-5.
Wojtowicz-Praga, S., J. Torri, M. Johnson, V. Steen, J. Marshall, E. Ness, R. Dickson, 
M. Sale, H. S. Rasmussen, T. A. Chiodo and M. J. Hawkins (1998). "Phase I
190
trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered 
orally to patients with advanced lung cancer.” J Clin Oncol 16(6): 2150-6.
Wong, M. and V. Mudera (2006). "Feedback inhibition of high TGF-betal 
concentrations on myofibroblast induction and contraction by Dupuytren's 
fibroblasts.” J Hand Sure fBr] 31(5): 473-83.
Wong, T. T., J. T. Daniels, J. G. Crowston and P. T. Khaw (2004). "MMP inhibition 
prevents human lens epithelial cell migration and contraction of the lens 
capsule.” Br J Ophthalmol 88(7): 868-72.
Wong, T. T., A. L. Mead and P. T. Khaw (2003). "Matrix metalloproteinase inhibition 
modulates postoperative scarring after experimental glaucoma filtration 
surgery.” Invest Ophthalmol Vis Sci 44(3): 1097-103.
Wrobel, L. K., T. R. Fray, J. E. Molloy, J. J. Adams, M. P. Armitage and J. C. Sparrow
(2002). "Contractility of single human dermal myofibroblasts and fibroblasts.” 
Cell Motil Cvtoskeleton 52(2): 82-90.
Zucker, S. and J. Vacirca (2004). "Role of matrix metalloproteinases (MMPs) in 
colorectal cancer.” Cancer Metastasis Rev 23(1-2): 101-17.
191
